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Malignant pleural effusion (MPE) is a common and regularly debilitating 
complication in a wide range of cancers. MPE confers a short prognosis (3-12 
months depending on the primary tumour) and efficient, enduring palliation is 
therefore a clinical priority. Non-expansile lung (NEL) frequently complicates 
definitive MPE management as it precludes successful talc slurry pleurodesis 
(TSP) resulting in recurrent symptoms and repeat pleural interventions. 
Indwelling pleural catheters (IPCs) may provide reliable symptom relief in the 
presence of NEL, but are not universally acceptable to patients. The aim of this 
thesis was to progress towards improving outcomes in MPE through the reliable 
detection of NEL. In Chapter 3, an observational multicentre cohort of patients 
with MPE diagnosed at local anaesthetic thoracoscopy identified NEL in 17-34%. 
Radiographic identification of NEL was subject to a high level of inter-observer 
variation (k 0.38–0.51). NEL was also associated with adverse survival (HR 2.2, 
95% CI 1.3–3.7), although the independence of this relationship was not 
externally validated. Chapter 4 presents the results of a feasibility randomised 
controlled trial (RCT) of a pleural elastance (PEL)-directed treatment pathway 
(Elastance-Directed IPC or TSP (EDIT management)) for symptomatic MPE. This 
trial, abbreviated to ‘pre-EDIT’, demonstrated the feasibility of this RCT design 
and treatment pathway in terms of recruitment rate (2.4 subjects/month), 
technical delivery (successful PEL assessment in 13/15 (87%) and 13/13 (100%) 
after an early equipment update) and safety (no directly attributable serious 
adverse events). Finally, in Chapter 5, additional data from pre-EDIT and an 
embedded treatment preferences survey (TPS) were explored to optimise the 
proposed EDIT pathway. Only 4/17 TPS respondents (24%) would choose first-line 
ambulatory pleurodesis via an IPC if offered, whereas 15/17 (88%) stated they 
would consider a 2-stage pleural intervention process incorporating PEL 
assessment. Motion-mode sonographic assessment performed poorly as an 
alternative pre-drainage NEL biomarker; adequate imaging was achieved in only 
10/13 (77%) and the AUC for NEL detection was 0.595 (95%CI 0.180-1.000). Novel 
volumetric magnetic resonance imaging pre- and post-aspiration from pre-EDIT 
validated the widely adopted clinical definition of PEL and further supports the 
use of PEL as a NEL biomarker. The findings from these chapters are incorporated 
into a proposed design for a Phase III trial of the efficacy of EDIT management.  
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1 Chapter 1: Introduction 
1.1 General Introduction 
Malignant pleural effusion (MPE) is a commonly encountered complication in a 
wide range of cancers. MPE refers to the accumulation of fluid within the pleural 
space which frequently leads to disabling morbidity, often in the form of 
significant breathlessness. It universally represents incurable disease and confers 
a median overall survival of only 3 to 12 months, predominately depending on 
the underlying tumour type. [1] Efficient and durable symptom control is 
therefore a priority in this patient group. 
Definitive MPE management is achieved through either complete evacuation of 
pleural fluid followed by pleurodesis to obliterate the pleural space, or regular 
pleural fluid drainage using an indwelling pleural catheter (IPC). Trials have 
demonstrated broadly similar outcomes in relation to patient-centred end points 
for these approaches. [2,3] The advantages and limitations of each should 
therefore be taken into account when choosing the most appropriate first-line 
intervention. However, a key consideration is the ability of the underlying 
atelectatic lung to re-expand as this is a pre-requisite for successful pleurodesis. 
Failure of adequate lung re-expansion is termed non-expansile lung (NEL). Where 
significant NEL is identified, pleurodesis cannot succeed and IPC insertion 
represents the standard of care. [4]  
NEL is encountered in up to 30% of patients undergoing MPE drainage [5] and 
appears to be under-represented in MPE treatment literature. [2,3] However, 
estimates of prevalence vary widely, largely due to the difficulty in defining 
NEL. Within existing clinical pathways, NEL is judged subjectively on post-
drainage plain chest radiographs (CXRs). Reliable NEL identification is therefore 
only possible after commitment to a particular treatment strategy. As such, 
occult NEL is a major cause of pleurodesis failure, recurrent breathlessness and 
a requirement for repeat pleural procedures.  
The overarching aim of this thesis is to refine the management of symptomatic 
MPE through the accurate recognition of NEL. Improvements in the definition of 
NEL post-drainage may improve the consistency of decision making within 
current clinical pathways. Additionally, a better understanding of the prevalence 
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and prognostic impact of NEL may inform the rational design of future MPE trials 
and supplement existing approaches to prognostication. Moreover, a reliable and 
accessible means of pre-drainage NEL detection would facilitate the 
development of an MPE treatment pathway stratified by the presence or absence 
of NEL. Such a strategy might allow patients with expansile lung to benefit from 
the advantages of pleurodesis, while protecting those with NEL from the 
inconvenience and risks of treatment failure. Elevated pleural elastance (PEL), 
calculated from pleural manometry data obtained during thoracentesis, is the 
most extensively cited pre-drainage NEL biomarker. The potential role for PEL-
directed definitive MPE management (ICD vs IPC) is explored for the first time in 
the work presented in this thesis. 
This introduction describes the context in which this thesis is set including the 
clinical significance of MPE, its pathogenesis and current evidence-based 
treatment approaches. The available literature on the detection of NEL both 
pre- and post-drainage is reviewed, including a detailed discussion of pleural 
manometry techniques used to calculate PEL, in order to provide a robust 
justification for the objectives set. Finally, an introduction to magnetic 
resonance imaging (MRI) as a volumetric gold standard is provided since its use 
has facilitated an exploration of the validity of the currently accepted definition 
of PEL.   
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1.2 Malignant Pleural Effusion 
1.2.1 Public health and clinical relevance 
The global burden of disease relating to MPE is significant although 
epidemiological studies to support this assertion are sparse. Frequently cited 
incidence rates of 250000 and 50000 new cases of MPE each year in the United 
States and United Kingdom respectively, are extrapolated from a dated but 
rigorous attempt to identify all cases of pleural effusion in a geographically well-
defined region of the Czech Republic. [6] Accepting the limitations of this 
approach, a typical UK district general hospital can expect to diagnose and 
manage around 250 cases of MPE per year. [7] With an ageing population, and 
therefore rising incidence of malignant disease overall, these figures are 
expected to rise further in coming decades.  
The majority of MPEs (57%) present with breathlessness although up to a quarter 
may be asymptomatic and identified incidentally. [8] Cough is also commonly 
encountered at presentation and up to a quarter of patients may have chest 
pain. [8] Relief of dyspnoea is typically reported as the priority for patients with 
symptomatic MPE and most interventions are delivered with this intent. [9] 
Despite the increasing potential for ambulatory management utilising IPCs, mean 
length of hospital stay associated with MPE remains greater than 5 days, which 
in many cases is a significant proportion of these patients’ remaining lives. [10] 
The burden on healthcare resource is also clearly substantial; US data indicates 
annual hospital charges associated with MPE to be greater than $5 billion per 
year. [10] 
1.2.2 Development of malignant pleural effusion 
1.2.2.1 The pleural cavity; normal anatomy and physiology 
The pleural cavity in healthy subjects is a thin (10 - 20µm), fluid-filled space in 
each hemi-thorax arising between visceral and parietal pleural membranes 
covering the lung, and lining the thoracic cage, respectively. Each pleural 
membrane is a smooth elastic layer of tissue formed from a superficial layer of 
mesothelial cells and 4 discrete deeper layers of connective tissue which also 
contain nerves, blood vessels and lymphatics. [11] 
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The purpose of the pleural cavity is poorly understood; however it appears to 
reduce friction between the lung and surrounding surfaces during movement 
associated with volume changes during the respiratory cycle. Despite this 
apparent function, marked variation in the structure and function of the pleura 
is noted between mammalian species. In particular, it is noteworthy that the 
adult elephant does not possess a pleural cavity, rather the pleural space is 
replaced by loose connective tissue in late gestation which permits an adequate 
degree of movement between the lung and adjacent structures. [12] This 
anatomical situation is analogous to that seen in humans following treatment of 
MPE by pleurodesis where the pleural cavity is obliterated without apparent 
functional deficit. 
Under normal physiological circumstances, a small volume of pleural fluid, 
typically around 12mL in adults, [13] is maintained within each pleural cavity 
under slightly sub-atmospheric pressure (-3 to -5 cm H2O) due to the elastic 
recoil forces of the surrounding lung and chest wall. This is produced from 
micro-vessel filtration of the systemic circulation, predominately within the 
parietal pleura, which follows a pressure gradient into the pleural cavity. Fluid is 
removed from the space via bulk flow into lymphatic channels which 
communicate with the parietal pleura through a network of lymphatic stomata. 
The flow rate of these lymphatic vessels has been shown to increase up to 20-
fold in response to increased pleural fluid production thereby facilitating an 
equilibrium between pleural fluid production and removal. [14] In health, this 
maintains a near static pleural fluid volume however the wide surface area of 
the pleural cavity and resting negative pressure state readily allows large 
volumes of pleural fluid to accumulate if these homeostatic mechanisms are 
disrupted. 
1.2.2.2 Pathogenesis of malignant pleural effusion 
Autopsy studies suggest the majority of pleural malignancies arise from 
haematogenous micro-embolisation of tumour cells to the visceral pleura which 
in turn leads to secondary seeding to the parietal surfaces. [15] Direct invasion 
of the pleural cavity from tumours in the lung, chest wall or diaphragm also 
occurs. The exact mechanism by which pleural tumour deposits lead to MPE 
formation are not fully understood but both enhanced production and decreased 
removal of pleural fluid are likely to be implicated. [16] It is speculated that 
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greater pleural permeability and inflammation associated with pleural tumour 
may give rise to greater pleural fluid production, while lymphatic disruption, 
either at parietal pleural stomata or the level of distant mediastinal lymph 
nodes, impairs fluid removal. [16,17] 
1.2.3 Breathlessness in malignant pleural effusion 
Breathlessness in MPE is multifactorial and also not fully understood, however 
reduction in respiratory, and particularly diaphragmatic, muscle function 
appears to be the single most significant pathophysiological contributor to the 
development of dyspnoea. [18] As pleural fluid accumulates, expansion of the 
thoracic cage takes precedence over compression of the underlying lung 
parenchyma to accommodate the additional volume. The resulting outward 
movement of the chest wall and, most significantly, downwards displacement of 
the dome of the diaphragm causes a reduction in diaphragm muscle fibre length 
which in turn reduces its mechanical efficiency (see Figure 1.1). Greater neural 
drive is therefore required to achieve an equivalent degree of ventilation which 
is detected by mechanoreceptors throughout the respiratory system. The 
discordance in this situation between efferent respiratory muscle stimulation 
and afferent ventilatory feedback to the sensorimotor cortex (termed 
‘neuromechanical uncoupling’) is thought to contribute significantly to the 
sensation of dyspnoea. [19] Removal of pleural fluid restores a normal chest wall 
and diaphragmatic conformation thus abolishing this effect even in the presence 
of significant NEL. 
1.2.4 Underlying tumour types causing malignant pleural effusion 
MPE may arise from a wide variety of tumour types. The relative prevalence of 
each depends on the population studied, largely due to regional variation in 
occupational asbestos exposure and therefore number of patients affected by 
malignant pleural mesothelioma (MPM). However, secondary pleural malignancy 
arising from carcinoma of the lung is by far the commonest cause of MPE. This is 
typically followed by metastatic breast cancer and then MPM. Gynaecological, 
renal, gastrointestinal and haematological metastases account for the bulk of 




Figure 1.1 T1-weighted coronal image of a patient with a large malignant pleural 
effusion and inverted left hemi-diaphragm, taken post-contrast using a 3T 
Siemens Magnetom PRISMA® MR scanner at the Glasgow Clinical Research 
Imaging Facility, QEUH 
 
Reproduced with the permission of Dr Selina Tsim. 
 
1.2.5 Prognosis in malignant pleural effusion 
Although MPE represents incurable disease, the prognosis it confers is highly 
variable and an essential consideration when planning palliative interventions. 
Underlying tumour type is well recognised as a key determinant of survival. By 
way of illustration, median overall survival in a large contemporary MPE cohort 
was 136 days but varied between only 43 days in metastatic melanoma, 74 days 
in lung cancer and 339 days in mesothelioma. [20] Since there is a widely 
differing time commitment associated with the range of palliative interventions 
now available, prognostication in MPE has an increasing importance in framing 




Figure 1.7 T1-weighted axial (Panel A) and coronal (Panel B) fat-saturated VIBE 
images of two patients with Malignant Pleural Mesothelioma, taken post-contrast 
using a 3T Siemens Magnetom Verio® MR scanner at the BHF Glasgow 
Cardiovascular Imaging Facility (Panel A) and a 3T Siemens Magnetom PRISMA® 
MR scanner at the Glasgow Clinical Research Imaging Facility, QEUH (Panel B). 
Panel A demonstrates enhancing pleural tumour and Panel B demonstrates 
nodular pleural thickening with chest wall invasion 
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A range of MPE prognostic markers have been explored. Clive et al examined 14 
potential variables in an international pooled cohort of unselected patients with 
MPE. This led to the development and subsequent external validation of the 
readily deployable ‘LENT score’ which is shown in Table 1.1. [1] More recently, 
Psallidas et al reported alternative prognostic scores derived from 25 potential 
clinical, radiographic and laboratory biomarkers; the ‘biological’ and ‘clinical’ 
PROMISE scores (see tables 1.2 (scoring system) and 1.3 (corresponding risk 
categories)). [21] Calculation of the biological score is impractical for routine 
clinic practice as it requires measurement of pleural fluid TIMP1 (tissue inhibitor 
of metalloproteinases 1) concentration. However, the more accessible clinical 
score also outperformed LENT in predicting 3-month mortality in an external 
validation cohort (PROMISE C-statistic 0.89 (95% CI 0·84-0·93) vs 0.75 (95% CI 
0·68–0·81) for LENT). [21]  
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Table 1.1 The LENT prognostic score 
 Variable Score 























T Tumour type 
Low risk 
• Mesothelioma 
• Haematological malignancy 
Intermediate risk 
• Breast cancer 
• Gynaecological cancer 
• Renal cell cancer 
High risk 
• Lung cancer 










LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Group; NLR, 




Table 1.2 The clinical and biological PROMISE prognostic scores 


















































































































Table 1.3 PROMISE score risk categories 
Total points Category Risk of death at 3 
months Clinical score Biological score 
0 – 20 0 – 20 A <25% 
21 – 27 21 - 28 B 25-50% 
28 - 35 29 – 36 C 50%-75% 




1.3 Malignant pleural effusion treatment options 
Percutaneous removal of pleural fluid is the mainstay of symptomatic MPE 
management. Large volume thoracentesis, intercostal drainage and chemical 
pleurodesis, and IPC insertion are widely practised. Pleurodesis is typically 
performed via an intercostal chest drain (ICD) but may also be delivered during 
thoracoscopy either under sedation (local anaesthetic thoracoscopy, LAT) or 
general anaesthetic and single lung ventilation (Video Assisted Thoracoscopic 
Surgery, VATS). Historically, open drainage followed by surgical pleurectomy or 
pleural abrasion was also advocated for MPE control but is no longer performed 
outside trial settings. Each drainage method is described here in further detail. 
1.3.1 Thoracentesis 
Large volume thoracentesis is typically the first intervention offered to patients 
presenting with symptomatic suspected pleural malignancy. The procedure can 
be performed as a day case in ambulant patients, thus providing efficient early 
symptom relief and access to pleural fluid for cytological examination. In 
addition, post-thoracentesis radiography may occasionally reveal underlying NEL 
through the finding of a ‘pneumothorax ex vacuo’; this concept and its 
significant limitations are discussed further in section 1.5.2 (page 48).  
In the minority of patients in whom an underlying highly chemotherapy-sensitive 
malignant aetiology is identified (such as lymphoma or small cell lung cancer) 
early systemic treatment may obviate a requirement for further pleural 
intervention. [22,23] However, the majority of patients with MPE experience 
fluid re-accumulation and therefore an early definitive pleural intervention is 
recommended once histocytological confirmation (where appropriate) is 
completed. [4] In those patients with symptomatic MPE and a particularly poor 
prognosis (< 1 month), ‘as required’ large volume thoracentesis is a useful 
palliative option. [4] 
1.3.2 Pleurodesis 
Pleurodesis refers to the fusion of visceral and parietal pleura in order to 
obliterate the pleural cavity. When successfully executed, pleural fluid cannot 
reaccumulate and long-term symptom control may be achieved. Pleurodesis is 
typically achieved through the delivery of a sclerosing agent directly into the 
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pleural space after complete pleural drainage. As previously described, 
adequate lung re-expansion, and therefore pleural contact, is a prerequisite for 
success. The efficacy of a wide range of compounds for this purpose has been 
explored. Although significant study-design heterogeneity has limited direct 
comparisons, sterile graded talc is typically regarded as the pleurodesis agent of 
choice, with success rates of 70% - 100% reported in the literature. [4,5,24]  
1.3.3 Method of talc delivery 
1.3.3.1 Poudrage vs slurry 
Intra-pleural talc may be administered either mixed with a sterile liquid (talc 
slurry), or insufflated as a dry powder during thoracoscopy (talc poudrage). 
While the former is widely available and relatively cheap to perform, historical 
data suggested the additional resources required for thoracoscopic management 
may be justifiable due to a shorter length of stay and greater pleurodesis 
success rates. [25] However, subsequent comparative trials have not supported 
this assertion. In a randomised trial of 482 patients, Dresler et al found no 
significant difference between slurry and poudrage in terms of radiological 
pleurodesis success at 30 days, although talc poudrage was associated with a 
higher rate of respiratory complications. [5] However, a post-hoc sub-group 
analysis revealed greater success with poudrage in those patients with primary 
lung or breast cancer compared with other underlying tumour types (82% vs 
67%), thus generating further hypotheses. This study also had to be interpreted 
in light of the fact that poudrage treatment was delivered in a surgical setting 
with general anaesthesia and single-lung ventilation, and that ungraded talc was 
used. These factors are likely to have contributed to the complication rates 
reported and therefore talc poudrage delivered at physician-led LAT under 
conscious sedation with graded talc may be a more attractive therapeutic 
option. This question has subsequently been addressed directly in the recently 
published TAPPS trial, a UK multicentre RCT in which 330 patients were 
allocated to talc poudrage at LAT (n=166) or talc slurry pleurodesis (TSP, n=164). 
[26] Graded European talc was used in all cases. The primary outcome was 
pleurodesis failure within 90 days defined clinically as a requirement for repeat 
pleural intervention. No significant difference was observed between the groups; 
poudrage 22% vs TSP 24%, adjusted odds ratio 0.91 (95% CI 0.54-1.55, p=0.74). 
Additionally, there was no statistically significant difference in length of hospital 
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stay within 90 days between poudrage and TSP groups. It is therefore hard to 
justify purely therapeutic LAT in current clinical practice given the significant 
resource implications, although talc poudrage delivered at diagnostic LAT 
remains an efficient strategy in patients with macroscopic pleural tumour.  
1.3.3.2 Chest drain size 
The optimal size of intercostal chest drain (ICD) to deliver talc slurry is 
uncertain. Current British Thoracic Society (BTS) guidelines (under revision in 
2019/20) recommend the use of small bore (10-14Fr) intercostal drains as trial 
evidence suggests equivalent pleurodesis success rates with these (based on 
radiologically-defined end points) and less pain compared with the use of large 
bore (24-32Fr) ‘surgical’ chest drains. [4] However, in the subsequently 
published TIME1 randomised controlled trial (RCT), small bore (12Fr) ICDs were 
associated with a higher rate of pleurodesis failure (30% vs 24%) than large bore 
(24Fr) ICDs, thus failing to meet non-inferiority criteria (difference, −6%; 1-sided 
95% CI, −20% to ∞;  p=0.14 for non-inferiority which was pre-specified at -15%). 
[27] Pleurodesis failure was robustly defined by the need for repeat pleural 
intervention for symptomatic MPE recurrence within 3 months. Additionally, a 
higher procedural complication rate was seen in those patients undergoing small 
bore ICD insertion (24% vs 14%, hazard ratio (HR) 1.9) although this increased 
rate was not statistically significant (p=0.20). [27] It is speculated that this 
signal may reflect a genuine increase in clinical risk due to the ‘blind’ nature of 
the Seldinger insertion technique used. These findings have yet to be 
independently reproduced. 
1.3.4 Pleurectomy 
Open pleurectomy has been historically described as a definitive treatment for 
symptomatic MPE but is associated with high complication and hospitalisation 
rates when compared to talc pleurodesis. [4] More recently, based on 
encouraging observational data and a speculative cyto-reductive survival 
benefit, partial pleurectomy delivered at minimally invasive video assisted 
thoracoscopic surgery (VATS-PP) was investigated as an alternative to ICD 
insertion and TSP for patients with symptomatic MPE secondary to MPM. [28] 
Despite these potential theoretical advantages, the investigators found no 
survival advantage associated with VATS-PP over TSP (median overall survival 
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13.1 months vs 13.5 months). Moreover, VATS-PP was associated with a longer 
hospital stay (median 7 days vs 3 days) and 31% in the VATS-PP group 
experienced a procedure-related complication in contrast to only 14% of those 
undergoing TSP. As such, pleurectomy is not recommended in routine clinical 
practice for any patients with symptomatic MPE. [4] However, it is hypothesised 
that VATS partial pleurectomy/decortication (VATS-PD) may be a useful 
treatment for those patients with underlying NEL since surgical removal of 
tumour rind may allow lung re-expansion. A pilot RCT (Meso-TRAP) comparing 
VATS-PD with IPC-based management of symptomatic MPE in patients with MPM 
and NEL is currently recruiting. [29]  
1.3.5 Indwelling pleural catheters 
IPCs are flexible tunnelled chest drains which facilitate regular domiciliary 
pleural drainage. IPCs may be inserted during a day case local anaesthetic 
procedure using a Seldinger technique. During insertion, IPCs are passed 
subcutaneously for approximately 50mm from a pleural entry site to an exit 
point on the lateral chest wall. They are formed from soft silicon tubing with a 
distal one-way valve. A Dacron cuff sited within the subcutaneous tract 
promotes the formation of fibrous tissue to secure the drain and minimise the 
risk of ascending infection. In the last decade, the wider availability of IPCs have 
led to a paradigm-shift in the management of patients with recurrent MPE where 
TSP has failed, [30] and increasingly, they facilitate first-line definitive fluid 
control within an ambulatory pathway. [31] 
1.3.5.1 IPC drainage schedules and autopleurodesis 
The principle aim of IPC drainage is to control fluid accumulation and therefore 
symptoms, however in a significant minority of patients, spontaneous pleural 
symphysis, termed autopleurodesis, may occur. [32] Drainage procedures are 
typically performed by community nursing teams or suitably trained patient 
relatives using disposable vacuum bottles. Varying drainage schedules are 
advocated. Aggressive daily drainage is performed in some centres based on 
evidence that such an approach is associated with a higher rate of 
autopleurodesis and therefore catheter removal. [33] In a study of 149 patients 
with MPE managed by IPC, autopleurodesis was achieved in 47% of those 
undergoing daily drainage versus only 24% in those whose IPCs were drained on 
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alternate days. [34] Conversely, some clinicians argue that less frequent 
drainage performed as required to control symptoms may reduce potential 
drainage-related complications and cost while achieving comparable relief of 
dyspnoea and improvements in quality of life. A direct comparison between daily 
drainage and ‘as required’ drainage strategies found no difference in 
breathlessness scores or complications, but confirmed a higher rate of 
autopleurodesis (37% vs 11%, hazard ratio 3·3 (95% CI 1.4–7.7)) and higher 
patient-reported quality of life scores associated with daily drainage. [35] 
1.3.5.2 IPC advantages and limitations vs TSP 
A total of 5 RCTs have now examined outcomes for patients randomised between 
IPC and TSP management of symptomatic MPE. [2,3,36-38] A subsequent meta-
analysis found no difference in overall survival or relief of breathlessness 
between these strategies. [39] However, since IPC pathways direct ambulatory 
management, they are consistently associated with significantly reduced length 
of hospital stay compared with TSP, which requires initial hospitalisation. [39] 
Economic analyses suggest IPC insertion is more cost-effective than TSP in 
patients whose survival is less than 14 weeks. [40,41] However, beyond this 
threshold, TSP is more cost-effective due to the on-going consumable costs and 
district nursing time required for IPC management. Importantly, from a patient 
perspective, regular drainage via an IPC may provide long-term relief of 
breathlessness even where underlying NEL is identified. [4]  
The advantages of IPC insertion must be balanced against a number of 
limitations, including a higher rate of clinically significant pleural infection (5-
10% over the lifetime of the catheter), [2,42] the inconvenience of indwelling 
prosthetic material which is recognised as unacceptable to a significant 
proportion of patients, [43] and the requirement for an additional invasive 
procedure to remove the catheter if/when autopleurodesis is achieved or the 
catheter is no longer functioning. It is also important to recognise that the 
requirement to schedule daily activity around several weekly drainage sessions 
may be burdensome to patients, particularly where this has to be coordinated 
with district nursing teams who may be unable to commit to narrow 
appointment windows.  
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1.3.5.3 Outpatient pleurodesis via IPC 
In some cases, outpatient pleurodesis via an IPC may combine the advantages of 
reduced hospitalisation with an improved chance of catheter removal. In the 
landmark IPC-PLUS RCT, successful talc pleurodesis at 10-weeks was reported in 
35 of 69 patients (51%) in whom intra-pleural talc slurry was instilled via IPC in 
contrast to 19 of 70 (27%) who received 0.9% saline placebo. [44] No significant 
difference in adverse events (including pleural infection), length of hospital stay 
or mortality were seen between the two groups. [44] Ambulatory pleurodesis has 
also been reported in a proof of concept study utilising a silver nitrate coated 
IPC which in future may further simplify this process and reduce the theoretical 
additional infection risk from a separate procedure to instil a sclerosing agent. 
[45]  
1.4 Summary of the current recommended approach to the 
management of symptomatic MPE  
The most recent BTS guidance dates from 2010 and was archived in 2017. 
Publication of new BTS pleural guidelines are expected in 2020. In the interim, 
evidence-based guidance from both the American Thoracic Society (ATS) and the 
European Respiratory Society (ERS) have been published. [46,47] Both ATS and 
ERS documents acknowledge the discrete advantages and limitations conferred 
by TSP and IPC drainage and accept that both approaches are equally valid in 
patients with expandable lung. Prior to delivery of a definitive intervention, the 
current ATS guideline (in common with the preceding BTS 2010 guidance) 
recommends large volume thoracentesis to assess whether symptoms are 
improved by drainage and to assess underlying lung re-expansion potential (see 
Figure 1.2). [46] In patients with apparently expansile lung, and without a 
predicted ‘very short’ survival, a discussion with the patient regarding the 
relative risks and advantages of IPC vs TSP vs combination approaches (see Table 
1.4) is recommended. [46] Thoracentesis has poor sensitivity for NEL detection 
(see Section 1.5.4.1) and therefore, in practice, a proportion of patients in 
whom an ICD is placed with a view to subsequent TSP will require subsequent 
IPC insertion to manage recurrent MPE due to radiographically occult NEL.  
The results of the recent IPC-PLUS study are likely to further increase the early 
use of IPCs once this evidence has been fully assimilated, externally validated 
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and incorporated into consensus guidance. However, it is important to recognise 
that the pleurodesis success rate reported in IPC-PLUS (51% at 10 weeks ) [48] is 
significantly inferior to that documented in RCTs involving TSP (71 – 78%). This 
can be achieved after only a short initial admission (around 3-7 days) [3,5] 
obviating the need for indwelling prosthetic material, which is undesirable for 
many patients [43] Therefore, although IPCs are a critical and important 
therapeutic option for MPE management, they should not be considered a 
panacea for all patients.  
In summary, a variety of interventions exist for the treatment of symptomatic 
MPE. These allow clinicians to tailor management to a significant degree based 
on expected prognosis and patient preferences, primarily based around TSP and 
IPC placement. However, radiographically occult NEL remains a persistent and 
unresolved confounder of truly precise deployment of these two strategies.  This 
reflects current difficulties in the early and reliable detection of NEL, resulting 
in futile admissions for TSP and a resultant requirement for repeat pleural 
procedures. The particular methods by which NEL may be assessed in current 
clinical practice and in research settings are discussed further in the following 
section.
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Table 1.4 Patient-centred considerations when choosing between IPC insertion and TSP as first-line interventions for symptomatic MPE 
 Talc pleurodesis IPC insertion Combination: IPC and 
ambulatory pleurodesis 
Advantages 
Where successful, pleurodesis 
provides lasting control of 
symptoms without need for 
indwelling prosthetic material  
 
May provide long term symptom 
control even where NEL present 
[4,46,47] 
As per IPC 
 
Additionally, significantly 
increased chance of IPC removal 
(51% at 10 weeks) [48] over IPC 
alone Lower risk of infection compared 
with IPC use [39] 
 
Can be inserted as a day case 
procedure [39] 
Disadvantages 
Requires 3-7 day hospital 
admission [3,5] 
Greater risk of infection 
compared with TSP over lifetime 
of IPC (5-10%) [2,42] 
 
As per IPC 
 
IPC-PLUS trial suggests no 
increased risk associated with 
instilling talc slurry via IPC, 
Bhatnagar:2018ce} however 
pleurodesis success rates remain 
lower than expected with 
inpatient TSP  
Fails in around 30%, [5] often due 
to underlying NEL 
Inconvenience of long-term 
indwelling prosthetic material and 
associated lifestyle restrictions 
e.g. unable to swim / bathe, 
uncomfortable in hot climates  
 
 
IPC, indwelling pleural catheter; TSP, talc pleurodesis; NEL, non-expansile lung 
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Figure 1.2 Flowchart of recommendations for the initial management of 
symptomatic known or suspected malignant pleural effusion (MPE) taken from 
American Thoracic Society 2018 guideline 
Reprinted with permission of the American Thoracic Society. Copyright © 2020 
American Thoracic Society. Feller-Kopman DJ, Reddy CB, DeCamp MM, 
Diekemper RL, Gould MK, Henry T, et al. Management of Malignant Pleural 
Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit 
Care Med. 2018 Oct 1;198(7):839–49. The American Journal of Respiratory and 
Critical Care Medicine is an official journal of the American Thoracic Society. 
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1.5 Non-expansile lung in malignant pleural effusion 
1.5.1 Nomenclature and pathophysiology 
Non-expansile lung, also referred to as ‘unexpandable lung’, is an umbrella term 
to describe incomplete re-apposition of the visceral and parietal pleura 
following drainage of a pleural effusion of any aetiology. [49] It may occur as a 
result of pleural restriction, ipsilateral endobronchial obstruction, or chronic 
atelectasis. [50] In clinical practice a spectrum of lung re-expansion is 
encountered ranging from ‘complete NEL’ to lesser degrees of NEL as shown in 













The terms ‘trapped lung’ and ‘lung entrapment’ are commonly used 
interchangeably to describe NEL. However, a different pathophysiological basis 
has been described in the literature. [49] The term trapped lung most accurately 
describes the situation in which there is an entirely fixed pleural cavity. This 
typically arises from defective healing of a pleural insult resulting in a 
constricting visceral peel. Over time, the initial active pleural inflammation may 
Figure 1.3 Chest radiographs showing varying degrees of NEL following drainage 
of MPE. Panel A shows no evidence of lateral or basal pleural re-apposition 
consistent with ‘complete NEL’. Panel B shows complete right upper lobe re-
expansion but incomplete middle and lower lobe re-expansion consistent with a 
degree of partial NEL. 
Panel A Panel B 
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resolve completely but the anatomical deficit is permanent. Classically, this 
results in an increasingly transudative pleural collection over time. [51] In 
contrast, entrapped lung describes the more common situation in which NEL is 
identified in the context of on-going active pleural inflammation that may 
potentially resolve without the development of permanent restriction. This 
distinction is particularly relevant in benign pleural disease such as 
parapneumonic effusion or haemothorax where prompt treatment with 
antibiotics and/or pleural drainage may prevent evolution to trapped lung. In 
the context of MPE however, the underlying mechanism and sub-type of NEL is 
relatively unimportant since all forms of significant NEL will render an attempt 
at inpatient TSP futile. 
1.5.2 Radiological assessment of post-drainage non-expansile lung  
1.5.2.1 Plain radiography 
NEL is typically defined based on the appearance of a post-drainage CXR using 
subjectively estimated criteria describing the proportion of lateral pleural re-
apposition. In a minority of cases, a pneumothorax (or hydro-pneumothorax) 
may be encountered. Historically, iatrogenic visceral pleural trauma was blamed 
for this finding, however point of care ultrasound guidance has reduced the rate 
of this complication from up to 18% [52] to around 1% when performed by an 
experienced operator. [53,54] This appearance is therefore most appropriately 
termed ‘pneumothorax ex-vacuo’ [4] and is thought to relate to transient 
parenychmal-pleural fistulae caused by pressure-dependent stress forces during 
aspiration when NEL is unable to conform to the shape of the thoracic cavity. 
[55] 
An assessment of lung re-expansion may take place after partial drainage at the 
time of diagnostic thoracentesis, or after an attempt at complete drainage via 
ICD prior to planned talc slurry delivery. The degree of pleural re-apposition 
required for successful pleurodesis is unknown, although expert consensus 
suggests TSP may reasonably be attempted where at least half the visceral and 
parietal pleura are re-apposed on x-ray. [4] Although readily available, this 
approach is grossly insensitive for NEL detection, particularly following partial 
drainage where pneumothorax ex-vacuo is rarely encountered. To illustrate 
further, there is a clear discordance between estimated NEL prevalence in MPE 
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(13-32%), [35,48] and post-thoracentesis pneumothorax rates (18/799 (2.3%) 
patients who underwent aspiration of >1500ml in a large prospective cohort 
study). [54] This low sensitivity for NEL detection is also illustrated by 
experience from clinical trials. For example, in the IPC-PLUS and TAPPS trials a 
significant proportion of randomised patients (13% and 7% respectively) were 
excluded from trial interventions due to inadequate lung re-expansion, despite 
lung entrapment being an explicit exclusion criterion.  [26,48] Post-thoracenetsis 
CXR appearances are therefore of limited utility in directing subsequent patient 
management. 
1.5.2.2 Cross-sectional imaging 
Use of 2-dimensional plain radiographs to estimate the total proportion of 
pleural re-apposition following pleural drainage is fundamentally limited since 
only the lateral position of the visceral pleura may be accurately delineated. 
Cross-sectional imaging using computed tomography (CT) or magnetic resonance 
imaging (MRI) allows a global assessment of pleural contact but are inherently 
unsuitable for bedside decision-making or immediate action in the OP clinic.  
1.5.2.3 Thoracic ultrasound 
The use of bedside thoracic ultrasound (TUS) is now ubiquitous in the practice of 
pleural medicine. [56] It is commonly employed to assess effusion size and guide 
decision making and site-selection for pleural procedures. There is also some 
evidence that post-drainage TUS appearances may predict subsequent TSP 
success. In a pilot study of 18 patients undergoing TSP by Corcoran et al, a 
systematic 9-point TUS was performed immediately before, and 1 day after, talc 
slurry instillation. [57] At each TUS site, lung sliding artefact was assessed and 
quantified as present (0), questionable (1) or absent (2) in order to calculate an 
overall pleural adherence score. Based on 15 subjects with adequate survival, a 
post-talc pleural adherence score of ³ 10 predicted subsequent TSP success 
(radiological recurrence and requirement for repeat pleural intervention) at 1-
month follow-up with a sensitivity of 82% at 92% specificity. [57]  
Although not explicitly devised to detect or describe NEL, the multi-site TUS 
exam reported above may also have utility in predicting TSP success in cases 
with incomplete lung re-expansion. However, the generalisability of this 
approach may be limited since the sonographic appearances of pneumothorax 
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ex-vacuo may be readily confused with lung sliding by less experienced 
operators. The use of a pleural adherence score to direct the management of 
patients undergoing TSP (specifically the timing of talc instillation and timing of 
post-talc ICD removal) is now under prospective evaluation an in appropriately 
powered multicentre RCT (SIMPLE). [58] The results of this study are likely to 
significantly enhance our understanding of the utility of TUS in defining NEL 
following MPE drainage. This concept is also being explored in the OPTIMUM 
study, where a multimodal assessment (CXR, TUS and PEL) of lung re-expansion 
following IPC drainage is undertaken prior to delivery of ambulatory intrapleural 
talc in patients with adequate pleural apposition. [59]  
1.5.3 Prevalence of non-expansile lung 
The true prevalence of NEL is difficult to ascertain since different definitions 
have been used in previous MPE studies, and the frequency of NEL is not 
reported at all in some. In most studies, NEL is defined based on post-drainage 
radiographic appearances. In the Phase III Intergroup RCT by Dresler et al, in 
which TSP and VATS talc poudrage were compared, NEL was defined as <90% 
lung expansion using subjective visual estimation of CXR appearances (TSP arm) 
or thoracoscopic appearances (VATS arm), and occurred in 30% of participants. 
[5] In a more recent observational MPE study of 70 patients with MPE (only 27% 
due to lung cancer), NEL was reported in 54% of patients using the same 
radiographic criterion. [60] In the AMPLE-2 trial, which compared alternative IPC 
drainage strategies, NEL was defined more grossly as air or fluid in the pleural 
space occupying 25% or more of the lateral chest wall after initial drainage. 
However, it was still a common finding, occurring in 32% of participants. [35]  
The IPC-PLUS investigators reported additional details on the proportion of 
patients affected by NEL since differing degrees of lung re-expansion at 
different time points were used to a) determine eligibility for enrolment, b) 
minimise imbalance between the study arms, and c) determine eligibility for 
randomisation and completion of the trial interventions (i.e. instillation of talc 
slurry or placebo). In this trial, 41/923 screened patients (4%) were immediately 
excluded on the basis of obvious lung entrapment. Of 250 enrolled patients, 32 
(13%) had “substantial” lung entrapment, defined as less than 75% pleural re-
apposition on CXR, or more than one third pleural opacification due to fluid 
(based on thoracic ultrasound), following attempted pleural drainage. These 
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patients were excluded from randomisation. Of the 154 who were randomised, 
30/154 (19%) subsequently had incomplete re-expansion (< 25% lung 
entrapment). [44]  
1.5.4 Pre-drainage identification of underlying non-expansile lung 
Detection of NEL prior to complete pleural drainage is challenging but highly 
desirable since this information could effectively be used to stratify the MPE 
pathway. In current practice, a subjective judgment on the likelihood of 
subsequent NEL is typically made by integrating pre-drainage CT predictors (e.g. 
overt proximal endobronchial obstruction, visceral pleural peel) and, where 
performed, the appearance of the visceral surface at LAT. However, such 
judgements are frequently inaccurate, prompting research interest in 
alternative pre-drainage markers of NEL such as M(motion)-mode and Speckle-
tracking US and pleural manometry. The diagnostic performance of each 
technique is reviewed in the following sections.  
1.5.4.1 CT appearances 
Underlying NEL is often inferred from pre-drainage CT appearances where overt 
endobronchial obstruction or visceral pleural thickening are seen. The latter is 
not easily distinguished from pleural fluid or atelectatic lung unless air is 
intentionally introduced into the pleural space at the time of thoracentesis to 
provide ‘air-contrast’ imaging. [61] This technique has only been described in 
patients who developed symptoms consistent with NEL (chest discomfort and 
cough) during thoracentesis and therefore its safety and diagnostic performance 
in a generalised MPE population is unknown. To date, no studies have assessed 
the ability of pre-drainage CT to predict subsequent lung re-expansion or 
pleurodesis success.  
1.5.4.2 Thoracoscopic appearances 
A small proportion of patients with MPE undergo surgical thoracoscopy under 
general anaesthesia (GA). In this situation, the degree to which the affected 
lung can re-expand on removal of pleural fluid can be visually assessed. During 
GA surgical thoracoscopy, this is done by controlled application of positive 
pressure ventilation via a dual lumen endotracheal tube and direct visualisation 
by the surgeon. The most appropriate definitive management strategy (TSP vs. 
IPC) can then be implemented during the same procedure. In a series of 127 
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patients, Qureshi et al detected NEL in 52/127 cases using this technique, and 
reported an improvement in symptoms (after 2-weeks) in 49/52 cases (94%). [62] 
However, GA thoracoscopy carries additional risks and is unsuitable for the 
majority of patients with MPE, particularly those with poor performance status. 
The procedure also clearly requires referral to a tertiary thoracic surgery centre. 
The visceral pleural surface can also be visualised during LAT in a spontaneously 
breathing patient. Although a single centres study reported by Ip et al reported 
modest success in predicting subsequent NEL (40/50 (80%) patients with NEL 
received an IPC; 34/53 (64%) patients with expandable lung received a ICD), this 
performance remains unacceptably error-prone. [63] In an earlier multi-centre 
survey based on video clips of LAT appearances, Hallifax et al reported even 
poorer performance with NEL correctly predicted in only 13% [64] These findings 
are consistent with unpublished audit data from the Glasgow Pleural Disease 
Unit which report correct identification of NEL at LAT in only 30% of patients 
[Personal communication: Prof Kevin Blyth, Glasgow Pleural Disease Unit]. 
1.5.4.3 Ultrasonography 
As previously discussed, point of care TUS is a cornerstone in the practice of 
pleural medicine. Use of this imaging modality to non-invasively detect NEL prior 
to attempting MPE drainage is therefore an appealing proposition. An alternative 
approach to early NEL detection has been described by an Australian group using 
ultrasound characteristics of underlying atelectatic lung. [65] In this work, 
Salamonsen et al used m-mode and speckle tracking ultrasonography to assess 
lower lobe atelectatic lung motion and strain associated with cardiac impulse 
during a breath hold in 81 patients with suspected MPE. Using a subset of 
patients as a development cohort, the authors identified optimal cut-points for 
radiographic NEL detection of 1mm and 6% for m-mode and speckle tracking 
sonography, respectively. In the validation group, speckle tracking significantly 
outperformed m-mode sonography in the detection of NEL; sensitivity/specificity 
50%/85% (m-mode) vs 71%/85% (speckle tracking) (95% CIs not reported). 
However, this study adopted a radiographic end point and therefore evidence of 
directly attributable patient benefit is lacking. Doubt also remains over the 
generalisability of these methods, particularly regarding strain assessment using 
speckle tracking which requires specialist equipment and training. Figure 1.4 




Figure 1.4 TUS image in a pre-EDIT trial subject with MPE showing m-mode data 
acquired from a region of interest placed over the underlying atelectatic lung 
during a breath hold 
 
1.5.4.4 Pleural Manometry 
Pleural elastance (PEL) an intrinsic property of the pleural space. It is defined as 
the change in intra-pleural pressure (IPP) per unit volume of pleural fluid 
removed (DIPP/DVOUT) and can therefore be readily calculated from data 
obtained during thoracentesis if concurrent IPP measurements are taken. [66] 
Abnormally high PEL has previously been associated with the subsequent 
radiographic finding of NEL. [67] However, PEL assessment has not matured into 
routine practice due to both technical challenges that make reliable IPP 
measurement difficult and a lack of evidence that manometry use directly 
improves patient outcomes.  
Over the preceding 6 years, we have collaborated with a commercial partner 
(Rocket Medical UK (Washington, UK)) to develop of a novel. custom-built digital 
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pleural manometer (DPM) that specifically addresses many of the technical 
issues encountered in the past. This provided a unique opportunity to robustly 
reassess the clinical utility of pleural manometry in MPE management. In the 
following section, I review the evolution of pleural manometry, including the 
technical limitations previously encountered and the new DPM that was 




1.6 Pleural manometry 
1.6.1 Development of pleural manometry 
Pleural manometry is not a new technique; measurement of IPP during fluid 
aspiration was originally described in the 19th century and found clinical utility in 
the guidance of pneumothorax induction for the treatment of pulmonary 
tuberculosis in the pre-chemotherapy era. [68] Interest in the clinical utility of 
pleural pressure measurements returned in the 1980s as a potential adjunct to 
therapeutic pleural aspiration – primarily with safety in mind during large 
volume aspiration. [66] In a seminal study by Light et al, 52 patients had IPP 
measurements taken intermittently (at 200ml intervals) using an analogue (U-
shaped) water manometer during large volume aspiration. Although the data 
from this study proved to be of limited diagnostic value for NEL, this report 
proved the technical feasibility of measurement acquisition, prompting 
development of improving apparatus and the growth of a pleural manometry 
research community. 
1.6.2 Pleural manometry: technical considerations 
1.6.2.1 Water column manometry 
Simple water column manometers were first used to perform pleural 
manometry. Although cheap, it is challenging for the operator to obtain accurate 
pressure readings with these devices due to oscillation of the column during the 
respiratory cycle. Damping of the water column using a fine bore needle (22 
gauge) has been described to mitigate this, but increases the complexity and 
inconvenience of the procedure. [69] The requirement for manual recording of 
data is a further disadvantage to this analogue technique.  
1.6.2.2 Electronic transduction 
Improvised electronic systems using haemodynamic transducers, originally 
intended for central venous pressure monitoring, were the next evolution but 
added further complexity to the procedural set-up. Sterility of the aseptic field 
may also be compromised by the need to for external wiring to link the 
transducer to its display and data recording remains burdensome as display units 
are not configured to present serial IPP measurements. Within the last 8 years, a 
commercially available single-use disposable digital manometer (Compass; 
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Mirador Biomedical, Williamston, USA) has been developed. While adding cost, 
this device simplifies electronic measurement of IPP and has been validated 
against water column and improvised electronic systems. [70] However, the 
Compass system remains confounded by poor pressure-damping resulting in rapid 
oscillations that make pressure recording at any given timepoint challenging. 
1.6.2.3 Continuous intra-pleural pressure measurement 
The methods described thus far in this thesis limit the operator to intermittent 
IPP measurement. This limitation exists because pressure is measured from the 
column of water within the main lumen of the aspiration equipment. Externally 
stimulated flow (e.g pleural fluid aspiraton) through a water column 
manometer, or in proximity to an electronic transducer, will thus confound data 
recordings. For example, significant negative IPP may arise in the unmonitored 
period whilst each aliquot of fluid is removed. A proof-of-concept study to 
overcome this limitation describes continuous IPP recording using an epidural 
catheter, linked to an electronic transducer, within the lumen of an intercostal 
chest drain. This apparatus was connected to urodynamics equipment and 
allowed real-time ∆IPP/∆VOUT data, and therefore PEL, to be plotted for the first 
time. [65] However, such a complex improvised arrangement is clearly 
impractical for widespread routine clinical use, prompting development of the 
bespoke, dual lumen manometry catheter with our commercial collaborators, 
Rocket Medical UK (Washington, UK).  
1.6.3 Rocket Medical (UK) digital pleural manometer 
The Rocket digital pleural manometry (DPM) catheter is shown in Figure 1.5. It is 
the first custom-built and fully integrated system specifically designed for 
pleural manometry during pleural aspiration. It is based on an existing 
commercially available 8Fr pleural aspiration catheter with verres safety needle 
to minimise the risk of visceral injury during insertion. An additional external 
“cuff” surrounds the base of the catheter. This incorporates a narrow second 
lumen allowing the electronic transducer to communicate with the pleural cavity 
independently of the fluid drainage channel and record spatially damped IPP 
once per second. During use, this disposable catheter is connected to a re-usable 
display unit which displays real-time IPP data as a rolling average of the 
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recorded IPP data over the preceding 5 seconds. Visual and audible warnings are 
given as increasingly negative IPP is reached. 
 
 
Figure 1.5 Rocket DPM catheter and display unit 
Copyright © Rocket Medical (UK) 
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1.6.4 Patterns of intra-pleural pressure change during thoracentesis and 
implication for diagnostic criteria for NEL 
Observational studies prior to development of the Rocket DPM have allowed 
recognition of three patterns of IPP change during fluid removal, which appear 
to correlate with distant biomechanical phenotypes (‘expandable’, ‘entrapped’ 
and ‘trapped’, see Figure 1.6 overleaf). [66,69,71,72] On this figure, Curve A 
represents normal pleural physiology and is associated with expandable lung. By 
contrast, Curves B, C and D all demonstrate an abnormally rapid fall in IPP 
during aspiration which is associated with NEL. In curves C and D, there is an 
early and rapid fall in IPP as fluid is removed. This pattern of pressure change is 
pathognomonic of the trapped lung sub-group of NEL in which there is a fixed 
pleural cavity. In contrast, curve B initially mirrors the behaviour of expansile 
lung until an inflection point is reached, beyond which the pleural cavity can no 
longer accommodate to volume of fluid removed. This pattern is seen in lung 
entrapment and reflects initial lung re-expansion.  
In the design of diagnostic criteria for NEL based on manometry data it is clearly 
of critical importance that curve patterns B, C and D can all be detected. This is 
because all are three biomechanical phenotypes are likely to result in TSP 
failure. The logical conclusion for this data is that optimal sensitivity for NEL will 
require a large volume of fluid to be aspirated.  In some patients with subtle 
degrees of NEL, it might ultimately maximise sensitivity to perform a near-
complete effusion aspiration procedure. However, current BTS guidelines, 
recommend that therapeutic aspiration is limited to 1.5L in a single procedure. 
[4]. This volume limit may preclude detection of all cases of biphasic NEL, and I 
hypothesise that for PEL assessment to be developed into a useful NEL biomarker 
larger aspiration volumes will be needed. This will be explored in Chapter 4 in 





Figure 1.6 Sequential intra-pleural pressure measurements in 4 subjects during 
thoracentesis plotted against aspiration volume to produce ‘pleural elastance 
curves’. Curve A represents normal pleural physiology associated with 
expandable lung. Curve B demonstrates ‘biphasic’ physiology associated with 
NEL. Curves C and D demonstrate ‘trapped lung’ which is a sub-group of NEL. 
Reprinted with permission of the American Thoracic Society. Copyright © 2018 
American Thoracic Society. From: Light RW, Jenkinson SG, Minh VD, et 
al. Observations on pleural fluid pressures as fluid is withdrawn during 
thoracentesis. Am Rev Respir Dis. 1980;121:799-804. The American Review of 
Respiratory Disease is an official journal of the American Thoracic Society. 
 






1.6.5 Risk associated with measurement of pleural elastance during a larger 
volume aspiration 
Current advice limiting therapeutic aspiration to 1.5L is based on the risk of 
iatrogenic pneumothorax or re-expansion pulmonary oedema (RPO). Of these 
events, RPO is the more significant, having a reported mortality rate of up to 
20%. [73] However, a recently published prospective series of 9320 procedures 
(performed without pleural manometry) confirm a low absolute risk of RPO but 
progressive probability of precipitating RPO as larger fluid volumes are removed. 
An incidence of 4/8486 (0.05%) was reported where 1-1500ml were aspirated 
compared with 6/799 (0.75%) for volumes greater than 1500ml (p<0.0001). [54]  
The exact pathophysiology of RPO is not fully understood but evidence from 
animal models shows an association between increasingly negative IPP and the 
development of pulmonary oedema.  In one study, rabbits with pneumothorax 
were exposed to an IPP of -20 mmHg (approximately -27 cm H2O) with minimal 
risk of pulmonary oedema compared with a significant risk when a pressure of -
40mmHg (approximately -54 cm H2O) was applied. [74] This led Light et al, 
somewhat arbitrarily, to choose -20 cm H2O as a cut-off point to terminate 
therapeutic thoracentesis in their seminal manometry work in which none of the 
52 participants developed RPO despite aspiration volumes of up to 3400ml. [66] 
In a larger series using the same IPP threshold, Feller-Kopman et al identified 
only one case of clinically apparent RPO in 185 patients undergoing therapeutic 
thoracentesis with a mean aspiration volume of 1670ml (range 1 - 6.5L, SD 
760ml). [75]  
In contrast to RPO, it was initially thought that iatrogenic pneumothorax was not 
prevented by IPP monitoring. In an observational cohort study of 192 subjects 
undergoing large volume thoracentesis with concurrent pleural manometry, 8 
developed an unintentional pneumothorax of which only 4 had evidence of 
abnormal PEL. [55] However, a subsequent RCT involving 124 participants who 
underwent therapeutic thoracentesis, with or without additional manometry-
directed stop criteria, identified only 6 cases of pneumothorax ex-vacuo, none 
of which were in the manometry arm (p=0.012). [76] 
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The consequences of pneumothorax in this situation also appear far less severe 
than RPO; they are typically asymptomatic and do not require further 
intervention. [76] These data support the use of larger aspiration volumes to 
enhance the diagnostic potential of PEL in the detection of NEL.  
1.6.6 Development of chest discomfort during pleural aspiration and 
relationship to pleural manometry 
A relationship between negative IPP and chest discomfort during thoracentesis 
has previously been reported. [61,77] In an observational study of 169 patients 
by Feller-Kopman et al, the mean IPP measured at the end of thoracentesis was 
-6.7 cm H2O in those without discomfort vs -13 cm H2O for those with discomfort 
(p=0.04). [77] Additionally, the mean change in IPP for those without discomfort 
was -12.4 cm H2O vs -20 cm H2O for those with discomfort (p=0.001). There was 
also a trend towards higher PEL in patients who experienced chest discomfort, 
but this association did not reach statistical significance. [77] These findings 
were supported by another observational study in which it was noted that in 
patients with post-thoracentesis discomfort, the iatrogenic reintroduction of 
intrapleural air, which was assumed to thereby increase IPP, frequently led to 
immediate relief of symptoms. [61] The authors termed this intervention 
‘therapeutic pneumothorax’.  
However, previous studies also identify important inconsistencies between 
negative IPP and the occurrence of chest discomfort. In their study, Feller-
Kopman et al identified a number of discordant findings; e.g. only 4/18 (22%) 
who experienced discomfort had excessively negative IPP, and 12/140 (9%) 
without symptoms had IPP < -20cm H2O. [77] These findings suggest that 
individual tolerance of negative IPP varies widely and it has been hypothesized 
that this may, in part, relate to regional variations in PEL and therefore 
variability in areas of visceral pleural stress. [55] 
The hypothesis that avoidance of excessively negative IPP during thoracentesis 
might reduce the likelihood of chest discomfort developing was prospectively 
tested in a rigorously conducted single-blind RCT recently reported by Lentz et 
al. [76] In this study, patients with symptomatic MPE were randomised to either 
a standard symptom-guided thoracentesis (terminated if chest discomfort or 
intractable cough developed) or a symptoms plus manometry-directed 
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thoracentesis (terminated by symptoms, or end-expiratory IPP £ –20 cm H2O, or 
IPP declined by more than 10 cm H2O between two measurements to a value less 
than or equal to –10 cm H2O). No difference in chest pain scores from the start 
of the procedure to 5 minutes post-procedure were seen between the groups. 
The previously described individual variation in negative IPP tolerance may 
account for this negative result. Another explanation proposed by the authors is 
that the use of intermittent IPP (using the in-line Compass system described in 
Section 1.6.2.2) rather than continuous IPP monitoring may have limited the 
ability of pleural manometry to detect significant falls in IPP prior to transient 
pleuro-parenchymal fistulation occurring. Nevertheless, this important negative 
study does not support use of intermittent IPP monitoring using the Compass 
system as a means of reducing chest discomfort. However Lentz et al do 
acknowledge that manometry may still have utility in the detection of NEL and 
the prediction of pleurodesis success, since these questions were not addressed 
in their study.   
1.6.7 Pleural elastance as a predictive biomarker of non-expansile lung 
To date, only one study has sought to prospectively evaluate the predictive 
value of PEL for the presence of NEL and subsequent pleurodesis success. Lan and 
colleagues found that PEL ³ 19 cm H2O/L measured during the initial 500ml of a 
therapeutic thoracentesis predicted NEL with a moderate sensitivity of 79% at 
94% specificity. Using the same cut-off, there were no patients with an elevated 
PEL who had successful pleurodesis compared with 98% success in the lower PEL 
group. [67] The relatively small aspiration volume used in this study to calculate 
PEL is probably the principle explanation that sensitivity for NEL was only 79%. 
Aspiration of only 500 ml fluid is unlikely to identify biphasic biomechanics due 
to entrapped lung (as discussed earlier in Section 1.6.4).  
Subsequent to the Lan et al study, the upper limit of normal PEL was established 
as 14.5 cm H2O/L, based on theoretical modelling and subsequent clinical 
validation in a series of 192 patients. [55] Using this lower cut-point, Chopra et 
al recently identified abnormal PEL in 36/70 (51%) patients undergoing large 
volume thoracentesis for MPE. [60] In this cohort, abnormal PEL was strongly 
associated with radiographic NEL (defined here as <90% expansion), although a 
number of discordant results were observed, which translate again into 
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insufficient sensitivity and specificity. 9/36 (25%) patients in this study who had 
abnormal PEL were considered false positives (low specificity) since they 
demonstrated complete lung re-expansion, while 11/34 (32%) patients with 
normal PEL were false negatives (low sensitivity) since they had subsequent 
radiographic NEL.  
Probable reasons for this poor performance include use of the in-line Compass 
system which only allows intermittent IPP recording and is poorly damped, 
making consistent recording at any single timepoint difficult. Other possibilities 
include loss of specificity due to the lower PEL cut-point used (≥14.5 cm H2O/L), 
or transient drops in IPP due to incomplete expansion that then resolves (likely 
subsegmental areas of atelectasis that take more than a few seconds to open 
up). Loss of sensitivity may have reflected early termination of the procedure 
for other reasons, e.g. chest pain due to pleural irritation from the catheter tip, 
or transient pressure dependent pleural-parenchymal fistulation may have led to 
paradoxical normalisation of PEL. The development of PEL into a clinical useful 
biomarker for NEL must learn from these data, and should also relate PEL values 





1.7 Validation of the definition of pleural elastance 
As described earlier, PEL is an intrinsic property of the pleural space, but it is 
defined as the change in intra-pleural pressure (IPP) per unit volume of pleural 
fluid removed (DIPP/VOUT). This definition therefore incorporates an assumption 
that the volume of pleural fluid removed is exactly equal to the volumetric 
change of the pleural space. However, this assumption and thereby the current 
definition of PEL have never been objectively validated.  
This is particularly important, since as already outlined, DIPP correlates with the 
development of chest discomfort, but PEL does not, [77] the assumption that the 
volume of fluid removed accurately represents the internal change in volume of 
the pleural cavity may be incorrect. Variable compliance of the lung, chest wall 
and diaphragm, and the potential for introduction of liquids (local anaesthetic, 
pleural fluid or blood) and air, either through instrumentation or clinically occult 
transient parenchymal-pleural fistulae, may account for this discrepancy.  
Pre- and post-thoracentesis volumetric MRI would provide gold standard 
measurements of internal pleural cavity volume change (DVMRI) without undue 
risk or inconvenience to study participants. This approach is supported by the 
experience from the recently completed DIAPHRAGM multicentre blood 
biomarker study, in which a well-tolerated pleural MRI sub-study was undertaken 
in a range of patients with varying sizes of pleural effusion. [78] DVMRI data can 
then be compared to corresponding aspiration volumes (VOUT) to assess the level 
of agreement, and in turn, the validity of the conventional definition of PEL. 
Basic MRI theory is briefly reviewed in the sections below, followed by a 
summary of the evidence supporting the use of this technique as a gold standard 
for intrathoracic volume assessment.  
1.7.1 Basic MRI theory 
1.7.1.1 Nuclear magnetic resonance 
Magnetic resonance imaging (MRI) utilises the nuclear magnetic properties of 
Hydrogen atoms within body tissues when exposed to magnetic fields of varying 
field strengths. Hydrogen atoms are abundant in body tissues (particularly fluids 
and adipose compartments) and comprise a central nucleus formed from a single 
proton, orbited by a single electron. However, for the purposes of MRI the 
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electron is considered redundant and the proton the focus of attention. All 
protons possess an inherent quantum property known as ‘spin’ which generates a 
magnetic field around each proton. The orientation of each protons’ spin axis is 
random. However, if a strong magnetic field is applied (termed B0), protons 
align with the direction of B0, either in a stable parallel (low energy) state, or an 
unstable anti-parallel (high energy) state. In addition, the protons ‘precess’ 
which means that their spin vector rotates around the direction of B0. The 
angular frequency of their precession (termed the Larmour frequency) is 
determined by the magnetic field strength and the gyromagnetic ratio, a 
constant for any given nucleus (42.57 MHz/Tesla for a single proton). Since the 
majority of protons align parallel to B0, the sum of each proton’s magnetic field 
forms a net longitudinal magnetisation in the direction of B0.  
1.7.1.2 Radiofrequency excitation 
During MRI scanning, an excitatory radiofrequency (RF) pulse is applied to the 
body. The protons with the same precessional frequency as the RF pulse 
frequency ‘flip’ into a higher energy state and, importantly, start to precess in 
phase with each other. The net effect is that the sum of the nuclear magnetic 
spins rotates into the transverse plane and is thus detectable since it is no 
longer dwarfed by the strong B0 longitudinal field. The degree to which the net 
magnetisation rotates is termed the flip angle and determined by the amplitude 
and duration of the RF pulse.  
1.7.1.3 Relaxation 
When the RF pulse is removed, protons lose the energy previously absorbed and 
relax into their original state. In doing so, RF energy is released which is 
detectable by receiver coils placed around the scanning subject. The detected 
returning RF pulse is termed a magnetic resonance (MR) signal.  
There are two independent forms of proton relaxation; T1, the recovery of 
longitudinal net magnetisation, and T2, the decay of transverse magnetisation 
due to the loss of in-phase precession. The rate of T1 and T2 relaxation of 
individual protons varies depending on the composition of the tissue in which 
they are located and is an important determinate of tissue contrast. MRI 
scanners can be manipulated to produce images weighted towards T1 or T2 
contrast.  
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1.7.1.4 Construction and appearance of magnetic resonance images 
In addition to a main electromagnet (to generate B0), MRI scanners contain 
weaker gradient coils which augment B0 and create a graded magnetic field in 
axial, coronal and sagittal planes. By creating a graded longitudinal magnetic 
field during the excitatory RF pulse, MR signals may be isolated to an individual 
slice in which the proton precessional frequency is known to match that of the 
RF pulse applied. This is termed a ‘slice encoding gradient’. Additional 
‘frequency encoding’ and ‘phase encoding’ gradients applied during MR signal 
measurement allow three-dimensional localisation of the MR signals. The raw 
analogue MR signals are digitised and deposited into ‘K-space’ prior to the 
construction of an MR image which takes place via a computer process known as 
Fourier Transformation.  
In the final MR images, areas of free water (e.g. pleural fluid) appear dark on 
T1-weighted images (see Figure 1.7) in contrast to fat which has a fast T1 
relaxation and therefore appears bright. From a pleural perspective, T1-
weighted images are therefore considered ideal for delineating anatomy and 
demonstrate excellent contrast between abnormalities in the pleural space and 
extrapleural fat. [79] On T2-weighted imaging, free fluid appears bright in 
contrast to lung and muscle (see Figure 1.8). T2 images therefore clearly 





Figure 1.7 T1-weighted axial image of a patient with a right pleural effusion 
(indicated by arrows), taken post-contrast using a 3T Siemens Magnetom 
PRISMA® MR scanner at the Glasgow Clinical Research Imaging Facility, QEUH  





Figure 1.8 T2-weighted axial image of a patient with a right pleural effusion 
(indicated by arrows), taken pre-contrast using a 3T Siemens Magnetom PRISMA® 
MR scanner at the Glasgow Clinical Research Imaging Facility, QEUH  
Reproduced with the permission of Dr Selina Tsim.  
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1.7.2 Magnetic resonance imaging: a volumetric gold standard 
MRI is a well-established technique for the non-invasive volumetric assessment 
of intrathoracic structures. Cardiac MRI (CMR) volumetry in particular has been 
extensively studied. For example, left ventricular (LV) volume measurement has 
been validated against calibrated ventricular angiography (an historical gold 
standard technique), [80] and subsequently shown a high degree of inter-
observer agreement. [81] Further ex vivo validation of CMR LV volume 
assessment has also been undertaken using a canine model; in a study involving 
12 explanted hearts, the authors report a very strong correlation between ex 
vivo and CMR LV volumes (r² = 0.98), although data on agreement was not 
reported. [82] Nonetheless, CMR volume assessment has been shown to 
demonstrate an exceptionally high level of interstudy reproducibility and is 
widely regarded as the gold standard non-invasive technique for this purpose. 
[83] 
A number of comparisons may be drawn between the internal volume of the 
cardiac ventricles and the pleural cavity; both are fluid-filled free-flowing 
intrathoracic structures and subject to similar imaging artefacts and challenges. 
It is therefore reasonable to assume that MRI represents an appropriate 




1.8 Evidence Synthesis and Design of an optimised treatment pathway 
1.8.1 Importance of NEL recognition 
As discussed, NEL is a common complication of MPE management. Future routine 
use of first-line IPC insertion either with, or without, ambulatory TSP may 
overcome many of the limitations of treatment with TSP but commits all 
patients to indwelling prosthetic material with its associated risks and 
inconvenience. Early detection of NEL would facilitate patient choice of initial 
management strategy (IPC vs TSP) for those with expansile lung and, 
importantly, protect those with NEL from futile attempts at TSP. It therefore 
logically follows that an optimal MPE treatment pathway should aspire to include 
an early assessment of lung re-expansion potential.  
1.8.2 Choice of NEL biomarker 
Existing clinical techniques (CT, LAT and CXR appearances following initial 
diagnostic thoracentesis) are insensitive in the pre-drainage detection of NEL. 
While TUS techniques show promise, there is a greater body of evidence to 
support the further development of peak PEL as a NEL biomarker. Additionally, 
the recent technical advances in pleural manometry equipment (Rocket Medical 
(UK) DPM) further enhance the potential widespread and rapid uptake of this 
technique if shown to be of benefit to patients. This decision is justified further 
in Section 4.1.3 (page 132). 
1.8.3 Choice of pleural elastance threshold 
The peak PEL threshold of 19 cm H2O/L adopted by Lan et al achieved 79% 
sensitivity for NEL detection over a 500ml aspiration volume. A higher sensitivity 
would clearly be desirable in an elastance-directed pathway to minimise TSP 
failure. As described in Section 1.6.7, a larger aspiration volume may facilitate 
detection of additional cases of biphasic NEL. However the consequences of a 
near maximal drainage of fluid may then compromise the operator’s ability to 
immediately place either an ICD or IPC since there may not be sufficient residual 
pleural fluid for Seldinger drain insertion. In Chapter 4, I will report on use of a 
abnormal PEL threshold over the course of a near maximal drainage, but will use 
TUS to ensure that sufficient volume of fluid remains to allow immediate tube 
placement. In addition, I will adopt a lower PEL threshold than Lan et al, in order 
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to increase the sensitivity of the procedure to detect NEL. Since the upper limit 
of normal PEL has now been established at 14.5 cm H2O/L, [55] this is a more 
logical cut-point to explore in the pre-EDIT trial. Any reduction in PEL threshold 
will inevitably compromise specificity for NEL detection, however I will seek to 
mitigate any potential loss of specificity by use of a rolling average of PEL during 
aspiration. This will avoid misclassification of cases as NEL due to transient falls 
in IPP that may arise as a result of temporary incomplete expansion, for example 
as a result of sub-segmental areas of atelectasis which require a short period of 
time to release. Use of a rolling average would theoretically also allow detection 
of abnormal physiology in biphasic cases at the earliest opportunity thereby 
minimising the aspiration volume required, and in turn, increasing the safety and 
technical ease of subsequent pleural access. This novel choice of NEL biomarker 
is discussed further in Section 4.1.5 (page 133). 
1.8.4 Evaluation of MPE treatment success 
Historically, radiographic endpoints have been used to define MPE treatment 
‘success’, often with poor correlation to patient reported symptoms and 
unknown inter-observer reliability. Latterly however, the adoption of more 
clinically relevant patient-centred end points has resulted in better quality 
evidence on which treatment decisions may be based. [9] Standardised MPE 
intervention trial end points have not been formally established, although the 
majority of recent high quality studies in the field have used the requirement for 
repeat pleural intervention (typically at 3 months), Visual Assessment (VA) 
scores, or duration of hospitalisation, as clinically relevant means of defining 
treatment success. [2,27,84] Quality of Life (QoL) scores are also often recorded 







1.9 Overall aim and hypothesis of this thesis 
The overarching aim of the work presented in this thesis was to refine the 
management of patients with symptomatic MPE through improvements in NEL 
detection. The central hypothesis was that NEL was clinically important and that 
precise detection of NEL will enhance clinical outcomes by allowing more 
rational deployment of inpatient TSP and outpatient IPC insertion. This 
hypothesis has been addressed through:  
• A retrospective multicentre MPE cohort study to determine the 
prevalence of NEL, the reproducibility of different radiographic 
definitions of NEL and any prognostic significance of these findings. 
• A prospective assessment of the feasibility of a RCT testing a novel, PEL-
directed MPE treatment pathway called EDIT (Elastance-directed IPC or 
TSP). 
The materials and methods for these studies are detailed in Chapter 2. The 
results are presented and discussed in three individual results chapters. The 
individual hypotheses for each results chapter are summarised below. 
1.9.1 Chapter 3: ‘Post-drainage radiographic identification of non-expansile 
lung and its prognostic significance’  
NEL is currently defined arbitrarily on the basis of subjective visual assessment 
of pleural re-apposition on post-drainage CXRs leading to significant variability in 
clinical decision making. Additionally, the clinical significance of NEL in terms of 
prevalence and potential prognostic impact are uncertain. These data are 
important in the rational design and conduct of future clinical research. The 
hypotheses of this chapter were:  
• NEL is common and is under-represented in important previous MPE 
intervention studies.  
• Greater objectivity in the radiological definition of post-drainage NEL 
would improve inter-observer agreement in post-drainage NEL detection 
and therefore the consistency of clinical decision making within existing 
MPE treatment pathways. 
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• NEL may have an association with survival and therefore contribute to 
prognostic scoring systems for clinical use and minimisation of imbalance 
between study groups in RCTs. 
1.9.2 Chapter 4: ‘Feasibility of a pleural elastance directed malignant 
pleural effusion treatment pathway’  
Assessment of PEL has shown potential as a pre-drainage biomarker of NEL. This 
chapter describes the feasibility results of the pre-EDIT study; an RCT of an 
elastance-directed treatment pathway (EDIT; Elastance-directed IPC or TSP) for 
MPE in which definitive pleural management was stratified per protocol by a 
prediction of lung re-expansion potential. The hypotheses of this chapter were: 
• EDIT management is technically feasible and safe to deliver. 
• It is feasible to recruit sufficient numbers of patient to a future RCT 
testing the efficacy of a PEL-directed MPE treatment pathway based on a 
patient-centred primary outcome measure. 
1.9.3 Chapter 5: ‘Optimisation of an elastance-directed management 
pathway for malignant pleural effusion’ 
The pre-EDIT study provided an invaluable opportunity to test assumptions 
regarding the current definition of PEL and elements of the potential future EDIT 
trial design. The hypotheses tested in this chapter were: 
• An initial TUS estimate of pleural effusion volume can be used to reliably 
calculate an aspiration volume that leaves a residual effusion large 
enough for safe Seldinger drain insertion at the same sitting (where 
residual effusion volume is arbitrarily set at 500ml) 
• Pleural aspiration volume during thoracentesis (VOUT) is equal to the 
pleural cavity volume change, and thus the current definition of PEL, is 
accurate 
• An aspiration volume greater than 500ml (which was used in previous 
studies) is required to detect all cases of NEL using PEL (including those 
exhibiting biphasic biomechanical physiology) 
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• Patients with symptomatic MPE consider inpatient TSP a valuable first-line 
definitive intervention, and it is not the case that all are willing to 
undergo outpatient IPC management. 









MATERIALS AND METHODS 
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2 Chapter 2: Materials and Methods 
2.1 Overview 
The aims of this thesis have been addressed through two discrete pieces of 
clinical research. First, a two-stage retrospective analysis of patients with 
pleural effusion drained at LAT, and second, a feasibility RCT that evaluated a 
novel elastance-directed MPE management pathway (the pre-EDIT study). This 
chapter describes the design and data collection for these studies. The Chief 
Investigator for both studies was Prof Kevin Blyth, Queen Elizabeth University 
Hospital, Glasgow, UK.  
2.1.1 Retrospective LAT analysis 
This retrospective work was performed in two stages. In the first stage, two 
novel definitions of post-drainage radiographic NEL were evaluated in a single-
centre cohort study of patients undergoing LAT. A univariate analysis testing the 
association between NEL and subsequent survival in this first cohort was also 
undertaken and proved positive. In the second stage, data regarding a larger 
cohort of LAT patients was therefore was collected to facilitate a multivariable 
analysis testing the relative importance and independence of the apparent 
prognostic impact of post-LAT NEL.  The external validity of these findings were 
then assessed in an independent cohort from another UK centre.  
2.1.2 Pre-EDIT study 
Pre-EDIT was designed to assess the feasibility of a future phase III trial 
evaluating the efficacy of a novel, PEL directed MPE treatment pathway 
(Elastance-Directed Indwelling pleural catheter or Talc slurry pleurodesis; EDIT 
management). In pre-EDIT, patients were randomised to either first-line TSP 
(control group) or EDIT management, allowing both technical feasibility and 
recruitment feasibility to be assessed. Pre-EDIT also provided an invaluable 
opportunity to refine technical aspects of the proposed EDIT pathway and trial 
design.    
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2.2 Post-drainage radiographic identification of Non-expansile Lung 
and its prognostic impact – Stage 1 
A single-centre retrospective cohort study was performed at the Queen Elizabeth 
University Hospital, Glasgow (QEUH). The study was sponsored by NHS Greater 
Glasgow and Clyde. Study activities were approved by the South Central - 
Hampshire B Research Ethics Committee (Ref: 17/SC/0351). This allowed use of 
unconsented linked anonymised data by clinicians directly involved in the 
patients’ care.  
2.2.1 Patient selection 
This stage of the study included consecutive patients who underwent complete 
drainage of a pleural effusion of any aetiology at diagnostic LAT between July 
2010 and January 2015.  
2.2.2 Study objectives and associated end points 
2.2.2.1 Primary objectives and associated end points 
The co-primary objectives were to determine a) the prevalence of NEL and b) 
the reproducibility of 3 different definitions of NEL based on visual assessment 
of post-drainage CXRs. The first definition is entirely subjective and is based on 
guidance provided by the BTS regarding the minimum extent of pleural re-
apposition required to attempt pleurodesis (≥50%) The two other methods tested 
were defined by me and are therefore novel: Re-Expansion Proportion (REP) and 
Lateral Apposition Ratio (LAR). Both methods are semi-objective and their 
definition is described in detail in Section 3.1.3.2.  
The primary end points were a) simple proportions and b) Cohen’s Kappa for CXR 
classifications (NEL or expansile) made by 2 independent blinded assessors using 
each of the methods (BTS, REP and LAR). 
2.2.2.2 Secondary objective and associated end points 
The secondary objective was to determine whether NEL on post-drainage CXR 
was associated with subsequent survival. The end points used were the post-
drainage CXR classifications ((NEL present or absent) for each definition (BTS, 
REP and LAR)), and each patient’s overall survival (OS), measured from the date 
of LAT. 
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2.2.3 Study procedures 
2.2.3.1 Collection of study data 
A prospectively maintained departmental database was used to identify patients 
for inclusion. The sole inclusion criterion was the presence of a pleural effusion 
undergoing complete pleural drainage at LAT. Patients were excluded if there 
was failure to complete pleural drainage, or their age was less than 18 years, or 
greater than 100 years. This database included an expert ‘final diagnosis’ of lung 
re-expansion status judged at 3-month follow-up by the responsible Consultant 
Respiratory Physician based on all available clinical and imaging data up to that 
point. Electronic healthcare records were interrogated on 23rd May 2017 to add 
date of death, or censor, to this database.  
2.2.3.2 Radiographic Measurements 
For all patients and all measurements, pre-discharge CXRs demonstrating 
maximum lung re-expansion were selected. REP and LAR were computed 
independently by 2 experienced respiratory physicians (GAM, ACK) using the 
following methods, which are also summarised in Figure 2.1. Each was blinded to 
the LAT database and the other’s results. To avoid recall bias, analyses using 
different methods were separated by a minimum of 2 weeks. 
REP was defined using a method modified from that described by Rahman et al 
to approximate the area of radiographic pleural fluid opacification in the MIST-2 
trial of intra-pleural enzyme therapy for pleural infection. [85] In that trial, 
response to treatment was quantified by the change in hemithorax pleural 
opacity based on measurement of regions of interest on a digital CXR. REP was 
similarly defined and is effectively the opposite of the pleural opacity area (see 
Figure 2.1).  
The definition of REP (and pleural opacity area) requires the user to subjectively 
estimate the position and shape of the ipsilateral hemi-diaphragm in patients 
with any degree of pleural effusion. Since this is a significant potential source of 
inter-observer variation, LAR was devised to approximate the hemi-diaphragm 
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Figure 2.1 Method for determining the Re-Expansion Proportion and Lateral 
Apposition Ratio on digital chest radiography 
 
2.2.3.3 Classification of Radiographs as NEL or Expansile 
For classification by the BTS method, the same 2 experienced respiratory 
physicians (GAM, ACK) independently reviewed each CXR and recorded each as 
showing NEL or expansile lung, based on a simple subjective assessment of 
whether of less than ≥50% pleural re-apposition had been achieved. 
For REP and LAR, classification was based on a pre-specified statistical analysis.  
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2.2.4 Statistical analysis  
All analyses were performed in SPSS v24.0 (Chicago, USA). A p-value of less than 
0.05 was used to define statistical significance. 
2.2.4.1 Primary objectives 
REP and LAR measurements made by the primary operator (GAM) were used to 
determine the value of REP and LAR in predicting NEL (for which the reference 
standard was expert judgement at 3-month follow-up). These data were used to 
plot Receiver Operating Characteristic (ROC) curves. Optimal REP and LAR cut-
points for prediction of NEL were calculated using likelihood ratios. REP and LAR 
data were then dichotomised around the optimal cut-point for each allowing 
creation of 2x2 contingency tables for ‘expansile lung’ or ‘NEL’. A  2x2 
contingency table based on the classification made by the primary operator 
using the BTS method was also created, allowing direct comparison between the 
three definitions. Inter-observer agreement using each method was assessed 
using Cohen’s Kappa Statistic (k) to compare the classification results by all 3 
methods by the 2 operators. 
2.2.4.2 Secondary objectives 
Kaplan-Meier methodology was used to assess survival by re-expansion status for 
each approach and operator for all patients with confirmed pleural malignancy. 
Final censoring was undertaken on 3 October 2018. The log-rank test was used to 
compare differences between expansion classification.  
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2.3 Post-drainage radiographic identification of Non-expansile Lung 
and its prognostic impact – Stage 2  
In stage 2 of this retrospective study, the QEUH LAT cohort (described in Section 
3.1.1) was extended and then filtered to include only those patients with a final 
diagnosis of MPE. An external cohort from Southmead Hospital (Bristol) was also 
collated and analysed. Changes from the Stage 1 study protocol were approved 
by research ethics committee (REC) as a Substantial Amendment to the original 
study protocol (SA April 2018). Ethical approval for research activities at 
Southmead Hospital were approved by the South West – Central Bristol Research 
Ethics Committee (Ref: 08/H0102/11) as part of the Pleural Investigation Study. 
[86] 
2.3.1 Patient selection 
Prospectively maintained databases in Glasgow (Cohort 1) and Bristol (Cohort 2) 
were used to identify consecutive patients who underwent complete MPE 
drainage at diagnostic LAT between July 2010 and March 2018 (Glasgow), and 
July 2013 and July 2017 (Bristol).  
2.3.2 Study objectives and associated end points 
2.3.2.1 Primary objectives and associated end points 
The primary objectives were to determine whether NEL on post-drainage CXR is 
associated with subsequent survival in a larger cohort of patients with MPE and 
then compare any association with recognised prognostic markers in MPE. The 
associated end points were a) the CXR classification (NEL or expansile) based on 
the BTS method (since this was associated with highest Kappa value in Stage 1), 
b) the total and individual components of the LENT prognostic score, and c) OS 
from the date of LAT. 
2.3.2.2 Secondary objectives and associated end points 
The secondary objectives and associated end points are shown in Table 2.1. 
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Table 2.1 Post-drainage radiographic identification of Non-expansile Lung and its 
prognostic impact – Stage 2; secondary objectives and associated end points 
Secondary Objective Associated End Points 
To determine the inter-observer 
agreement associated with the BTS 
method of lung re-expansion 
classification 
CXR classification using BTS method 
by two independent assessors in 
Cohort 1 and two further independent 
assessors in Cohort 2 
To determine any prognostic 
association between extreme NEL (no 
lateral pleural apposition post-
drainage) and complete re-expansion 
(complete apposition) 
• Lung re-expansion classified 
into ‘extreme expansion’ 
phenotypes by subjective visual 
estimation 
• OS 
BTS, British Thoracic Society; CXR, chest radiograph; NEL, non-expansile lung; 
OS, overall survival 
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2.3.3 Study procedures 
2.3.3.1 Collection of study data 
A study database was created collating data from the 2 study centres as 
described in Section 2.3. For all patients included, the following data was 
retrospectively recorded using electronic NHS record systems:  
• Demographics (age and gender) 
• Effusion laterality 
• Tumour type  
• Mode of diagnosis   
• The components of LENT score; pleural fluid lactate dehydrogenase level 
(LDH), Eastern Cooperative Group Performance Status (PS), blood 
neutrophil to lymphocyte ratio (NLR), LENT tumour type score. LDH, PS 
and NLR were recorded from the time of diagnosis. Where any of these 
data were not available within 28 days of diagnosis, they were recorded 
as missing and the case excluded from analysis 
• OS recorded from date of diagnostic LAT to death (or censor) 
2.3.3.2 Radiographic analyses 
Post-drainage CXRs demonstrating maximal lung re-expansion pre-discharge 
were classified as NEL or expansile for all patients by 2 independent assessors in 
Cohort 1 (GAM, ACK) and a further 2 independent assessors in Cohort 2 (PH, AB) 
using the BTS method. All assessors were experienced respiratory physicians who 
routinely assess CXRs for NEL in clinical practice. An additional subjective visual 
judgment was used to classify patients into 3 groups; extreme NEL (no lateral 
pleural apposition), incomplete lateral pleural apposition, and complete re-
expansion. Those with extreme NEL and complete re-expansion were termed 
‘extreme expansion’ phenotypes.  
2.3.4 Statistical analysis  
Analyses were performed in SPSS v24.0 (Chicago, USA) and GraphPad Prism 
v8.0.2 (San Diego, USA). Patient characteristics and baseline variables were 
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tabulated by study site; differences were assessed by unpaired t-test, Mann-
Whitney or Fisher’s exact test as appropriate.  
2.3.4.1 Primary objectives 
Univariate Kaplan-Meier methodology was used to assess survival stratified by re-
expansion status for each operator. Multivariable Cox regression analysis was 
then performed to determine the hazard ratio for death associated with a) NEL, 
b) a single increment in total LENT score, and c) each component of the LENT 
score. For this purpose, a proportional hazard model was constructed after 
exclusion of any co-linearity between predictor variables. The model included 
NEL (present/absent), in addition to the individual components of the LENT 
score: LDH (as a continuous variable), NLR (continuous), PS (as a categorical 
ordinal variable, with PS 3 and 4 grouped together) and tumour type (as a 
categorical variable). Tumour types were coded according to LENT classification 
as 0 (mesothelioma or haematological malignancy), 1 (breast, gynaecological or 
renal cell carcinoma) or 2 (lung cancer or any other tumour type). These 
analyses were repeated in Cohort 2. 
2.3.4.2 Secondary objectives 
In both cohorts, Cohen’s Kappa statistic was used to describe inter-observer 
agreement for lung re-expansion classification between assessors. Univariable 
Kaplan-Meier methodology was used to assess survival stratified by ‘extreme 
expansion’ phenotypes. 
2.3.5 Data handling 
The electronic study database and CXR assessment data were stored on 
password protected NHS computers. Once CXR assessment and survival data 
were added, identifiable patient data (Community Health Index numbers) was 




2.4 Pre-EDIT: A randomised, feasibility trial of Elastance-Directed 
Intra-pleural catheter or Talc Pleurodesis (EDIT) in the 
management of symptomatic Malignant Pleural Effusion without 
obvious non-expansile lung 
2.4.1 Trial setting 
Pre-EDIT was a single centre randomised controlled feasibility trial based at the 
Pleural Disease Unit (PDU) at the QEUH. The trial was sponsored by NHS Greater 
Glasgow & Clyde. Pre-EDIT was funded by unrestricted grants from the West of 
Scotland Lung Cancer Research Group and Rocket Medical (UK). All consumables 
related to pleural manometry were provided by Rocket Medical (UK), who had no 
input into the trial design or data analysis. The trial was open to recruitment for 
a period of 55 weeks from August 2017 to September 2018. 
2.4.2 Study objectives and associated end points 
2.4.2.1 Primary objective and associated end point 
To determine whether it was possible to recruit and randomise 30 patients over 
12 months (or 15 patients in any 6-month period) between the EDIT treatment 
model and TSP (standard care control group). The end point was the recruitment 
rate over the 12-months during which the study was open. 
2.4.2.2 Secondary objectives and associated end points 
Secondary objectives and associated end points are shown in Table 2.2. 
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Table 2.2 Pre-EDIT trial secondary objectives and associated end points 
Secondary Objectives Secondary End Points 
To determine the feasibility of 
PEL computation using the novel 
Rocket Medical DPM system 
The time taken to perform the EDIT large 
volume aspiration, including measurement 
of ΔIPP using DPM, recording of ΔV and 
computation of PEL 
The failure rate of the procedure, defined 
as the proportion of patients in whom PEL 
cannot be computed 
To determine the safety and 
tolerability of PEL computation 
using the novel DPM 
The occurrence of chest pain, cough or 
breathlessness during the procedure 
Adverse Events (AEs) and Serious AEs 
(SAEs) associated with use of the DPM  
To assess the pleural fluid 
aspiration volume required to 
detect abnormal pleural 
elastance (where present) 
The pleural fluid aspiration volume at 
which the rolling average pleural 
elastance over the preceding 250ml 
(PEL250) first exceeds the upper limit of 
normal (14.5cm H2O/L)  
To determine the proportion of 
patients allocated to EDIT 
management (Group A) who 
require pneumothorax induction 
to facilitate safe ICD/IPC 
insertion following DPM 
The proportion of patients in which 
pneumothorax induction is required to 
facilitate safe ICD/IPC insertion in the 
EDIT arm (Group A) 
To test the assumption that 
pleural cavity ΔV is equivalent to 
the volume of pleural fluid 
removed during aspiration 
Pleural fluid aspiration volume (DVOUT)  
Pleural cavity volume change, as 
measured directly using volumetric MRI 
(DVMRI; defined as pre- minus post-




To test the accuracy of a 
predictive model of pleural 
effusion volume (VTUS) based on 
thoracic ultrasound (TUS) 
measurements, which is a 
proposed inclusion criterion for 
the EDIT study 
TUS estimated total pleural effusion 
volume (VTUS)  
Pre-pleural fluid aspiration pleural cavity 
volume (VMRI) 
PEL, pleural elastance; DPM, digital pleural manometry; EDIT, elastance 
directed indwelling pleural catheter or talc pleurodesis; IPP, intra-pleural 
pressure; V, pleural cavity volume; ICD, intercostal drain; IPC, indwelling 
pleural catheter; MRI, magnetic resonance imaging; TUS, thoracic ultrasound 
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2.4.3 Patient selection 
Patients with symptomatic MPE were identified at cancer multidisciplinary team 
(MDT) meetings, routine outpatient appointments, and during inpatient reviews. 
The following eligibility criteria were applied: 
2.4.3.1 Inclusion criteria 
• Clinically confident diagnosis of MPE defined as any of the following: 
o Pleural effusion with histocytologically proven pleural malignancy 
OR 
o Pleural effusion in the context of histocytologically proven 
malignancy elsewhere, without a clear alternative cause for fluid 
OR 
o Pleural effusion with typical features of malignancy with pleural 
involvement on cross-sectional imaging (CT/MRI) 
• Degree of breathlessness for which therapeutic pleural intervention would 
be offered 
• Expected survival > 3 months 
• Age >18 years 
• Written, informed consent 
 
2.4.3.2 Exclusion criteria 
• Age < 18 years 
• Females who are pregnant or lactating 
• Clinical suspicion of NEL for which TP would not be offered  
• Patient preference for 1st-line IPC insertion 
• Previous ipsilateral failed TP 
• Estimated pleural fluid volume < 1 litre, as defined by TUS based on the 
Goecke Model (see Appendix 7) 
• Any contraindication to chest drain or IPC insertion, including: 
o Irreversible coagulopathy  
o Inaccessible pleural collection, including lack of suitable IPC tunnel 
site 
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• Any contraindication to MRI scanning, including: 
o Claustrophobia 
o Cardiac pacemaker 
o Ferrous metal implants or retained ferrous metal foreign body 
o Previously documented reaction to Gadolinium-containing 
intravenous contrast agent 
o Significant renal impairment (estimated glomerular filtration rate 
<30 ml/min) 
2.4.4 Co-enrolment guidelines 
Patients were excluded from entry into any other clinical trial that aimed to 
directly influence pleural fluid production, management or drainage for the 
duration of their participation within the study. Treatment decisions relating to 
the underlying malignancy were directed by the MDT in the usual fashion. Access 
to trials of systemic anti-cancer therapies was permitted. In the event of 
bilateral MPE, patients were only eligible for entry into the trial once.   
2.4.5 Screening and recruitment 
2.4.5.1 Pre-screening 
Patients with symptomatic MPE were identified at cancer MDT meetings, routine 
outpatient appointments, and during inpatient reviews at three hospital sites 
within the Greater Glasgow & Clyde health board; the QEUH, the Beatson West 
of Scotland Cancer Centre and the Glasgow Royal Infirmary. These patients were 
recorded in a pre-screening log. Those patients eligible for the trial were 
provided with a study patient information sheet (PIS) (see Appendix 1) at the 
earliest opportunity. Patients pre-screened after implementation of a 
substantial amendment to the protocol in January 2018 also received a 
Treatment Preferences Survey (TPS) PIS (see Appendix 2)  
2.4.5.2 Consent to formal screening 
After initial introduction to the trial and receipt of the PIS, a member of the 
clinical team made separate contact with the patient to assess whether they 
wished to consider participation. This was typically done the following day. If 
patients were agreeable to trial involvement, a member of the research team, 
identified a suitable opportunity to address any questions and to seek written 
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informed consent (see screening consent form, Appendix 3) to attend for a 
formal screening visit. Where patients did not advance from pre-screening to 
formal screening, the reason(s) were recorded in the pre-screening log. 
2.4.5.3 Formal screening, Eligibility Assessment and Consent 
At the formal screening visit, all eligibility criteria were systematically examined 
using a checklist. This process included bedside TUS during which pleural 
effusion volume (VTUS) was estimated based on the lateral and sub-pulmonic 
effusion extent using the Goecke formula. [87] Details of this estimation method 
are provided in Appendix 7. Patients meeting all eligibility criteria, including 
VTUS > 1 litre, were then invited to give additional written consent to 
randomisation and trial enrolment (see pre-EDIT consent form, Appendix 4). A 
period of at least 24 hours was required between the patient receiving the study 
PIS and giving consent to full trial participation.  
2.4.5.4 Treatment Preferences Survey consent 
All pre-screened potential pre-EDIT participants were eligible for participation in 
the TPS following a substantial amendment to the protocol which was approved 
on the 9th February 2018. After sufficient time to consider their involvement, 
those agreeable to TPS completion gave separate informed written consent (see 
TPS consent form, Appendix 5). Patients were able to complete the TPS without 
participating in the main pre-EDIT study and vice versa. 
2.4.6 Study procedures and assessments 
The pre-EDIT study design and procedures are summarised in Figure 2.2. 
2.4.6.1 Admission to Pleural Disease Unit  
Outpatients consenting to full pre-EDIT participation were urgently admitted to 
the GPDU, based on ward 7b, QEUH. Those consenting to participation as QEUH 
inpatients were transferred to the PDU for trial-specific management. In 
parallel, a research MRI appointment was provisionally booked to coincide with 
availability of the patient and research team to facilitate delivery of study 
interventions within a clinically appropriate timescale (< 14 days in all cases).  
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2.4.6.2 Treatment Preferences Survey 
TPS participants completed this simple semi-structured survey at the point of 
pre-screening or at a formal pre-EDIT screening visit, where performed. The TPS 




Figure 2.2 Pre-EDIT design summary; eligibility criteria, recruitment pathway, 
study procedures and follow-up arrangements 
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2.4.7 Baseline assessments 
Baseline assessments were completed following full consent and recorded on the 
relevant CRF by a member of the trial team prior to randomisation. Data 
recorded included:  
• patient demographics  
• mode of presentation 
• smoking history 
• physical characteristics 
• symptoms 
• current diagnosis 
• performance status 
• current medication 
• previous pleural interventions 
• past medical history 
• pain and breathlessness 100mm VA scores  
• recent blood test results (within 10 days)  
• baseline TUS findings 
2.4.8 Randomisation 
Randomisation was performed immediately after completion of the baseline 
assessments using a validated online system (www.sealedenvelope.com). 
Patients were allocated 1:1 using random permuted blocks into one of two 
groups:  
A: EDIT management 
B: Standard Care 
Minimisation or stratification was not used in pre-EDIT. However, the availability 
of complete participant LENT scores at the time of randomisation was recorded 
since this is a major prognostic indicator which may be used to minimise 
imbalance between groups in a subsequent definitive EDIT study. 
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2.4.9 Post randomisation 
Definitive pleural management according to group allocation was implemented 
within 72 hours of allocation and followed trial specific instructions (TSIs) (see 
Appendices 7-9).  
2.4.10 Standard Care 
Following procedure-specific written consent (recorded on generic NHS GG&C 
consent forms), a 12Fr ICD was placed at a bedside TUS-marked site under strict 
aseptic conditions using a Seldinger technique. Details of the drain insertion 
were recorded in the study intervention case report form (CRF). Passive pleural 
drainage was performed at a rate not exceeding 1000ml/hour. A post-insertion 
chest radiograph (CXR) was performed.  
A repeat CXR was performed 18-24 hours after ICD insertion; if there was no 
evidence of NEL or significant residual pleural fluid then TSP was attempted. 
Pre-medication with oral morphine (Oramorph 10mg) and intra-pleural 1% 
lidocaine (3mg/kg) was given 10 minutes prior to intra-pleural administration of 
a sterile slurry comprising 4g sterile graded talc (Novatech SA, France) 
suspended in 50ml 0.9% sodium chloride solution. After slurry installation and a 
2-hour period of ICD clamping, patients were placed on thoracic suction using a 
Thopaz ambulatory suction unit, if available. Suction was commenced at -10 
cmH2O and titrated to -20 cmH2O, if tolerated. Pleural drainage volumes were 
recorded at least 8 hourly. Twice daily 0.9% sodium chloride solution ICD flushes 
were delivered from the time of insertion to the time of removal. The ICD was 
left in situ for at least 24 hours after the talc slurry had been administered and 
removed once the fluid output fell below 250ml in the preceding 24-hour period. 
A CXR was performed following ICD removal prior to discharge. 
Where NEL or residual fluid was identified, ICD patency was assessed by flushing. 
Thoracic suction was applied at the discretion of the primary physician. An 
additional CXR was repeated after 18-24 hours. Talc slurry was administered 
once at least 50% visceral and parietal pleural re-apposition was achieved based 
on visual estimation. Where NEL persisted within 48 hours of ICD placement, 
further management was at the discretion of the primary physician. Patients in 
this situation remained in the study and were followed up as planned.   
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2.4.11 EDIT management 
The EDIT management pathway is summarised is Figure 2.3 overleaf. 
2.4.11.1 Pre-DPM TUS 
On completion of MRI scanning, participants were transferred back to the 
Clinical Research Facility and a TUS scan was performed by me. Where possible, 
a Siemens Acuson SC2000 US machine with 6C1 HD curvilinear array (1.5 - 6.0 
MHz) was used. If this machine was unavailable, a Sonosite M-Turbo with C60xi 
curvilinear array (2.0 – 5.0 MHz) was utilised. Full procedural details are shown 
in the combined TUS/DPM TSI (Appendix 7). In brief, pre-DPM TUS scanning 
comprised of 3 stages: estimation of pleural effusion volume (VTUS) using the 
Goecke method, [87] M-mode cardiac impulse transmission assessment of the 
atelectatic lung during breath holding, and finally, identification and marking of 
a safe DPM catheter insertion site. 
M-mode image analysis was undertaken following completion of DPM. The 
maximal atelectatic lung excursion observed during a breath hold at the end of 
tidal expiration (functional residual capacity) was measured over 3 separate 
cardiac cycles and a mean of these values recorded on the study CRF. Images 
acquired on the Siemens Acuson SC2000 were analysed with integrated Siemens 
software and a specific m-mode measurement tool. Images acquired using the 
Sonosite M-Turbo were exported in Digital Imaging and Communications in 
Medicine (DICOM) format and analysed in Horos v3.3.3 (an open source medical 




Figure 2.3 The EDIT management treatment pathway delivered within the pre-EDIT study 
MPE, malignant pleural effusion; TUS, thoracic ultrasound scan; IPP, intrapleural pressure; PEL, pleural elastance; MRI, magnetic 
resonance imaging; IPC, indwelling pleural catheter. MRI volumetric analyses are presented in Chapter 
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Figure 2.4 M-mode TUS image in pre-EDIT subject 19 acquired during a breath 
hold at functional residual capacity using a Sonosite M-Turbo/C60xi curvilinear 
array showing atelectatic lung excursion measurements made in Horos v3.3.3 
 
2.4.11.2 Pre-DPM MRI scanning 
Patients attended the Clinical Research Imaging Facility within the Institute of 
Neurological Sciences at the QEUH. An MRI safety checklist was completed by a 
member of the research imaging team. Informed written consent specifically 
relating to MRI scanning was then recorded. All MRI scans were performed using 
a 3.0T Siemens PRISMA® MRI scanner.  
Pre-DPM, the affected thoracic cavity was localised, and an isotropic T1-
weighted volume acquired using volumetric interpolated breath-hold 
examination (VIBE) sequences. A stack of axial slices covering the entire lung 
and surrounding pleura was acquired as a set of short breath-holds. Time-
resolved 3D MR imaging of the complete thorax was then obtained during tidal 
free-breathing and maximal inspiratory/expiratory efforts. A modified time-
resolved angiography with interleaved stochastic trajectories (TWIST) sequence 
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was utilised for this purpose. Following this, Gd-DTPA contrast (Gadovist) was 
administered as a 15-40 ml bolus (0.05 mmol/kg). VIBE sequences were 
reacquired at copied slice positions to provide comparative post-contrast images 
at multiple time points. 
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2.4.11.3 DPM and computation of PEL250 
Procedure-specific informed written consent for DPM was taken (recorded on 
generic NHS GG&C consent form). Under strict asepsis, the Rocket Medical DPM 
aspiration catheter was inserted following the detailed TSI shown in Appendix 7. 
Opening end expiratory IPP measurement was recorded. Pleural fluid was then 
removed in 50ml aliquots until any of the following occurred: 
• the patient developed chest discomfort or excessive coughing 
• an intra-pleural pressure of ≤ -20cmH2O was reached   
• target aspiration volume reached 
The target aspiration volume was initially defined by subtracting 500ml from the 
estimated total pleural effusion volume estimated by the Goecke TUS equation, 
see Appendix 7. [87] Following early experience in the delivery of EDIT 
management, this method was changed to intermittent mid-procedure TUS 
assessment with aspiration terminated when a horizontal costal-lung distance of 
≤ 30mm was reached. This amendment to the protocol is discussed further in 
Section 4.3.3.3. 
Sequential end expiratory IPP measurements were recorded after each 50ml 
aliquot. Additionally, the highest and lowest IPP values recorded during maximal 
respiratory manoeuvres at aspiration volumes of 200ml, 500ml and 1000ml were 
recorded. Post procedure, PEL250, the rolling average of PEL over the preceding 
250 ml of fluid removed was calculated at each 50ml interval. The highest 
recorded PEL250 in each case (MaxPEL250) was documented on the intervention 
CRF. At the end of the aspiration procedure, the mass of drained pleural fluid 
with its associated drainage bag and tubing was recorded. 
2.4.11.4 Post-DPM MRI scanning 
Following DPM, patients returned to the Clinical Research Imaging Facility to 
undergo a further MRI scan. Again, the affected thoracic cavity was localised, 
and a post-aspiration isotropic T1-weighted volume acquired using VIBE 
sequences. Repeat TWIST imaging of the complete thorax during tidal free-
breathing and maximal inspiratory/expiratory efforts was performed but further 
Gadovist administration and contrast-enhanced imaging was not undertaken.  
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2.4.11.5 Definitive intervention 
Definitive pleural management was instigated within 24 hours of DPM and, where 
possible, on the same day. Definitive management was allocated based entirely 
on the recorded MaxPEL250 as follows: 
MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC 
MaxPEL250 < 14.5 cm H2O/L: allocated to 1st-line ICD and TP 
Note that the rationale in selecting this threshold is described in the 
Introduction (Chapter 1, Section 1.8.3) and in Chapter 4 (pre-EDIT Results, 
Section 4.1.5). 
Separate procedure specific informed written consent was recorded prior to the 
allocated intervention and documented on generic NHS GG&C consent forms. 
Pre-intervention, a further TUS scan was performed to determine whether 
sufficient residual fluid, in the judgment of the operator, remained to allow safe 
ICD or IPC placement using a standard Seldinger insertion technique. All 
interventions were performed in single rooms within the PDU in accordance with 
the appropriate TSI (Appendix 8 relates to ICD insertion and Appendix 9 relates 
to IPC insertion).  
In cases of insufficient residual fluid to safely allow a standard Seldinger 
insertion, the 1st-line allocated procedure was delivered using a Boutin-type 
needle to provide blunt pleural access. This was performed with the patient in a 
lateral decubitus position and allowed formation of an iatrogenic pneumothorax 
with minimal risk of visceral injury. The standard Seldinger guidewire was then 
introduced into the pleural space and the remainder of the procedure was 
completed in the usual fashion. Finally, a CXR was performed post-procedure to 
assess the drain position. 
2.4.11.6 Post intervention 
Where 1st-line IPC insertion was performed, subsequent management followed 
local practice. This comprised overnight admission for observation on the 
evening of insertion and IPC drainage immediately post insertion, the evening of 
insertion and the following morning before discharge. Domiciliary IPC drainage 
was initially performed daily with sequential reductions in drainage frequency 
if/when volumes reduced. In those patients undergoing elastance-directed ICD 
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insertion +/- TSP, on-going management was identical to those patients 
receiving Standard Care.  
2.4.12 Estimation of pleural fluid aspiration volume during DPM 
The total pleural fluid volume removed during DPM (VOUT) was estimated as 
follows: 
 
VOUT = (MTOTAL – MBAG) / SG 
MTOTAL = mass of aspirated fluid and associated drainage bag/tubing  
MBAG  = mass of drainage bag/tubing 
SG = estimated specific gravity of pleural fluid based on protein 
concentration, based on a prior publication [88] 
Where: 
   SG = P / 353 + 1.0076 
P  = pleural effusion protein content in g/L 
2.4.13 Computation of pleural cavity volume change on MRI 
MRI scans were used to provide a ‘gold standard’ measure of pleural cavity 
volume. The change in pleural cavity volume was calculated as the difference 
between pre- and post-DPM pleural cavity volumes assessed on MRI (DVMRI). For 
this purpose, T1 weighted isotropic VIBE sequences were analysed by semi-
automated segmentation using Myrian® software (Intrasense, Paris, France). 
This required the manual application of a threshold contour to every fourth or 
fifth axial slice. A threshold mask extrusion algorithm was then launched to 
interpolate the pleural cavity between marked slices. The volume of the pleural 
cavity was automatically calculated by the software multiplying the sum of 
voxels within the extrusion mask and the known voxel volume. An example 
threshold contour and complete threshold mask is shown in Figure 2.4.  A 
blinded second assessor (WH, ST5 Radiology) repeated volumetric measurements 
for assessment of inter-rater reproducibility.  
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Figure 2.5 Screenshots from Myrian® software (Intrasense®, Paris, France) 
showing T1 VIBE axial and coronal images with an overlying extruded threshold 
mask of the pleural cavity and associated 3-dimensional reconstruction. 
 
2.4.14 MRI Phantom 
To provide a reference standard for MRI volumetric data acquired in pre-EDIT a 
deformable trial-specific pleural cavity MRI phantom (see Figure 2.5) was 
developed by collaborators from the NHS MR Physics Group, NHS Greater 
Glasgow and Clyde. The phantom comprised an acrylic frame containing a 2L 
latex bag (analogous to the parietal pleura), in which a smaller 1L latex bag 
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(analogous to the visceral pleura) was placed. Both bags were attached to the 
frame by their necks and connected to independent tubes to allow filling with 
known volumes of water and air, respectively. At the foot of the frame an 
adjustable piston plate formed a simulated ‘diaphragm’. The phantom was 
repeatidly imaged according to the pre-EDIT MRI protocol while containing a 
range of fluid volumes from 300ml – 1000ml. This work was performed entirely 
by collaborators from the NHS MR Physics Group (MSc student Saumya Josan, co-
supervised by Drs Mark McJury and John Foster), but described in my thesis since 
it was essential to the validity of my MRI volumetric studies.  
 
 
Figure 2.6 Pre-EDIT MRI Phantom 
Reproduced with permission from Ms Saumya Josan, Dr Mark Majury and Dr John 




2.4.15 Visual assessment scoring 
Visual analogue (VA) scores for chest pain and breathlessness were documented 
as part of baseline assessments for all study participants and then daily for 7 
days following ICD or IPC placement. Participants were asked to complete these 
scores at approximately the same time each day. Following this, patients were 
asked to complete VA scores weekly on a specific document. 
Patients were instructed not to complete VA scores retrospectively with the 
exception of weekly scores which could be completed within 48 hours. Omission 
of daily VA scores, or weekly VA scores not completed within 48 hours, were 
treated as missing data.  
2.4.16 Radiographic definition of NEL 
Lung re-expansion following trial interventions was assessed by me using 
subjective visual estimation. In those patients receiving TSP, the post-ICD 
removal, pre-discharge CXR was assessed. In those who underwent IPC insertion, 
the CXR obtained 14 days from discharge was assessed to avoid false positive 
NEL classification due to unavoidable air ingress during the IPC insertion 
procedure. Radiographs were classified as showing: 
• Expansile lung (>75% expansion) 
• NEL75 (<75% but >50% expansion) 
• NEL50 (<50% expansion)  
2.4.17 Follow-up arrangements 
Patients in both treatment groups were offered routine clinical appointments at 
approximately 7, 28, 60 and 90 days from discharge, with an additional visit 14 
days from discharge for those managed with IPC. A single trial follow-up visit at 
90 days (+/- 10) was arranged to coincide with clinical appointments, where 
possible, or completed by review of electronic records.  At this research visit, a 
chest radiograph was acquired and details of the number of hospital admissions, 
repeat pleural interventions, clinic visits and survival status was recorded based 
on clinical history (if available), augmented by NHSGGC electronic records 
systems (Clinical Portal and PACS). Electronic review of case records +/- 
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telephone visit was used to collect these details for patients unfit to attend 
clinic.  
2.4.18 Recurrent breathlessness following study intervention 
In the event of urgent hospital admission during the follow-up period, 
emergency management, including further pleural procedures, was not 
restricted by study participation and delivered at the discretion of the 
responsible acute team according to standard practice.  
Where study participants experienced sub-acute recurrent breathlessness during 
trial follow-up, comprehensive clinical and radiological (CXR / TUS) assessment 
by the research team was undertaken to elucidate the likely cause. All trial 
participants were provided with direct contact details for a clinical nurse 
specialist to facilitate early review in the event of symptoms developing 
between review appointments.  
Where recurrent MPE was identified and occupied greater than an estimated one 
third of the hemithorax on CXR, further pleural intervention in the form of IPC 
insertion or therapeutic pleural aspiration was offered where clinically 
appropriate. In the event of smaller volume MPE recurrence, further 
management was discussed with a second respiratory physician blinded to trial 
group allocation. Further pleural intervention was offered where a consensus 
was achieved.  
2.4.19 Trial images 
All CXR, CT and MRI images relating to trial participation have been securely 
stored on NHS Picture Archiving and Communication Systems (PACS) in line with 
routine clinical practice. Representative TUS images and m-mode cine clips have 
been stored on an encrypted study hard drive. 
2.4.20 End of trial 
Trial recruitment was completed on 18th September 2018, approximately 55 
weeks after opening, at which point 30 patients had been recruited, randomised 
and completed their allocated pleural management. Trial participation ceased 
on 13th December 2018 when all patients had completed their 90-day study 
follow-up visit or were deceased.  
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2.4.21 Bias reduction 
Blinding of patients or clinicians to trial group allocation was not attempted as a 
‘sham’ DPM procedure would be associated with an unacceptably high degree of 
clinical risk. The researcher performing DPM was clearly aware of group 
allocation and excluding them from further involvement in the participant’s 
care, to facilitate blinding of a separate clinician providing ongoing care, was 
considered impractical. The influence of potential bias was minimised through 
use of objective and prescriptive TSIs for the peri-procedural management 
within each arm of the trial.  
2.4.22 Schedule of study activity 
A schedule of study activity is shown in Figure 2.5
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Figure 2.7 Pre-EDIT study schedule of activities 
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2.4.23 Patient Withdrawal 
Patients were withdrawn from the study if any of the following occurred: 
• Patient withdrawal of consent 
• Patient no longer fit for therapeutic pleural aspiration, DPM or ICD 
insertion 
• Clinical opinion of the doctor that the patient should withdraw 
2.4.24 Statistical Considerations 
2.4.24.1 Sample Size 
As a feasibility study, pre-EDIT did not seek to test the efficacy of EDIT 
management and therefore a formal sample size calculation was not performed. 
Instead, it was proposed that recruitment of 30 patients would provide a 
reasonable view of the barriers which might be met in delivering EDIT 
management and provide adequate opportunity to explore possible solutions to 
problems encountered.  
The data collected on survival, 90-day failure rate, and recruitment (including 
any drop-outs) may potentially contribute to a future sample size calculation for 
a full scale phase III trial aiming to detect a clinically meaningful reduction in 
failed 1st-line treatment of MPE.  
2.4.24.2 Statistical Analysis Plan 
The following data analysis plan was included in the trial protocol: 
• The demographic and clinical characteristics of the study population were 
described using means (with standard deviations) or medians (with inter-
quartile ranges) to summarise continuous variables and proportions to 
summarise categorical variables.  
• The primary objective of recruitment rate was estimated as the number 
of patients recruited, divided by the number of patients identified as 
eligible pre-screening and will be expressed as a rate per month. 
• The time taken to perform DPM, the failure rate of DPM and the incidence 
of AEs and SAEs associated with DPM and definitive intervention were 
reported by simple descriptive statistics or proportions where 
appropriate.  
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• Simple descriptive statistics were also used to report the aspiration 
volume required to detect abnormal PEL. 
• The number of patients who require pneumothorax induction for ICD/IPC 
insertion was reported as a proportion. 
• The agreement between DVOUT and DVMRI measurements was examined 
using the Bland-Altman method.  
• The agreement between VTUS and VMRI pre-DPM measurements was 
examined using the Bland-Altman method. 
Post hoc, the following analyses were performed: 
• 2x2 Contingency Tables were used to assess the sensitivity and specificity 
of high PEL for NEL50 expressed as percentages with 95% confidence 
intervals. Statistical analyses were performed using GraphPad Prism 
v8.0.2 (San Diego, USA). 
• M-mode excursion data and associated post-drainage final radiographic 
lung expansion classification data were used to plot receiver operator 
characteristic (ROC) curves. The diagnostic performance of M-mode lung 
excursion for NEL50 and NEL75 was expressed as area under the ROC curve. 
This analysis was performed in SPSS v24.0 (Chicago, USA). 
2.4.25 Safety Reporting 
All Adverse Events were reported directly to the trial sponsor. 
2.4.25.1 Adverse Event (AE) 
An adverse event is any untoward medical occurrence that the patient 
experiences whilst participating in a clinical trial. This includes occurrences that 
are not necessarily caused by or related to the trial intervention. All AEs were 
recorded in the patient’s medical records as they were reported. Full details of 
AEs including the nature of the event, start and stop dates, severity, 
relationship to study intervention and outcome were recorded. AEs were 
followed until resolution.  
2.4.25.2 Serious Adverse Event (SAE)  
A serious adverse event (SAE) is defined where an AE is associated with any of 
the following, whether or not considered related to the trial intervention: 
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• Results in Death 
• Life-threatening (i.e. at the time of the event)* 
• Requires inpatient hospitalisation or prolongation of existing 
hospitalisation† 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly/birth defect 
• Is considered medically significant by the Investigator‡ 
*Life threatening means that the patient was at immediate risk of death from 
the event as it occurred. It does not include an event that, had it occurred in a 
more serious form, might have caused death. 
†Requires in-patient hospitalisation should be defined as a hospital admission 
required for treatment of an adverse event. 
‡Considered medically significant by the Investigator are events that may not 
result in death, are not life threatening, or do not require hospitalisation, but 
may be considered a serious adverse experience when, based upon appropriate 
medical judgement, the event may jeopardise the patient and may require 
medical or surgical intervention to prevent one of the outcomes listed above. 
2.4.26 SAEs Related to Study Procedures 
Related SAEs were defined as any SAE that was reported as possibly, probably or 
definitely related to the use of the DPM, subsequent pleural procedures in Group 
A (EDIT) patients or administration of gadolinium contrast. Table 2.3 shows the 
definitions used when assessing the nature of the relationship between any SAEs 
occurring and pre-EDIT study procedures.  
2.4.27 SAEs Related and Unexpected 
Any SAEs that were related to the use of the DPM, subsequent pleural 
procedures in Group A (EDIT) patients or the administration of gadolinium 
contrast and were not an expected event for this substance were subject to 
expedited reporting to the Main Research Ethics Committee. 
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Table 2.3 Definitions of SAE relationship to trial procedures 
Relationship Description 
Unrelated There is no evidence of any causal relationship 
Possible There is some evidence to suggest a causal relationship 
(e.g. the event occurs within a reasonable time after 
undergoing a study procedure), however the influence of 
other factors may have been contributed to the event (e.g. 
the patient’s clinical condition, other concomitant 
treatments) 
Probable There is evidence to suggest a causal relationship and the 
influence of other factors is unlikely 
Definitely There is clear evidence to suggest a causal relationship and 




2.4.28 Compliance, Audit and Protocol Deviations 
2.4.28.1 Good Clinical Practice 
This study was conducted in accordance with the protocol, the Sponsor’s 
standard operating procedures, national regulatory requirements, provisions of 
the relevant ethics committees and Good Clinical Practice (GCP) principles. 
2.4.28.2 Audits 
An independent internal Glasgow Clinical Research Facility audit of compliance 
with the principles set out in Section 2.8.1 was undertaken on 24th July 2018. 
The study may be subject to additional future audit by NHS GG&C under their 
remit as Sponsor. 
2.4.28.3 Protocol Deviation Reporting 
A protocol deviation is any departure from the approved protocol. All deviations 
were recorded and reported to the sponsor.  
2.4.29 Data Handling 
Data generated by the study was stored in a linked anonymised fashion on a 
password-protected computer. Subject paper notes were stored in a locked 
filing cabinet in a locked office of a secure building. Case report forms from the 
trial were stored in line with current regulatory requirements. Other essential 
documents (including source data, consent forms, and regulatory 
documentation) have been archived, in an appropriate archive facility in line 
with current regulatory requirements and made available for monitoring, audit 













POST-DRAINAGE RADIOGRAPHIC IDENTIFICATION OF 




3 Chapter 3: Post-drainage radiographic identification of 
non-expansile lung and its prognostic significance 
3.1 Introduction 
MPE may be complicated by NEL, resulting in pleurodesis failure, recurrent 
symptoms and additional pleural interventions. Radiographic detection of NEL 
following initial thoracentesis, or post-ICD insertion, is an essential element of 
bedside decision-making when planning admission for TSP or deciding whether or 
not to instil talc once a patient has committed to a pleurodesis attempt. 
Furthermore, limited data exist regarding the prevalence and prognostic 
significance of NEL. Any impact on survival should also be considered in the 
rational design of future MPE trials.  
At present, a universally accepted definition of NEL does not exist. In current 
clinical practice, radiographic visual estimation of lung re-expansion is used to 
identify NEL. This approach is subjective and based on varying thresholds of re-
expansion favoured by individual clinicians. However, a widely accepted 
minimum pleural apposition standard prior to attempting talc instillation is 
derived from a consensus statement in the 2010 BTS pleural guideline suggesting 
that pleurodesis is unlikely to be successful where less than half of the visceral 
and parietal pleura are in contact. [4] The reproducibility of this judgment is 
unknown but such a subjective assessment is vulnerable to inconsistency 
between (and within) readers, with resulting adverse effects on patient care. 
Greater objectivity in the method of judging NEL may improve inter-observer 
reliability and the consistency of clinical decision making. This in turn may 
improve the quality of reporting regarding the prevalence of NEL and its impact 
on survival in MPE studies. 
In this retrospective cohort study, I evaluated two novel semi-objective 
radiographic definitions of NEL (termed REP (re-expansion proportion) and LAR 
(lateral apposition ratio)), relative to the ‘BTS Method’ and rigorously assessed 
the prognostic value of the most reproducible of these.  
In Stage I, REP and LAR were assessed followed by a univariable survival analysis 
based on the most reliable definition and data from a single centre. In Stage II, a 
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multivariable survival analysis was performed and the results of this validated in 
an independent cohort from another centre. The specific objectives and 
associated outcome measures for Stages 1 and 2 are detailed in Chapter 2, 
Sections 2.2.2 and 2.3.2. 
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3.2 Materials and methods 
A detailed description of materials and methods for this work is provided in 
Chapter 2, Sections 2.2 and 2.3. A brief summary follows. 
3.2.1 Stage 1 
A cohort of patients undergoing local anaesthetic thoracoscopy (LAT) at the 
Glasgow Pleural Disease Unit between July 2010 and January 2015 was studied 
retrospectively. All cases had been categorized as NEL present or absent during 
the prospective recording of data for routine service evaluation. This judgment 
was made after 3 months follow-up by the pleural consultant in charge of the 
patients care and was based on all available clinical and imaging data. Survival 
status of included patients with confirmed diagnosis of pleural malignancy was 
assessed in May 2017 using electronic records.  
3.2.1.1 Radiographic Analyses 
Pre-discharge chest radiographs (CXRs) showing maximal re-expansion were 
assessed by 2 experienced respiratory physicians (GAM, ACK) using two semi-
objective definitions of NEL (REP and LAR) and the BTS visual estimation 
method. Details are provided in Section 2.2.3.2. 
3.2.1.2 Statistical Analyses 
Data recorded by the primary operator (GAM) was used to determine the 
predictive value of REP and LAR for subsequent NEL (expert 3-month 
classification) by plotting Receiver Operating Characteristic curves. Optimal cut-
points for NEL were calculated using likelihood ratios allowing patients to be 
classified as having ‘expansile lung’ or ‘NEL’ based on their REP and LAR data. 
Inter-observer agreement was calculated as a proportion for continuous data 
(raw REP and LAR data) and using Cohen’s Kappa Statistic for all methods 
(dichotomised REP and LAR classification, and BTS classification). 2x2 
contingency tables generated using the primary operator’s REP, LAR and BTS 
method data, were used to calculate the predictive value of each for subsequent 
NEL (expert 3-month judgement). Kaplan-Meier methodology was used to assess 
survival by re-expansion status for each approach and operator in those patients 
with confirmed pleural malignancy. 
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3.2.2 Stage 2 
Prospectively populated databases were used to identify consecutive patients 
treated at two UK pleural tertiary referral centres (Glasgow Queen Elizabeth 
University Hospital and Bristol Southmead Hospital) who underwent complete 
MPE drainage during diagnostic local anaesthetic thoracoscopy (LAT) between 
July 2010 and March 2018 (Glasgow, Cohort 1; an extension of the cohort utilised 
in Stage 1 which was filtered to include only patients with malignant pleural 
effusion), and July 2013 and July 2017 (Bristol, Cohort 2). Demographics and 
LENT MPE prognostic score components (pleural fluid lactate dehydrogenase 
(LDH), performance status (PS), blood neutrophil-to-lymphocyte ratio (NLR), 
tumour type) acquired at/within 28 days of LAT were recorded. OS was recorded 
from LAT to death (or censor). Cases with missing data were excluded.  
3.2.2.1 Radiographic Analyses 
The presence or absence of NEL was evaluated on the post-LAT, pre-discharge 
CXR that showed the maximum expansion as judged by primary assessors at each 
site (GAM; PH) using the previously described BTS method. Blinded secondary 
assessors (ACK; AB) independently classified the same CXRs using the same 
definition. Post hoc, CXRs were further sub-classified by a single assessor at each 
site into extreme expansion phenotypes; ‘Complete NEL’ (where no lateral 
pleural apposition was achieved) and ‘Complete Expansion’ (where total pleural 
apposition was achieved).  
3.2.2.2 Statistical Analysis 
Inter-observer agreement regarding NEL, between primary and secondary 
assessors at each site, was quantified by Cohen’s Kappa statistic. Kaplan-Meier 
curves and multivariable Cox regression (a priori model inputs: LDH, PS, NLR, 
LENT tumour risk score, NEL) were used to identify any association between the 
presence of NEL, as defined by the primary assessor, and OS in each cohort. For 
this purpose, Cohort 1 was used as a test set and Cohort 2 as an independent 
validation set. In a subsequent post hoc analysis, differences in OS between 
extreme re-expansion phenotypes (‘Complete NEL’ vs ‘Complete Expansion’) 




The structure of the study, sequence of analyses and number of cases included 
in each analysis is summarised in Figure 3.1. 
3.3.1 Optimal NEL definition and univariable survival analysis (Stage 1) 
3.3.1.1 Study population 
Ninety-three post-LAT CXRs were analysed. Based on the expert judgement at 3 
months, the overall incidence of NEL was 18/93 (19%). 65 patients (70%) had a 
diagnosis of MPE and, of these, 10/65 (15%) required a further pleural 
intervention within 3 months of definitive pleural management performed during 
LAT admission. Demographics and final diagnoses are summarised in Table 3.1. 
3.3.1.2 Radiographic NEL definitions: inter-observer agreement 
The mean inter-observer difference in REP was 8% (range 0 – 39%, standard 
deviation (SD) 7.5%) whereas the mean inter-observer difference in LAR was 17% 
(range 0 – 86%, SD 21%). Following application of optimal cut-points to the 
continuous data (NEL defined as REP <90% or LAR <0.67), inter-observer 
agreement (k) for REP, LAR and the BTS method were 0.46, 0.53 and 0.68, 
respectively.  
3.3.1.3 Radiographic NEL definitions: prediction of 3-month expert judgement 
REP predicted NEL with a sensitivity of 0.61 (95% Confidence Interval (CI) 0.49 - 
0.72) and specificity of 0.94 (95% CI 0.73 – 1.00). LAR predicted NEL with a 
sensitivity of 0.56 (95% CI 0.44 – 0.67) and specificity of 0.94 (95% CI 0.73 – 
1.00). Finally, the BTS method predicted NEL with a sensitivity of 0.81 (95% CI 
0.71 – 0.89) and specificity of 0.87 (95% CI 0.81 – 1.00).  
3.3.1.4 Prognosis in patients with MPE stratified by lung re-expansion status 
Sixty-five patients (70%) had a confirmed diagnosis of pleural malignancy. 
Survival data for all patients with MPE classified by expansion status is shown for 
each method and assessor in Figure 3.2.
 117 
  
LAT, local anaesthetic thoracoscopy; NEL, non-expansile lung; MPE, malignant pleural effusion; REP, re-expansion proportion; LAR, 
lateral apposition ratio; BTS, British Thoracic Society; LDH, lactate dehydrogenase; PS, performance status. *highest Kappa statistic
Figure 3.1 Flowchart summarising study sequence and patient numbers included 
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Table 3.1 Patient demographics and final pleural diagnosis in a single centre 




















BAPE, benign asbestos pleural effusion; NEL, non-expansile lung  
Age, mean (95% CI)  73 (71 – 75) 
Male, n (%)  72 (77) 
Right sided, n (%) 
 
 46 (49%) 
Final pleural diagnosis, n (%) 
Malignant: 
  
Mesothelioma  33 
Lung   16 












NEL, n (%) 18 (19) 
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Figure 3.2 Kaplan-Meier plots illustrating survival stratified by presence or 
absence of NEL for each operator and method of CXR analysis in 65 patients with 
confirmed MPE (Stage 1). A – Primary assessor (GAM) using Re-expansion 
Proportion (REP), B – Secondary assessor (ACK) using REP, C – GAM using Lateral 
Apposition Ratio (LAR), D – ACK using LAR, E – GAM using BTS method (BTS), F – 
ACK using BTS.  
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3.3.2 Prognostic significance of NEL: multivariable analysis (Stage 2) 
3.3.2.1 Study population 
214 eligible patients were identified. Complete data were available for 183/214 
(86%: Cohort 1 n=97, Cohort 2 n=86); cases with any missing data were excluded 
(Cohort 1: 23 LDH, 4 PS; Cohort 2: 3 LDH, 2 PS). Demographics and clinical data 
were broadly similar between cohorts (Table 3.2). However, more patients in 
Cohort 2 were male and had a diagnosis of MPM, and more patients were in PS 
group 2.  
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Table 3.2 Patient demographics, clinical characteristics and median overall 
survival in two independent MPE cohorts who underwent diagnostic LAT (Stage 2) 
 
IQR, interquartile range; CI, confidence interval; CUP, carcinoma of unknown 
primary; SCC, squamous cell carcinoma; NLR, neutrophil-to-lymphocyte ratio; 
LDH, pleural fluid lactate dehydrogenase; NEL, non-expansile lung.  





Age, mean (95% CI)  71 (69 - 74) 72 (70 - 75) 0.581 
Male, n (%)  65 (67) 69 (80) 0.047 
Right sided, n (%)  56 (58) 44 (51) 0.457 
Tumour type, n (%)     
Mesothelioma  56 (58) 64 (74) 0.012 
Lung   21 (22) 10 (12) 0.079 
Breast   6 (6) 5 (6) 0.999 
Genitourinary   5 (5) 2 (2) 0.450 
Gastrointestinal   3 (3) 3 (3) 0.999 
Haematological   1 (1) 0 (0) 0.999 
Other 5 (5) 2 (2) 0.450 
Performance 
status, n (%) 
    
0  18 (19) 14 (16) 0.702 
1  64 (66) 53 (62) 0.643 
2  9 (9) 16 (19) 0.085 
3  6 (6) 3 (3) 0.504 
NLR, median (IQR) 4.2 (2.8 - 5.9) 4.16 (2.79 - 5.29) 0.878 
LDH, median IU/mL 
(IQR) 
0.36 (0.21 - 0.63) 0.52 (0.35 - 0.79) 0.003 
Total LENT score, 
median (IQR)  
1 (1 - 3) 1.5 (1 - 2) 0.534 
Median overall survival, 
days (IQR) 
267 (116 - 525) 360 (172 - 537) 0.122 
NEL, n (%) 33 (34) 15 (17) 0.012 
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3.3.2.2 Lung re-expansion and inter-observer agreement 
Maximal lung re-expansion was observed within 24 hours of LAT in 53/97 (55%) in 
Cohort 1 and 53/86 (62%) in Cohort 2. The prevalence of NEL, based on the 
radiographic classification made by the primary assessor at each site, was 34% 
(33/97) in Cohort 1 and 17% (15/86) in Cohort 2. However, inter-observer 
agreement between assessors at each site regarding NEL was only fair-to-
moderate [89] (Cohort 1 k 0.38 (95% CI:0.21–0.55); Cohort 2 k 0.51 (95% CI:0.30–
0.72)).  
3.3.2.3 Prognostic impact of NEL 
Patients with NEL, as defined by the primary assessor, had shorter median OS 
than patients without NEL in both cohorts (Figure 3.3). In Cohort 1, NEL defined 
in this manner, was independently associated with adverse survival (HR 2.19, 
95% CI:1.31–3.66), but this was not replicated in Cohort 2 (HR 1.42, 95% CI:0.71–
2.87 – Table 3.3). However, in a subsequent post hoc analysis, median OS was 
significantly shorter in both cohorts in cases with Complete NEL (Cohort 1, 6/97 
(6%); Cohort 2, 5/86 (6%)) compared to those with Complete Expansion (Cohort 
1, 19/97 (20%); Cohort 2, 44/86 (51%)), see Figure 3.4. Figure 3.5 shows 
examples of CXRs classified by the primary assessor in Cohort 1 as a) NEL on the 
basis of <50% pleural apposition for the primary outcome, and examples of 
extreme re-expansion phenotypes used in the post hoc analysis: b) Complete NEL 








Figure 3.3 OS stratified by lung re-expansion status (Expansile lung vs NEL) 
following LAT in 2 cohorts of patients with MPE (Cohort 1 n=97, Cohort 2 n=86) 
 
 
















median OS 371 days (95% CI 176 - 566)
NEL
median OS 188 days (95% CI 44 - 332)
Log-rank p = 0.005
















median OS 412 days (95% CI 340 - 484)
NEL
median OS 192 days (95% CI 90 - 294)
Log-rank p = 0.028
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Table 3.3 Results of univariable and multivariable Cox regression analysis in two MPE cohorts. Multivariable model outputs report the 
association between predictors of overall survival (OS), including NEL and individual components of the LENT prognostic score. 
Predictors independently associated with OS are highlighted in bold. 
 Univariable analysis Multivariable analysis 
 HR (95% CI) p HR (95% CI) p 
COHORT 1 (n=97)     
NEL 1.93 (1.21 – 3.06) 0.006 2.19 (1.31 – 3.66) 0.003 
LENT tumour score* 1.69 (1.31 – 2.19) 0.000 1.65 (1.24 – 2.19) 0.001 
Pleural fluid LDH (IU/mL) 1.29 (1.09 – 1.54) 0.004 1.25 (1.03 – 1.52) 0.025 
NLR 1.12 (1.04 – 1.21) 0.004 1.09 (1.01 – 1.18) 0.026 
ECOG PS 1.93 (1.40 – 2.67) 0.000 1.27 (0.88 – 1.85) 0.206 
COHORT 2 (n=86)     
NEL 2.08 (1.07 – 4.04) 0.032 1.42 (0.71 – 2.87) 0.322 
LENT tumour score* 1.78 (1.32 – 2.38) 0.000 2.24 (1.60 – 3.15) 0.000 
Pleural fluid LDH (IU/mL) 2.04 (1.37 – 3.05) 0.000 2.34 (1.50 – 3.64) 0.000 
NLR 1.00 (0.93 – 1.07) 0.916 0.95 (0.88 – 1.02) 0.173 
ECOG PS 1.26 (0.90 – 1.75) 0.184 1.27 (0.88 – 1.84) 0.197 
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NLR, neutrophil-to-
lymphocyte ratio; LDH, lactate dehydrogenase; IU/mL, International Units/millilitre; NEL, non-expansile lung. * Tumour-type risk score 





Figure 3.4 Overall Survival stratified by extreme expansion phenotypes 
(Complete NEL vs Complete Expansion) following LAT in a post hoc analysis of 
subgroups of Cohort 1 (n=25) and Cohort 2 (n=49) 
 
  
















median OS 576 days (95% CI 465 - 687)
Complete NEL
median OS 116 days (95% CI 0 - 356)
Log-rank p = 0.010
















median OS 414 days (95% CI 297 - 531)
Complete NEL
median OS 122 days (95% CI 86 - 159)
Log-rank p = 0.002
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Figure 3.5 Examples of lung re-expansion classification based on subjective 
visual estimation before and after complete malignant pleural effusion drainage 
at Local Anaesthetic Thoracoscopy (LAT): (a) NEL on basis of <50% pleural 





(a) NEL on the basis of <50% pleural apposition 
  
(b) Complete Expansion 
  
(c) Complete NEL 
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3.4 Discussion 
3.4.1 Optimal radiographic identification of post-drainage NEL 
In Stage 1 of this retrospective cohort study, poor agreement was identified 
between assessors for 2 semi-objective definitions of NEL, based on the pre-
discharge chest radiograph following LAT, and only moderate inter-observer 
agreement using the subjective BTS method. Based on the primary assessor’s 
data, the BTS method demonstrated a high degree of sensitivity and specificity 
in the prediction of a subsequent expert diagnosis of NEL. This finding was 
unsurprising as it is likely that the expert assessor was heavily influenced by the 
BTS guideline statement concerning NEL (see further discussion in Section 3.4.5). 
The semi-objective definitions of NEL (REP and LAR) performed poorly in this 
regard.  
3.4.1.1 BTS definition 
This definition of NEL was based on guidance made in the 2010 BTS Pleural 
Guideline, which advises that pleurodesis is unlikely to be successful in cases 
with clear evidence of NEL, as defined by <50% pleural apposition. [4] The level 
of agreement between clinicians in Stage 2 (k <0.5 for both cohorts) was 
significantly lower than observed in Stage 1 (k 0.68). The reasons for this sizable 
difference in agreement between stages of the study are unclear. However, the 
discrepancy may reflect the challenge of judging pleural contact in malignant 
cases (comprising 70% of the cohort in Stage 1 vs 100% in Stage 2), due to the 
presence of bulky pleural metastases or malignant pleural thickening which may 
mimic residual pleural fluid. 
3.4.1.2 Re-expansion proportion 
The REP technique is likely to have been limited by large variations in 
delineating the hemidiaphragm position and lower limit of lung re-expansion 
where significant residual pleural fluid remained. In the MIST-2 study, on which 
the REP method is based, all measured regions of interest (ROIs) varied by less 
than 5%. [85] In contrast, our REP data varied by up to 39% with a mean 
difference between assessors of 8%. There may be several reasons for this 
difference, including the involvement of expert thoracic radiologists in the MIST-
2 study measurements. Although ultimately not required during the conduct of 
the trial, the MIST-2 protocol also mandated a joint review of ROIs if significant 
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inter-observer variation was observed, allowing a final, jointly agreed ROI to be 
defined. While application of a similar approach to the current study may have 
minimized variance and potentially improved the predictive performance of the 
REP method, it would not reflect clinical practice and therefore be of limited 
generalisability. These findings suggest that the REP method is subject to 
considerable variation when routinely applied by respiratory clinicians. 
3.4.1.3 Lateral apposition ratio 
The LAR approach makes approximation of the ipsilateral costophrenic angle 
more consistent between observers, which perhaps accounts for the slight 
improvement in inter-observer agreement once measurements were 
dichotomised. However, the raw continuous LAR measurements demonstrate 
large variation between assessors. It appears likely that this relates to 
considerable difficulty in reliably differentiating between pleural thickening, 
tumour deposits and non-dependent fluid in cases with residual pleural 
opacification. This particular challenge may be overcome through use of 
systematic thoracic ultrasound (TUS), which is capable of reliably differentiating 
between these and identifying clear sites of ‘lung sliding’, and therefore certain 
pleural apposition. This technique is currently under evaluation in the 
randomised SIMPLE trial (ISRCTN16441661). [58] 
3.4.2 Prevalence of NEL 
NEL following complete drainage of MPE at LAT was relatively common (Stage 2; 
Cohort 1 34%, Cohort 2 17%). However, it is difficult to compare these data to 
the existing MPE literature since the definition of NEL used in earlier studies 
varies widely. In the AMPLE trial, [3] which compared TSP with IPC management, 
NEL was defined pragmatically as ‘incomplete lung expansion’, and was reported 
in only 3% (5/146) participants. In contrast, 32% (28/87) patients had NEL in 
AMPLE-2, [35] which compared different IPC drainage strategies, based on a 
definition of <75% lateral apposition. Other studies report rates that lie between 
these extremes, possibly reflecting different definitions and/or exclusion 
criteria, e.g. 6% in TIME2 (based on <50% pleural apposition), [2] 13% in IPC-PLUS 
(based on <75% pleural apposition), [48] and 29% in the Phase III Intergroup 
Study (based on <90% expansion). [5]  
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3.4.3 Prognostic impact of NEL in MPE 
In Stage 1, all measures of NEL were strongly and consistently associated with a 
2-4-fold reduction in median survival in a single centre cohort of patients with 
confirmed MPE. This effect was seen using all methods by all observers, with the 
greatest mortality risk associated with low LAR results. This finding was 
confirmed using the most reproducible definition (BTS) in 2 independent cohorts 
in Stage 2 of the study. In this analysis, NEL was independently associated with 
adverse survival in Cohort 1 (HR for death 2.19, 95% CI:1.31–3.66, p=0.003), but 
this was not replicated in Cohort 2, in which the HR for death crossed 1 (HR 
1.42, 95% CI:0.71–2.87, p=0.322). This may reflect the smaller number of NEL 
cases in that series (17% (15/86) vs 34% (33/97)), with an attendant reduction in 
statistical power and a type II error. Clearly, it is also possible that this failure 
to validate means the survival effect observed in Cohort 1 is not externally valid, 
i.e. that NEL is not generally associated with adverse survival in MPE patients. 
However, it is likely that the variability also reported in classifying NEL 
radiographically may contribute to borderline cases being incorrectly classified 
and potentially confounded survival estimates in these cases. This possibility 
prompted a post hoc analysis based on ‘extreme expansion’ phenotypes since 
there is no real risk of misclassification in these cases. This analysis, which 
demonstrated significantly inferior survival in cases with ‘Complete NEL’ vs 
those with ‘Complete Expansion’ in both cohorts supports the assertion that the 
prognostic effect of NEL identified is genuine.  
3.4.3.1 Previous studies relating NEL to survival 
In an earlier retrospective study, Leemans et al reported similar adverse survival 
(median OS 66 days vs 169 days) in patients with MPE (due to a range of tumour 
types) who failed thoracoscopic talc pleurodesis due to NEL. [90]  In malignant 
pleural mesothelioma (MPM), visceral pleural tumour, a frequent cause of NEL, 
has historically been associated with adverse survival. [91] More recently, Bibby 
et al confirmed this association based on radiographic NEL. In that study the HR 
for death was 1.80 (95% CI:1.16–2.80)) in 192 patients with MPM, 64 of whom 
(33%) developed NEL at some point during their disease course. [86] The use of 
serial chest radiographs over a long follow-up period and inclusion of only MPM 
in this study differs from the work presented in this thesis but the observation of 
excess mortality is concordant with the conclusions presented. 
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3.4.3.2 Potential mechanisms 
The most intuitive potential explanation for this prognostic finding is that NEL is 
simply associated with more advanced disease; i.e. a thicker concentric pleural 
tumour rind or bulkier proximal disease leading to airway obstruction. It was 
beyond the scope of the current study to explore such mechanisms as its 
retrospective nature precluded the collection of sufficiently detailed anatomical 
and staging information. However, it is noteworthy that in patients with MPM, 
Bibby et al recently reported that adverse survival associated with NEL was 
independent of disease stage, and that NEL was more common in early stage 
disease. [86] Accepting the limitations of staging in MPM, their data suggests less 
obvious biological mechanisms are likely to be implicated, at least in patients 
with malignant effusion associated with MPM. Given the heterogenous nature of 
the cohorts studied here, several alternative mechanisms are likely to be 
implicated. Physiological compromise or additional pleural 
procedures/hospitalisation associated with NEL may also be relevant. A larger 
study would be required to assess these important questions. 
3.4.4 Clinical significance 
Radiographic interpretation is a cornerstone in the management of patients with 
MPE. In patients undergoing fluid drainage, CXR findings directly determine the 
timing of talc slurry instillation and chest drain removal. [4] As such, variation in 
CXR interpretation regarding lung re-expansion (and the presence of NEL) is of 
critical importance and could result in futile talc slurry instillation and 
inappropriate prolongation of hospitalisation if NEL is under-recognised. 
Conversely, such variation may also result in missed opportunities to deliver talc 
pleurodesis and lasting symptom control if expansile lung is mis-classified as 
NEL. Although data relating a particular CXR definition to subsequent TSP 
success do not exist, the findings described in this thesis of only fair-to-
moderate inter-observer agreement support the use of consensus judgments 
regarding lung re-expansion rather than relying on a single assessor. In 
particular, this approach should be considered in clinical trial design where 
patients may be excluded from enrolment or study procedures based on a single 
observer’s judgement. [84] 
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The level of disagreement reported here highlights the challenges involved in 
radiographic NEL assessment, even when experienced assessors are involved. 
Development of a reliable method of NEL detection should therefore be a 
clinical imperative. Evaluation of 3-dimensional lung expansion based on a 2-
dimensional image is an inherently flawed concept and a technique which 
provides a global assessment of the pleural cavity is clearly required. As 
described in the introduction to this thesis, a range of potential techniques to 
address this challenge are under investigation. With particular reference to post-
drainage NEL identification, two UK multicentre studies are currently indirectly 
evaluating the potential utility of systematic multiplanar thoracic ultrasound 
scanning to detect post-drainage NEL. [58,59] Future research of novel NEL 
detection methods should also seek to establish the relationships between 
varying expansion thresholds and clinical outcomes. However, as previously 
discussed, a robust method to identify NEL prior to attempting complete pleural 
drainage would appear to offer the greatest potential benefit to patients. 
Possible methods of pre-drainage NEL detection are discussed further in Chapter 
4. 
3.4.5 Study limitations 
Both stages of this study were limited by their retrospective designs. 
Consequently, missing data was inevitable, and the statistical power of the study 
was inherently constrained. Patient numbers also precluded sub-group analyses 
and exploration of a potential interaction between MPM disease stage, NEL and 
mortality, which is entirely plausible based on previous research. [91] 
In Stage 1, subjective expert judgment was used to define a ‘gold standard’ for 
NEL to allow the predictive performance of each method to be established. This 
was likely to have been heavily influenced by the use of the BTS method, 
therefore biasing the predictive performance results in favour of that approach. 
However, the expert judgement was not exclusively based on the BTS method of 
radiographic assessment; it also integrated all available imaging (CT and US) and 
clinical acumen. It was therefore justified as a pragmatic tool to allow optimal 
cut-points for REP and LAR to be established, and, in turn, dichotomise the data 
for direct comparison with the BTS method. 
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Due to reliance on LAT databases, and its geographical basis in post-industrial 
coastal cities, this study included a higher proportion of patients with MPM than 
is encountered in routine practice in other areas. Since the natural course of 
MPM is to readily proliferate from parietal to visceral pleura surfaces, the 
generalisability of our prognostic findings to a more heterogeneous MPE cohort 
should not be assumed. Additionally, in most centres, the majority of patients 
with symptomatic MPE will be managed by closed pleural drainage via ICD or IPC 
rather than open drainage at LAT. However, expansion outcomes are unlikely to 
vary meaningfully between closed drainage and LAT since neither decortication 
nor any significant division of adhesions is undertaken during the latter.  
Finally, it is important to note that the guideline statement used to derive the 
‘BTS’ NEL definition used here was not designed to be a precise diagnostic 
criterion and other studies have used alternatives (e.g. <75% pleural apposition). 
[35,48,86] An alternative definition of NEL might improve inter-observer 
variability, but may be less clinically relevant since subtle NEL might still be 
amenable to a pleurodesis attempt. Addressing this question was beyond the 
scope of the current study. 
3.4.6 Conclusions 
NEL following drainage of MPE at LAT is a common finding (17–34%). A similar 
prevalence of underlying NEL might be expected in a generalised population of 
patients with MPE but cannot be assumed. Accepting this limitation, NEL appears 
to be under-represented in significant trials of MPE management (e.g. TIME-2 
and AMPLE). [2,3]  
Radiographic identification of NEL is subject to a high level of inter-observer 
variation. NEL is associated with adverse survival, although the independence of 
this relationship was not externally validated in this work, probably due to an 
inadequate sample size. These findings should be considered in clinical decision-
making and MPE trial design, particularly when single observers are used. Future 
research should seek to identify clinically deployable biomarkers for NEL that 
are associated with less inter-observer variation. An ideal biomarker would 
reliably detect underlying NEL prior to committing patients to complete effusion 
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4 Chapter 4: Feasibility of a randomised controlled trial 
of elastance-directed management in malignant pleural 
effusion  
4.1 Introduction 
This chapter describes the pre-EDIT trial; a prospective feasibility RCT of a 
pleural elastance (PEL)-directed treatment pathway (EDIT management) in 
patients with symptomatic MPE. [92] Pre-EDIT was designed to assess the 
feasibility of delivering, and inform the design of, a potential future randomised 
Phase III RCT testing the efficacy of EDIT management compared to inpatient 
TSP as a standard of care.  
The feasibility of this study design is described in this chapter in terms of 
patient recruitment, the technical deliverability of EDIT management, and 
limitations of this approach, including a description of adverse events 
encountered. The background to this trial and rationale for its design is first 
reiterated.   
4.1.1 Current treatment of symptomatic malignant pleural effusion 
As previously discussed, MPE frequently leads to disabling breathlessness which 
may be definitively managed by either day case insertion of an IPC to facilitate 
regular domiciliary drainage, or TSP during a 4-7 day hospital admission. [46,47] 
Inpatient TSP provides long-term symptom control in 71-78% of patients, [3,5] 
and avoids the inconvenience and risks (notably pleural infection) associated 
with IPC drainage. [31] However, MPE associated with underlying NEL is not 
amenable to successful TSP and is most appropriately managed with IPC 
insertion. [4] Since reliable pre-drainage detection of NEL is not feasible within 
existing pathways, clinically occult NEL is a frequent cause of TSP failure. 
Universal IPC-based management has been suggested as a solution to overcome 
this unpredictability, particularly since the delivery of talc via IPC has been 
shown to improve pleurodesis rates if the lung re-expands. [93] However, this 
strategy still requires IPC placement, which is unattractive to a significant 
proportion of patients [43] and associated with higher healthcare costs in 
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patients who require prolonged drainage beyond 14 weeks. [40,41] It is also 
important to note that ambulatory TSP delivers a pleurodesis success rate that is 
significantly inferior (51% at 10 weeks) [93] to that associated with inpatient 
TSP, albeit based on non-comparative data.  
4.1.2 An optimal MPE treatment pathway 
A logical refinement to MPE management would therefore be the development 
of a treatment pathway which makes the best use of the relative advantages and 
disadvantages of TSP and IPC drainage. An early assessment of lung re-expansion 
potential might allow clinicians to deliver TSP with greater confidence of success 
by excluding patients with NEL and instead directing these individuals towards a 
first-line IPC. This concept is particularly important because, as detailed in 
Chapter 3 (Section 3.4.2), NEL is almost certainly under-represented in the 
evidence base underpinning current MPE management (6% NEL in TIME2, 3% NEL 
in AMPLE), [2,3] and clinical equipoise between IPC insertion and TSP as first-
line definitive interventions cannot be assumed. 
4.1.3 Pre-drainage detection of NEL 
Pleural elastance (PEL) and atelectatic lung excursion/strain related to cardiac 
impulse have previously been reported as biomarkers of NEL. 
[50,61,67,71,94,95] The former is an intrinsic property of the pleural space 
derived from pleural manometry data recorded during thoracentesis, while the 
latter may be assessed using either motion-mode (M-mode) and speckle tracking 
ultrasonography. These techniques are discussed in detail in the Introduction to 
this thesis (Section 1.6 and Section 1.5.4.3).  
For pre-drainage detection of NEL, I chose to focus on assessment of PEL over 
ultrasound methods based on an interest in our unit in this area, a larger body of 
preceding research and a judgement that there was greater scope to optimise 
the technique (see Section 4.1.3.2 below), and integrate it into a single 
intervention procedure in a future definitive trial. However, given its 
widespread availability, I also included M-mode sonography as a subsidiary end-
point in pre-EDIT. The validity of these design choices were explored in a 
number of subsidiary analyses within the pre-EDIT trial and the results of these 
analyses are presented separately in Chapter 5. I intentionally did not 
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incorporate ultrasound strain assessment, which I judged to be inherently 
unsuitable for use in routine clinical practice due a requirement for specialist 
equipment and operator training.  
Previously published data regarding PEL in the detection NEL has already been 
summarised in the Introduction (section 1.6.7). In the following sections the 
rationale used to define the PEL threshold and measurement methodology used in 
pre-EDIT has been summarised. 
4.1.4 Pleural elastance as a NEL biomarker 
PEL is a well-recognised physiological metric that has been studied extensively in 
observational settings. It is defined as the intrapleural pressure (IPP) change 
divided by the volume of pleural cavity volume change during thoracentesis, 
which is generally assumed to be equal to the volume of pleural fluid aspirated. 
Characteristic patterns of IPP change during thoracentesis, associated with 
expansile lung and NEL (subdivided into ‘entrapped’ and ‘trapped’ lung), are 
described in Introduction section 1.6.4. However, to date, only one study by Lan 
et al has identified an association between PEL and pleurodesis success, defined 
in that study as elimination of the requirement for further therapeutic 
thoracentesis to alleviate symptoms at 1-month post-pleurodesis. [67] Lan et al 
reported that point estimates of PEL ³19 cmH2O/L over an aspiration volume of 
500ml were associated with radiographic NEL with a sensitivity of 79% (95% 
confidence interval (CI) 49-94%) and specificity of 94% (95% CI 83-99%). Using the 
same PEL threshold, subsequent pleurodesis success was predicted with a 
sensitivity of 75% (95% CI 22-99%) and a specificity of 100%. The sensitivity of 
this approach is clearly only moderate, and is likely to have been limited by a PEL 
threshold significantly above the upper limit of normal, which was subsequently 
defined as 14.5 cmH2O/L, [13] and the small aspiration volume used (500ml), 
which is likely to have been inadequate to detect all cases of biphasic NEL (see 
section 1.6.4). 
4.1.5 Choice of PEL threshold in pre-EDIT 
As described in Section 1.8.3, use of a lower PEL threshold than Lan et al (19 
cmH2O/L) and measurement over a larger total aspiration volume would be 
expected to increase the sensitivity of NEL detection, but could potentially 
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sacrifice specificity, particularly if IPP rises transiently due to coughing, an 
inadvertent Valsalva manoeuvre or unknown measurement artefacts. Therefore, 
in pre-EDIT, a lower PEL threshold was used (14.5 rather than 19 cmH2O/L) over 
the course of a large volume aspiration, but we decided that this would only be 
met if it was sustained over at least 250ml of fluid removed. This required 
definition of an entirely novel definition based on a rolling average of PEL 
recording over the preceding 250ml fluid removed (termed PEL250). In pre-EDIT, 
aspiration volume was limited only by the development of symptoms (chest 
discomfort or excessive coughing), a drop in IPP below previously reported 
safety thresholds, or a target pleural effusion depth (designed to retain 
sufficient residual fluid to facilitate a safe definitive intervention on the same 
day). NEL was therefore defined by a maximum PEL250 ≥ 14.5 cm H2O/L occurring 
at any point during large volume aspiration. This definition aimed to detect NEL 
at the earliest possible opportunity with a high degree of sensitivity while 
preserving specificity. 
4.1.6 Technical considerations in IPP measurement 
Previous pleural manometry equipment has been hampered by technical 
limitations, largely relating to poor damping of pressure variations related to 
normal respiration and/or the need for cumbersome improvised equipment. 
During the work presented in this thesis, a purpose-built, single-use, CE-marked 
digital pleural manometry (DPM) catheter was developed in conjunction with 
Rocket Medical (UK) which allows continuous IPP measurement during 
thoracentesis. The device measures IPP once per second and is mechanically 
damped via the narrow independent lumen linking the pleural cavity to the 
electronic transducer. IPP is also temporally damped as the equipment displays a 
mean IPP on a re-usable digital display unit, based on the preceding 5 seconds of 
data recorded. The precision and accuracy of the electronic transducer within 
the manometry system was laboratory tested by Rocket Medical (UK) during 
product development and found to read within +/- 5% of a calibrated laboratory 
device at simulated pressures between +20 cmH2O and -30 cmH2O. The 
manometer was electromagnetic compatibility tested and passed BS EN 60601-1-
2:2015 and BS EN 60601-1:2006+A1:2013. 
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4.1.7 Delivery of PEL-directed management and safety considerations 
By definition, the EDIT pathway requires a large volume thoracentesis procedure 
prior to allocation to TSP or IPC. If the allocated procedure cannot be delivered 
promptly, and ideally at the same sitting, any pathway efficiency gained through 
the detection of NEL is lost. However, placement any form of Seldinger drain 
may be technically challenging after removal of the majority of the effusion 
during PEL assessment. Therefore, within the EDIT protocol, a target aspiration 
volume was included as a stop criterion during aspiration. The method of 
assessing this target volume evolved during the conduct of the trial and is 
discussed further in Chapter 5. The protocol also allowed that, if required, a 
‘Boutin-type’ needle could be employed for pneumothorax induction to ensure 
safe placement of PEL-allocated IPC or TP. This is regularly practiced at level II 
thoracoscopy centres when no, or minimal, pleural fluid is present at LAT. [7] A 
2mm diameter ‘Boutin-type’ pleural access needle without biopsy side gate 
(Novatech SA (France)) was deliberately chosen for this purpose over a more 
conventional 3mm Boutin trocar in order to avoid inadvertent tissue damage 
from an open biopsy gate during trocar removal (see Figure 4.1). In normal use, 
the Boutin biopsy gate would be safely occluded by the internal stylet prior to 
removal, however within pre-EDIT the trocar would potentially be used to pass a 
thin Seldinger guidewire into the pleural space thus precluding stylet 
replacement. It was also acknowledged in the development of the study that if a 
regular requirement for pneumothorax induction was identified, there would 
clearly be implications for the feasibility of any subsequent multi-centre Phase 














Figure 4.1 Single-use pleural access needles © Novatech SA (France). A – 2mm 
diameter ‘Boutin-type’ needle without biopsy side gate used in pre-EDIT. B - 
Conventional 3mm diameter Boutin pleural trocar showing cutting biopsy side 
gate. Both needle designs have a working length of 78mm and are equipped with 
a sharp and a blunt stylet. 
  
This Figure has been removed due to copyright restrictions 
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4.1.8 Treatment Preferences Survey 
Limited data exists regarding the factors most important to patients when 
weighing up their management options for MPE. Qualitative data from the 
Oxford pleural group indicate that in a sample of 18 patients who underwent 
inpatient TSP for symptomatic MPE, over half indicated that they would not 
consider IPC management. [43] Furthermore, 12/15 (80%) survey respondents 
who underwent inpatient TSP believed outpatient management would have 
either no effect or a negative effect on their quality of life. However, in 
contrast, 7/8 (88%) who underwent IPC drainage rated the experience as 
positive. Further research is therefore clearly needed to better appreciate the 
heterogeneous range of patient preconceptions and treatment priorities, and 
thus inform the design of future MPE therapeutic trials. During the conduct of 
pre-EDIT, the opportunity was taken to gather additional semi-qualitative data 
on patient decision-making around MPE management using a Treatment 




4.2 Materials and methods 
A full description of the pre-EDIT study design is provided in Chapter 2, Section 
2.4 and in a published open-access trial protocol paper. A brief summary is 
provided in this section. [92]  
4.2.1 Trial Design  
Pre-EDIT was a single centre, randomised, controlled, open-label feasibility 
trial. The design is summarised in Chapter 2, section 2.4.6 (Figure 2.7).  
4.2.2 Trial Objectives and Outcome Measures 
The primary objective was to determine whether sufficient numbers could be 
recruited and randomised for a future multi-centre Phase III trial to be 
considered feasible. Feasibility was defined a priori as the recruitment and 
randomisation of 30 patients over 12 months (or 15 patients over any 6-month 
period). The primary outcome measure was recruitment rate. Secondary 
objectives and associated outcome measures addressing important safety and 
practicality issues are shown in Chapter 2, Table 2.2. Additional secondary and 
exploratory objectives related to volumetric Magnetic Resonance Imaging (MRI) 
validation of the current definition of PEL, and the embedded patient TPS, are 
described in Chapter 5 of this thesis. A post hoc analysis was also performed 
regarding the sensitivity and specificity of high PEL for radiographic NEL; defined 
here as NEL50 (see section 2.4.16).  
4.2.3 Screening, Enrolment and Randomization 
Eligibility criteria are shown in Chapter 2, Section 2.4.3.  All potentially eligible 
patients were pre-screened at the QEUH using electronic records. Those without 
obvious exclusion criteria were invited to a formal screening visit. Specific 
written consent to screening was taken. Patients meeting all eligibility criteria 
after screening provided further written consent before enrolment and were 
randomly allocated 1:1 between EDIT management and Standard Care (TSP). 
4.2.4 Trial Interventions 
Study interventions, according to group allocation, were performed at the QEUH 
within 72 hours of randomisation. 
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4.2.4.1 Standard Care 
Standard Care involved placement of a 12F intercostal chest drain (ICD), 
complete drainage +/- attempted TSP in patients demonstrating ≥50% pleural re-
apposition on post-drainage CXR. [4] 
4.2.4.2 EDIT management 
EDIT management was a 3-step process. Step 1 involved PEL assessment during a 
large volume pleural fluid aspiration using the bespoke DPM catheter (Rocket 
Medical (UK)). IPP was recorded at 50ml intervals until any of the following: 
chest discomfort or excessive coughing; IPP ≤-20cmH2O; horizontal pleural cavity 
width ≤30mm adjacent to catheter on ultrasound. No volume limit for fluid 
aspiration was used. The second step involved computation of the maximum 
sustained PEL and unbiased allocation to an attempt at TSP or IPC placement. 
This is discussed in detail in Chapter 2, Section 2.4.11.3. The final step involved 
delivery of elastance-directed pleural management within 24 hours. Patients 
with normal PEL, defined as MaxPEL250 < 14.5 cmH2O/L at all points, underwent 
12F ICD placement with a view subsequent inpatient TSP. Patients with high PEL, 
defined as MaxPEL250 ≥ 14.5 cmH2O/L at any point, underwent IPC placement. 
4.2.5 Follow-up 
In addition to routine clinical follow-up (approximately 14-, 30- and 60-days 
post-discharge), a single trial follow-up visit at 90 days (+/-10) was arranged. A 
CXR was acquired and details of hospital admissions, repeat pleural 
interventions, and clinic visits were recorded. Telephone consultations were 
permitted in patients unable to attend. Survival data were recorded from 
electronic records.  
4.2.6 Sample Size and Statistical Considerations 
As a feasibility trial, an a priori sample size calculation was not performed. The 
primary outcome measure (trial recruitment) was expressed as a mean monthly 
rate over the trial period and each 6-month interval. Secondary outcome 
measures were reported by descriptive statistics or proportions. 2x2 Contingency 
Tables were used to assess the sensitivity and specificity of high PEL for NEL50 
expressed as percentages with 95% confidence intervals. Statistical analyses 




Recruitment took place between August 2017 and September 2018. In total, 31 
patients were recruited and randomised (16 to EDIT management (1 allocation 
failure – see Figure 4.3), 15 to Standard Care). The mean trial recruitment rate 
was 2.4 patients per month. The a priori primary objective of recruitment 
feasibility was achieved at week 35 at which point 15 patients had been 
recruited over the preceding 6 months (2.5 patients/month). A trial recruitment 
graph is shown in Figure 4.2 below.  
 
 
Figure 4.2 Recruitment to pre-EDIT from August 2017 to September 2018 plotted 







































4.3.2 Study Population 
Baseline characteristics were similar between groups, particularly regarding age, 
tumour-type, performance status and symptoms (see Table 4.1). Patient flow is 
summarized by the CONSORT diagram below (Figure 4.3). 
 
 
Figure 4.3 Pre-EDIT study flow chart 
MRI, magnetic resonance imaging; IPC, indwelling pleural catheter; TSP, talc 
slurry pleurodesis; TUS, thoracic ultrasound scan; EDIT, elastance-directed 
indwelling pleural catheter or talc slurry pleurodesis; LVA, large volume 
aspiration.  
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 Table 4.1 Pre-EDIT participant baseline characteristics 
 
Standard Care (n=15) EDIT (n=15) 
Age (median (range)) 66 (48 – 90) 71 (51 – 90) 
Male (n (%)) 8 (53%) 4 (27%) 
Right-sided (n (%)) 12 (80%) 6 (40%) 
Tumor type (n (%)) 
  
    Mesothelioma 1 (7%) 1 (7%) 
    Lung 6 (40%) 5 (33%) 
    Breast 3 (20%) 6 (40%) 
    Ovarian 1 (7%) 2 (13%) 
    Others 4 (27%) 1 (7%) 
ECOG PS, number (n (%)) 
  
    0-1 11 (73%) 9 (60%) 
    2 2 (13%) 5 (33%) 
    3 2 (13%) 1 (7%) 
VAS Dyspnoea (mm (SD)) 50 (31) 47 (30) 
VAS Pain (mm (SD)) 17 (15) 19 (29) 
 
EDIT, Elastance Directed Intrapleural catheter or Talc pleurodesis; ECOG PS, 
Eastern Cooperative Group Performance Status; VAS, Visual Analogue Score; SD, 
Standard Deviation  
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4.3.3 Technical feasibility 
4.3.3.1 Elastance assessment 
The mean time taken to complete PEL assessment was 33 minutes (range 17–51 
minutes). IPP data were incomplete in the first 2/15 EDIT patients due to a 
software reset mid-procedure. On both occasions, the device reset immediately 
following an episode of coughing during the procedure. The hypothesis that 
sharp elevations in IPP were responsible for the reset was confirmed after 
discussion with Rocket Medical engineers who advised that the device had been 
programmed to reset in response to measured pressures >30cmH2O. A software 
update was performed to remove this reset threshold. Following this, complete 
data were acquired in the subsequent 13 cases. The procedural failure rate was 
therefore 2/15 (13%), but 0/13 (0%) after the software update. 
4.3.3.2 Requirement for Boutin-type Needle 
A single case (1/15, 7%) had insufficient residual pleural fluid following PEL 
assessment to allow a definitive intervention using a standard Seldinger 
technique. In this case, a Boutin-type blunt pleural access needle, without 
pleural biopsy gate, was used to induce a pneumothorax. The Seldinger 
guidewire was then introduced into the pleural space via the needle following 
the removal of the blunt access stylet.  
4.3.3.3 Target aspiration volume 
Early iterations of the trial protocol (v2.0 (dated 4/3/2017) to v2.3 (dated 
4/8/2017)) utilised a target maximum pleural aspiration volume while pleural 
manometry was performed (unless symptoms or IPP £ -20cmH2O reached first). 
The target volume was calculated by subtracting 500ml from the ultrasound-
based pre-procedure effusion volume estimate (see Section 2.4.11.3). This 
method was used to set an upper limit to aspiration during the management of 
pre-EDIT subjects 1-4. During the management of subject 4 (allocated to EDIT 
management) pleural aspiration was terminated when the target maximum 
aspiration volume was reached, however it was noted that a substantial residual 
effusion volume (subjectively far greater than 500ml) remained. Since the 
Goecke ultrasound volume estimate was derived from a series of drained 
effusions up to only 1650ml, it was judged that this technique was likely to have 
substantially underestimated the total effusion volume, thus leading to an 
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unnecessarily early termination of the DPM procedure and potentially 
compromising the sensitivity of the procedure to detect NEL, particularly in 
biphasic cases. A substantial amendment (resulting in protocol v2.4, dated 
09/10/2017) was therefore implemented to replace the target maximum pleural 
aspiration volume with mid-procedure target ultrasound appearances in order to 
maximise the available manometry data for rolling PEL calculation. This approach 
was adopted in all subsequent cases, although I continued to acquire US 
estimates of pre-drainage effusion volume for all subsequent cases. A detailed 
description of the aspiration volumes taken in pre-EDIT, the volumes required to 
detect abnormal PEL, and a detailed assessment of the accuracy of the Goecke 
effusion volume estimate in pre-EDIT cases relative to volumetric MRI, are 
provided in Chapter 5.  
4.3.4 Diagnostic performance of PEL250 for radiographic NEL 
Pleural manometry data for patients who underwent EDIT management is 
summarised in Figure 4.4 below. Normal PEL (<14.5cmH2O/L at all stages) was 
recorded in 6/13 patients with complete data, of whom 0/6 subsequently 
developed NEL. High PEL (³14.5cmH2O/L at any point) was recorded in 7/13 
patients, of whom 4/7 developed NEL. Therefore, the pre-specified definition of 
high PEL was associated with 100% sensitivity (95%CI 51-100%) and 67% specificity 
(95%CI 35-88%) for a subsequent a degree of NEL that would normally preclude 
an attempt at slurry pleurodesis (<50% pleural re-apposition). Figure 4.5 shows 
examples of (a) normal and (b) abnormal PEL curves with corresponding 
radiographic appearances from EDIT management cases. In example (a), intra-
pleural pressure (IPP) was recorded during aspiration of 2400ml, terminated at 
target ultrasound appearances (≤30mm visceral to costal distance). In this case, 
MaxPEL250 was 12cmH2O/L (normal) therefore the patient was allocated to TSP 
and an ICD was inserted on the same day. The lung was fully re-expanded before 
discharge. In example (b), IPP was recorded during aspiration of 1400ml, 
terminated at the onset of excessive coughing. In this case, MaxPEL250 was 
32cmH2O/L (high) therefore the patient was allocated to IPC insertion on the 
same day. The lung failed to fully re-expand, as shown on follow-up radiograph 
at 14 days.  
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Figure 4.4 PEL curves (IPP change / cavity volume change) were plotted in 13/15 EDIT cases with complete IPP data. PEL was high 
(MaxPEL250 ≥14.5cmH2O/L at any point) in 7/13 patients, prompting same day IPC placement. PEL was normal (MaxPEL250 <14.5cmH2O/L at 
all points) in 6/13 patients, prompting same day ICD insertion for subsequent TSP. High PEL curves are shown on the left x-axis and 
normal PEL curves on the right x-axis. 
PEL, pleural elastance; EDIT, elastance-directed indwelling pleural catheter or talc slurry pleurodesis; IPP, intrapleural pressure; 
MaxPEL250, maximum pleural elastance sustained over a 250ml aspiration volume at any point during a large volume aspiration; IPC, 
indwelling pleural catheter; ICD, intercostal chest drain; TSP, talc slurry pleurodesis. 
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Pleural aspiration was terminated at target volume or ultrasound appearances in 
11/15 (73%) and due to persistent cough in 4/15 (27%). Chest pain led to 
termination in 0/15 cases. No serious adverse events (SAEs) directly attributable 
to EDIT were reported. A summary of all adverse events is presented in Table 
4.2. 1/15 (7%) cases had insufficient fluid for immediate IPC placement using a 
standard Seldinger technique. In this case, a ‘Boutin-type’ needle was used for 
pneumothorax induction prior to IPC placement without any complication. As 
previously discussed, a standard Boutin needle was unsuitable for this purpose as 
the integrated pleural biopsy gate may have caused trauma to the chest wall if 





Table 4.2 Summary of all adverse events within the pre-EDIT trial 
Date Study 
ID 
Classification Severity Related to 
trial 
interventions 
Description of event and outcome 
18/9/17 3 AE Mild Definitely Sensor reset due to high IPP during coughing. Procedure completed 
without further incident but IPP data discontinuous and therefore 
unsuitable for further analysis. 
27/9/17 4 AE Mild Definitely Sensor reset due to high IPP during coughing. Procedure completed 
without further incident but IPP data discontinuous and therefore 
unsuitable for further analysis. 
28/11/17 7 AE Mild Definitely Leakage of a few drops of pleural fluid from 3-way tap during manometry 
procedure. 3-way tap replaced, and procedure completed without further 
incident.  
1/12/17 3 SAE Moderate Unrelated Patient admitted with community acquired pneumonia. 
7/3/18 15 AE Mild Probably Minor asymptomatic subcutaneous swelling at site of manometry catheter 
insertion. Resolved within 8 days. 
6/4/18 17 AE  Mild Definitely Sensor reset following cough after removal of 100ml fluid. Manometry 
catheter was removed, recalibrated and re-inserted without 
compromising asepsis. Manometry data incomplete and therefore 
unsuitable for further analysis. No clinically adverse consequences. 
11/4/18 18 AE Mild Definitely Leakage of a few drops of pleural fluid from manometry catheter one-way 
valve following removal of verres introducer needle. No clinically adverse 
consequences. 
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11/4/18 18 AE Mild Definitely Difficulty inserting manometry catheter. Required use of Seldinger 
dilation kit, prolonging the procedure by approximately 1 minute. No 
clinically adverse consequences. 
20/4/18 11 SAE Moderate Possibly 
related 
Patient with lung cancer admitted with abdominal pain and swelling. CT 
scanning revealed widespread disease progression despite recently 
initiated anti-PDL1 immunotherapy. This included multiple sites of 
visceral disease, plus disease in the chest wall and flank ipsilateral to the 
trial intervention. It was considered possible that these findings may have 
reflected procedure tract metastases, but the pattern was that of 
widespread disease progression, possibly anti-PDL1 hyper-progression.   
2/9/18 27 SAE Moderate Unrelated Patient re-admitted with a combination of nausea, vomiting and 
unsteadiness. Presenting symptoms likely due to dihydrocodeine use and 
constipation.  
AE, adverse event; SAE, serious adverse event; IPP, intrapleural pressure
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4.4 Discussion 
4.4.1 Feasibility of investigating the efficacy an elastance-directed 
treatment pathway for MPE 
4.4.1.1 Recruitment 
Pre-EDIT was a positive study which has demonstrated the feasibility of 
recruitment to an RCT in which patients with symptomatic MPE are randomised 
between an elastance-directed treatment pathway (EDIT) and inpatient TSP. The 
a priori primary objective was achieved through trial enrolment, randomisation 
and delivery of per protocol definitive pleural intervention to 15 patients within 
a 6 month period (2.5/month). The overall trial recruitment of 31 patients over 
12 months (with only 1 allocation failure) equates to a mean recruitment rate of 
2.4 participants/month. This is considerably higher than the median recruitment 
rate reported in UK randomized controlled trials (0.92 participants/month (IQR 
0.43-2.79)) [96] and compares favourably to recently reported multicentre MPE 
trials (0.26 and 0.60 participants/month/centre, for IPC-PLUS [93] and AMPLE 
[3], respectively), suggesting that the EDIT design is feasible to deliver in 
reasonable numbers.  
4.4.1.2 Sample size for phase III study 
Pre-EDIT was designed to test whether a recruitment rate of 2.5 
participants/month could be achieved at a single centre. Although this exact 
figure was somewhat arbitrary, it was chosen since if up scaled to a practically 
deliverable multicentre trial, this RCT design would be likely to deliver a 
sufficiently large sample to robustly assess the efficacy of EDIT management.  
A definitive study of EDIT efficacy would require the use of a clinically relevant 
patient-centred primary outcome measure, such as need for repeat pleural 
intervention for symptomatic recurrence within 3 months. For example, in order 
to detect a reduction in TSP failure rate from 25% in the control arm (TSP, based 
on rates in previous studies of 22-29% [3,5]) to 10% in the intervention arm 
(EDIT), with 90% power, a 2-sided a=0.05, and assuming a 10% loss to follow-up 
(3% in TAPPS [26], 17% in TIME-1 [27]), 292 patients will be required (146 in each 
arm). Given the findings from pre-EDIT, such a trial would be deliverable within 
the well-developed pleural research networks in the UK, Europe and the US over 
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10-12 sites recruiting for 24 months. Furthermore, since MRI contraindications 
accounted for 20/48 (42%) pre-screen failures in pre-EDIT, and MRI would not be 
performed in a Phase III trial, the recruitment rate may be considerably higher. 
4.4.1.3 Technical deliverability and safety 
In total, fifteen patients underwent EDIT management within pre-EDIT. PEL 
assessment, calculation of PEL250 and delivery of an elastance-directed definitive 
pleural intervention was successfully completed in 13/15 patients (87%), and in 
all patients (13/13) following an early software update to the digital pleural 
manometry equipment. In all EDIT cases with complete data (13/15), elastance-
directed management (IPC or ICD) was delivered on the same day as PEL 
assessment and there were no procedure-related SAEs. Boutin-type needle 
pneumothorax induction was required prior to definitive management in only 
one case. These findings support the assertion that EDIT management is 
potentially widely deliverable should its efficacy be demonstrated. Additionally, 
in pre-EDIT, the (MRI-incompatible) manometry catheter had to be removed 
before placement of the elastance-directed treatment (IPC or ICD). In future 
delivery of EDIT management, a guidewire could simply be placed through the 
lumen of the manometry catheter facilitating immediate exchange for an IPC or 
ICD, greatly improving the efficiency and risk profile of the pathway. Further 
potential refinements to the EDIT pathway are discussed in Chapter 5. 
4.4.2 Relationship to Previous Studies 
Pre-EDIT is the first comparative study that has allocated patients to TSP or an 
IPC based on any biomechanical marker of lung expansion potential. Although 
Lentz et al recently reported an important negative randomised Phase III trial 
testing the effect of manometry-directed thoracentesis on chest pain, [76] no 
attempt was made in their study to direct definitive management based on IPP 
data.  
4.4.2.1 Diagnostic performance of PEL250 for radiographic NEL 
Pre-EDIT was not designed to detect radiographic NEL. As detailed in Chapter 3, 
radiographic NEL is associated with poor inter-observer agreement and has not 
been correlated with patient-centred outcomes; it is therefore inherently 
unsuitable as a trial outcome measure. However, a post hoc analysis of the 
diagnostic performance of PEL for NEL was used to indirectly assess the 
 155 
suitability of the novel abnormal elastance definition (PEL250 ³ upper limit of 
normal PEL (14.5 cm H2O/L)) prior to utilising this in a future trial. Accepting the 
limitation of radiographic NEL as a poor surrogate for pleurodesis failure, it is 
logical to compare the NEL diagnostic performance data obtained in pre-EDIT to 
that from previous studies.  
In an earlier prospective observational study using an improvised manometer, 
Lan et al reported that elevated PEL (a single point estimate ³19 cm H2O/L) 
during removal of 500ml fluid was associated with 79% sensitivity and 94% 
specificity for NEL. [67] Using the same PEL threshold but averaged over 
complete effusion drainage, Salamonsen et al reported lower sensitivity (40%) 
but 100% specificity for NEL. [94] The PEL threshold used to allocate cases to IPC 
in pre-EDIT was intentionally lower (≥ 14.5 cm H2O/L) than in both of these 
studies in order to increase sensitivity to a degree of NEL that would normally 
preclude slurry pleurodesis. This reflected the view that false positive high PEL 
was a ‘lesser evil’, simply resulting in IPC placement in those with expansile 
lung, which may be amenable to subsequent ambulatory pleurodesis. False 
negative results, conversely, would lead to a futile hospital admission for 
attempted TSP. Furthermore, in contrast to Lan et al, the use of a large 
aspiration volume in pre-EDIT was designed to identify delayed abnormal 
physiology, or ‘biphasic NEL’, [50] which might only be evident on removal of 
larger volumes. The finding of high sensitivity (100% (95% CI 51-100%)) is 
encouraging in this regard, but requires cautious interpretation given the 
underpowered and post hoc nature of this analysis. This sensitivity is also far 
higher than that reported by Chopra et al using the same PEL threshold (≥ 14.5 
cm H2O/L) for NEL diagnosis (sensitivity 71% (95% CI 55-83%)), however in their 
study a more stringent definition of expansile lung (³ 90% expansion) was 
adopted, which is likely to be the principle reason for the discrepancy in 
sensitivity seen here. [60] Additionally, a rolling average PEL was adopted in pre-
EDIT in an attempt to mitigate against a predictable reduction in specificity, by 
requiring a sustained increase in elastance (over at least 250ml) to diagnose 
NEL. Although the reported specificity (67% (95% CI 35-88%)) is lower than in 
previous studies, the novel PEL250 definition arguably represents a logical 
compromise worthy of further large-scale investigation given the previously 
described clinical imperative to prioritise sensitivity. 
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4.4.3 Study Strengths and Limitations 
Pre-EDIT was a prospective RCT conducted in accordance with CONSORT 
guidelines and reported transparently throughout, including clinical trial 
registration (clinicaltrials.gov) and publication of the trial protocol. As a 
feasibility trial, pre-EDIT recruited a small sample resulting in inevitably wide 
confidence intervals relating to radiographic NEL prediction and clearly this also 
precluded an assessment of alternative PEL thresholds or definitions. 
Nonetheless, pre-EDIT was able to robustly assess its primary objective of 
recruitment feasibility and refine technical aspects of the novel EDIT pathway 
design which are discussed further in Chapter 5. 
4.4.4 Conclusions 
Pre-EDIT is the first prospective randomised controlled trial to examine PEL-
directed MPE management. This work has demonstrated the feasibility of a 
definitive phase III trial, representing a significant first step towards a 
personalised treatment pathway for patients with MPE. The delivery of a 
definitive study of EDIT management efficacy is feasible in terms of both 
expected recruitment and technical deliverability. From this finding, it follows 
that experience from the delivery of pre-EDIT, and data relating to secondary 
and exploratory objectives, should be used to further optimise the EDIT pathway 
prior to a definitive study. These suggested developments and supporting data 
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5 Chapter 5: Optimisation of an elastance-directed 
management pathway for malignant pleural effusion 
5.1 Introduction 
Pre-EDIT has been the first prospectively conducted trial in which definitive 
malignant pleural effusion (MPE) management was delivered to patients on the 
basis of a pre-drainage prediction of lung re-expansion potential. The successful 
conduct of this trial, detailed in Chapter 4 of this thesis, demonstrates the 
suitability of key elements of this study design for use in future research. As a 
wholly novel concept, the development of the EDIT management pathway 
necessarily encompassed a number of areas of uncertainty. It is also noteworthy 
that pre-EDIT represented the first clinical use of the Rocket Medical digital 
pleural manometer (DPM) and the performance of this equipment in vivo was 
hitherto unknown. Pre-EDIT therefore provided an invaluable opportunity to 
thoroughly test the practicality of EDIT management, identify any unforeseen 
shortcomings, and test possible solutions in order to increase the reliability and 
efficiency of EDIT delivery. 
As previously discussed in this thesis, several trials and a subsequent meta-
analysis have shown equivalent symptom relief and survival between those 
patients with MPE managed with first-line talc slurry pleurodesis (TSP) and those 
managed with indwelling pleural catheter (IPC) drainage. [39] Since a significant 
minority of patients undergoing TSP experience treatment failure due to occult 
non-expansile lung (NEL), it follows that pre-drainage exclusion of NEL may 
enhance TSP success rates in patients without NEL, and direct those with NEL 
away from the possible harms of futile TSP and towards a more appropriate first-
line IPC management strategy. EDIT management was developed to realise these 
theoretical advantages. In doing so, the following assumptions were made: 
• Where possible, a significant proportion of patients would prefer TSP 
over IPC i.e. first-line IPC management is not universally acceptable 
• Pleural elastance (PEL) is the optimal biomarker for NEL detection 
• The definition of PEL (the change in intra-pleural pressure (IPP) for a 
given pleural aspiration volume during thoracentesis (VOUT)) correctly 
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assumes VOUT is an accurate reflection of the true pleural cavity volume 
change which occurs during thoracentesis 
• A near-maximal aspiration volume is required in order to achieve an 
acceptable degree of sensitivity and specificity for the detection of NEL 
using PEL 
o This objective may be achieved using a target aspiration volume 
based on a pre-procedure estimate of MPE volume calculated from 
bedside TUS measurements 
The rationale behind each assumption based on available literature is outlined in 
this introduction.  
5.1.1 Patient preferences in the management of MPE 
Given established evidence regarding the clinical equivalence (based on 
symptom scores and survival) of TSP and IPC insertion in management of 
symptomatic MPE, [39] international guidelines universally highlight the 
importance of individualised shared decision-making for this patient group. 
[46,47] However, there is no published data to indicate what proportion of 
patients might choose inpatient TSP when provided with objective information 
and an unbiased offer of either option. Early patient survey data from the 
Oxford pleural unit, where both inpatient TSP and IPC insertion are routinely 
offered to patients with symptomatic MPE, indicates that the majority of 
patients (18/26 in their series) opted for TSP. [43] Of those patients who chose 
TSP, over half indicated they would not consider IPC insertion, and 80% of those 
surveyed felt outpatient management would either have no effect, or a negative 
effect, on their quality of life. [43] While broadly supportive of further work to 
enhance inpatient TSP success rates, these data must be interpreted with 
caution given the small number of cases involved. Collection of further data on 
patient preferences for MPE management is therefore important to guide future 
research to improve relevant patient outcomes. The results of a Treatment 
Preferences Survey embedded within the pre-EDIT trial contributes to this 
knowledge-base and is presented in this Chapter. 
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5.1.2 Pleural elastance performance relative to Ultrasound measures 
The choice of PEL assessment, rather than non-invasive imaging techniques, to 
detect NEL is discussed and justified in Chapter 4, Section 4.1. However, the 
opportunity was taken during the conduct of pre-EDIT to acquire comparative M-
mode TUS images. These data are reported in this chapter.  
5.1.3 Validation of PEL definition 
PEL is currently defined indirectly, based on the assumption that the change in 
pleural cavity volume during thoracentesis is exactly equal to the volume of 
pleural fluid that is removed. This definition assumes that unmeasured liquid 
(e.g. pleural fluid, blood, local anaesthetic) or gases (e.g. air from the 
environment or lung parenchyma) are neither added nor lost from the pleural 
cavity during the conduct of pleural manometry. Clinical experience would 
suggest that these assumptions are probably valid in the majority of cases, 
perhaps except in those where there is significant lung entrapment and transient 
air ingress across the visceral surface. Nonetheless, pre-EDIT provided a unique 
opportunity to validate these assumptions directly further using volumetric MRI 
pre- and post-thoracentesis. In this chapter the true pleural cavity volume 
change derived using these measurements (DVMRI) is compared with aspiration 
volumes (DVOUT) in patients undergoing EDIT management. Analysis of these data 
are essential in understanding the diagnostic performance of PEL and further 
optimising the DPM technology used. 
5.1.4 Selection of the optimal aspiration volume for EDIT management 
Selection of the optimal aspiration volume for EDIT management introduces an 
inherent compromise between maximising the diagnostic performance of PEL 
data (sensitivity will increase as aspiration volume rises) and the technical ease, 
and importantly, the safety of the subsequent definitive pleural intervention. 
This is because Seldinger insertion techniques involve more risk of damage to 
intrathoracic organs when the volume of the effusion being drained is small.  
Since pre-EDIT adopted a novel definition of abnormal PEL (MaxPEL250 ³ 14.5 
cmH2O/L, see discussion in Chapter 4, section 4.4.2.1), the minimum aspiration 
volume required to reliably detect abnormal PEL, where present, was unknown 
prior to the study. The protocol therefore directed as large an aspiration volume 
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as possible while retaining the technical feasibility of Seldinger drain insertion 
(ICD or IPC). This was because a frequent requirement for pneumothorax 
induction, using a Boutin-type needle to facilitate safe blunt pleural access, 
would seriously compromise deliverability of routine EDIT management. This aim 
was achieved through the use of a target aspiration volume; initially based on an 
ultrasound based estimate of pleural effusion volume (detailed in Chapter 1, 
section 2.10) [87] and latterly, following experience during the trial conduct, 
based on serial mid-procedure thoracic ultrasound (TUS) measurements. This 
Chapter reports both the range of aspiration volumes required to detect 
abnormal PEL (where present), and the accuracy of the Goecke TUS pleural 
effusion volume estimate initially used, but subsequently abandoned for clinical 




5.2 Materials and methods 
The data in this chapter were acquired during the pre-EDIT study which is 
described in detail in Chapter 2. Specifically, the methods pertaining to these 
results are detailed in: 
• Sections 2.4.5.1, 2.4.5.4 and 2.4.6.2 regarding the Treatment Preferences 
Survey 
• Sections 2.4.11.1 M-mode ultrasound, section 2.4.11.3 DPM, and section 
2.4.16 regarding radiographic NEL definition 
• Section 2.4.11.2 and section 2.4.11.4 Volumetric MRI acquisition and 
analysis  
• Section 2.4.11.1 Goecke TUS effusion volume estimate (see also Appendix 
7) 
5.2.1 Patient preferences 
As described in section 2.4.5.1, consecutive patients with symptomatic MPE who 
were pre-screened for participation in pre-EDIT were invited to complete a short 
semi-structured survey of their preferences with regards to MPE treatment. The 
TPS is shown in appendix 5.  
5.2.2 Performance of TUS in the detection of NEL 
M-mode TUS assessment was undertaken in pre-EDIT participants allocated to 
EDIT management prior to thoracentesis and DPM. The method of TUS image 
acquisition and analysis is detailed in section 2.4.11.1. Following TUS and MRI 
scanning, thoracentesis (see TSI in appendix 7) was performed with pleural 
manometry measurements taken at 50ml intervals as described in section 
2.4.11.3.  
Following definitive intervention (IPC insertion or ICD followed by complete 
pleural drainage and attempted TSP), NEL was defined by the appearance of the 
post-ICD removal, pre-discharge CXR in those receiving TSP, or the CXR obtained 
14 days from discharge in those who underwent IPC insertion. Radiographs were 
classified by me using subjective visual estimation as showing: 
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• Expansile lung (>75% expansion) 
• NEL75 (<75% but >50% expansion) 
• NEL50 (<50% expansion)  
As described in section 2.4.24.2, 2x2 contingency tables were used to calculate 
the sensitivity and specificity of high PEL for NEL50 whereas the diagnostic 
performance of M-mode lung excursion for NEL50 and NEL75 was expressed as 
area under the ROC curve. 
5.2.3 Validation of PEL definition 
This work was performed in patients allocated to EDIT management which is 
described fully in section 2.4.11. 
5.2.3.1 MRI acquisition 
Pre- and post-DPM volumetric MRI scanning was performed according to the 
imaging protocol detailed in sections 2.4.11.2 and 2.4.11.4.  
5.2.3.2 MRI Phantom 
To provide a reference standard for MRI volumetric data acquired in pre-EDIT, a 
deformable trial-specific pleural cavity MRI phantom was developed by 
collaborators from the NHS MR Physics Group, NHS Greater Glasgow and Clyde. 
The MRI phantom is discussed in more detail in section 2.4.14.  
5.2.3.3 MRI analysis 
The pleural cavity volume change (DVMRI) was defined as the difference between 
the pre- and post-aspiration pleural cavity volumes on T1 VIBE images. The 
volumetric analysis was performed using Myrian® software v2.0 (Intrasense®, 
Montpellier, France) as described in section 2.4.13. Briefly, in each EDIT case, 
the volume of the pleural cavity pre- and post-DPM was measured. A free-hand 
tool was used to outline a region of interest ‘contour mask’ over the pleural 
cavity on approximately every fourth or fifth axial image. The region of interest 
contour mask was then extended through the complete image series semi-
automatically to create a 3-dimensional contour mask; the volume of which was 
automatically calculated by the Myrian® software. The accuracy of this contour 
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mask was visually assessed, and small adjustments made using free-hand 
drawing tools, if required, prior to the cavity volume being recorded.  
5.2.3.4 MRI volumetric analysis reproducibility 
The MRI volumetric analysis described above was repeated by a second 
independent operator (WH, ST5 radiologist) who was blinded to the results of my 
analysis. The Bland-Altman method was used to assess agreement between 
operators to establish the reproducibility of this technique.  
5.2.3.5 Comparison between VOUT and DVMRI 
VOUT was calculated from the mass of aspirated fluid based on individual 
estimates of fluid density derived from each effusion’s protein concentration as 
described in section 2.4.12. Agreement between VOUT and DVMRI were made using 
the Bland-Altman method. 
5.2.4 Selection of Optimal Aspiration Volume 
Again, this work was based on data acquired from pre-EDIT participants 
randomised to EDIT management. In each case, prior to DPM, an estimate of 
total effusion volume was made using the Goecke formula (VTUS) based on TUS 
measurements of the lateral and sub-pulmonic effusion dimensions as per the TSI 
shown in Appendix 7. [87] Agreement between VOUT and pre-DPM VMRI were made 
using the Bland-Altman method. 
Additionally, the aspiration volume was recorded at which abnormal PEL250 (i.e. 





5.3.1 Patient preferences 
TPS participation commenced on 7th March 2018 (approximately 7 months after 
pre-EDIT had opened to recruitment) and concluded with the recruitment of the 
final patient to pre-EDIT on 18th September 2018. A total of 17/40 potentially 
eligible patients (43%) completed the pre-EDIT TPS. 13/17 (76%) participated in 
the full pre-EDIT trial and 4/17 (24%) completed the TPS following an invitation 
to do so at pre-screening.  
All TPS respondents (17/17 (100%)) indicated that they had been provided with 
sufficient information to make a decision about their treatment. All respondents 
(17/17 (100%)) also indicated that their preference would be to receive an 
inpatient talc slurry pleurodesis. The majority (9/17 (53%)) cited the avoidance 
of ‘long term’ indwelling prosthetic material (if TSP were successful) as their 
principle reason for choosing first line TSP. Lower risk of infection (5/17 (29%)), 
less discomfort in the long term (1/17 (6%)) and a requirement for care of the 
drain site and a ‘reminder’ of their illness (1/17 (6%)) were also reported as 
reasons to favour TSP. The rationale for their treatment preference was left 
unanswered by a single respondent.  
The next section of the questionnaire outlined the findings of the IPC-PLUS trial 
[48] and asked respondents to indicate whether they would change their initial 
decision for first-line inpatient TSP if an attempt at outpatient TSP via an IPC 
(following the IPC-PLUS protocol) were offered to them. 4/17 (24%) indicated 
they would change their mind and choose an IPC-based strategy while the 
remaining 13/17 (76%) said their preference would remain an attempt at 
inpatient TSP. When asked whether they would consider a 2-stage pleural 
intervention process incorporating pleural manometry and an assessment of PEL, 
the vast majority (15/17 (88%)) indicated they would consider this an acceptable 
treatment, with 2 participants stating they were already content with their 
decision would not want to have a second procedure.  
5.3.2 Performance of TUS in the detection of NEL 
M-mode sonographic assessment of pre-aspiration atelectatic lung excursion due 
to transmitted cardiac impulse was successfully recorded in 10/15 (67%) patients 
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who received EDIT management. Missing data was attributed to failure to save 
images (2/15 (13%)), an inadequate sonographic window (2/15 (13%)), and an 
inability to analyse M-mode recording due to breathing artefact (1/15 (7%)). The 
range of lung excursion encountered and associated subsequent radiographic 
lung re-expansion classification is shown in Table 5.1. The area under the ROC 
curves (Figure 5.1) for M-mode lung excursion prediction of subsequent NEL50 
was 0.595 (95% CI 0.180-1.000) and 0.680 (95% CI 0.328-1.000) if NEL was 
defined as NEL75.  
 
Table 5.1 Measured atelectatic lung excursion due to cardiac impulse measured 
by M-mode ultrasonography in EDIT management cases (n=10) and associated 
final post-drainage radiographic lung re-expansion classification 
Subject number Atelectatic lung 
excursion (mm) 
NEL50 NEL75 
3 2.30 Absent Present 
4 3.50 Present Present 
7 3.70 Absent Absent 
10 2.30 Present Present 
11 2.50 Absent Absent 
15 2.20 Absent Absent 
19 4.20 Absent Absent 
27 1.43 Absent Present 
28 1.23 Absent Absent 
29 0.51 Present Present 
 
M-mode, Motion-mode; EDIT, Elastance Directed Intrapleural catheter or Talc 
pleurodesis; NEL50, non-expansile lung defined by £ 50% pleural apposition; 















Figure 5.1 ROC curves for atelectatic lung excursion, due to cardiac 
impulse measured by M-mode ultrasonography, prediction of subsequent 
(a) NEL50 and (b) NEL75 in EDIT management cases (n=10) 
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5.3.3 Validation of PEL definition 
5.3.3.1 MRI acquisition 
A standard MRI protocol was used for all patients, as summarised in Methods 
sections 2.4.11.2 and 2.4.11.4. At deployment, Field-of-View (FoV), slice 
thickness and the number of slices were adjusted to accommodate the size of 
each patient’s thorax. FoV varied from 400mm to 459mm. Slickness varied from 
1.8mm to 2.0mm. The number of slices varied from 104 to 128. Complete 
volumetric T1 VIBE MRI sequences were acquired in 12/15 (80%) EDIT subjects; 
1/15 (7%) missed their allocated MRI scanning appointment due to a delayed 
inter-hospital transfer, 1/15 (7%) was unable to tolerate MRI scanning due to 
orthopnoea, and 1/15 (7%) had incomplete image acquisition (lower border of 
costophrenic recess erroneously omitted from scanned volume). ICC between 
assessor measured volumes are shown in Table 5.3.  
5.3.3.2 MRI Phantom 
As previously described, this work was performed entirely by collaborators in the 
MR Physics Group without my direct involvement. The percentage error 
associated with measuring the dynamic phantom fluid volume on T1 VIBE 
imaging using Myrian® software ranged from 0.6% to 16.7%. Smaller fluid 
volumes were associated with a larger percentage error. Where fluid volumes of 
500 – 1000ml were analysed, the percentage error ranged from 0.6% to 6.4%.  
5.3.3.3 MRI analysis 




Table 5.2 Pleural cavity volumes measured on volumetric T1 VIBE MRI pre- and post-aspiration by primary (GAM) and secondary (WH) 




volume GAM (ml) 
Post-aspiration 
volume GAM (ml) 
DVMRI GAM (ml) Pre-aspiration 
volume WH (ml) 
Post-aspiration 
volume WH (ml) 
DVMRI WH (ml) 
3 1861 686 1175 2156 1148 1008 
4 4313 2904 1409 4489 2950 1539 
7 1910 1049 861 2143 1001 1142 
8 1569 642 927 1729 717 1012 
10 1813 965 848 1786 796 990 
11 4533 2263 2270 4671 2246 2425 
15 2082 891 1191 2114 877 1237 
19 1157 667 490 1312 690 622 
26 1784 967 817 1955 1037 918 
27 979 484 495 1006 493 513 
28 1020 435 585 1164 502 662 
32 1706 516 1190 1711 543 1168 
DVMRI, change in pleural cavity volume measured by pre- and post-aspiration volumetric magnetic resonance imaging
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5.3.3.4 MRI reproducibility 
Agreement between primary and secondary assessors is summarised as intra-
class correlation coefficients in Table 5.3. 
 
 
Table 5.3 Inter-observer agreement of semi-automated volumetric assessment of 
pleural cavity volumes performed by primary (GAM) and secondary (WH) 
assessors 
 ICC 95% CI 
GAM vs WH pre-aspiration 0.997 0.988-0.999 
GAM vs WH post-aspiration 0.981 0.936-0.994 
GAM vs WH DVMRI 0.976 0.918-0.993 
 
ICC, Intraclass Correlation Coefficient; 95% CI, 95% Confidence Interval  
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5.3.3.5 Comparison between VOUT and DVMRI 
The change in pleural cavity volume inferred from the volume of fluid aspirated 
(VOUT) and corresponding change in pleural cavity volume measured on 
volumetric MRI (DVMRI) by the primary assessor (GAM) are recorded in Table 5.4. 
The agreement between VOUT and DVMRI are presented as a Bland-Altman plot in 
Figure 5.4. 
 
Table 5.4 Change in pleural cavity volume inferred from fluid aspiration volume 




DVMRI (ml) VOUT (ml) DVMRI - VOUT 
(ml) 
3 1175 1236 -61 
4 1409 1292 117 
7 861 820 40 
8 927 846 81 
10 848 876 -28 
11 2270 2427 -157 
15 1191 1102 89 
19 490 482 8 
26 817 816 1 
27 495 480 15 
28 585 565 20 






Figure 5.2 Bland-Altman plot showing agreement between change in pleural 
effusion volume inferred from fluid aspiration volume (DVOUT) and measured by 
volumetric MRI (DVMRI) in EDIT cases with complete MRI acquisition (n=12) 
Dotted lines indicate 95% Limits of Agreement 
  














5.3.4 Selection of Optimal Aspiration Volume 
5.3.4.1 Agreement between VTUS and VMRI 
Pre-aspiration TUS estimates of effusion volume (VTUS), and corresponding 
pleural cavity volume measured on MRI (VMRI) by the primary assessor, are 
recorded in Table 5.5. Agreement between VTUS and VMRI are presented as a 
Bland-Altman plot in Figure 5.3.  
 
 
Table 5.5 Pre-aspiration pleural effusion volume estimated by Goecke thoracic 
ultrasound method (VTUS) and measured by volumetric MRI (VMRI) in EDIT cases 
with complete MRI acquisition (n=12) 
Subject 
number 
VMRI (ml) VTUS (ml) VMRI-VTUS (ml) 
3 1861 2023 -162 
4 4313 2002 2311 
7 1910 1862 48 
8 1569 1897 -328 
10 1813 1652 161 
11 4533 2478 2055 
15 2082 2394 -312 
19 1157 1309 -152 
26 1784 1568 216 
27 979 1820 -841 
28 1020 1603 -583 





Figure 5.3 Bland-Altman plot showing agreement between pre-aspiration pleural 
effusion volume estimated by Goecke TUS method and measured by volumetric 
MRI (primary assessor) in EDIT cases with complete MRI acquisition (n=12) 
Dotted lines indicate 95% Limits of Agreement  
















5.3.4.2 Aspiration volume required to detect abnormal PEL 
The median volume of fluid aspirated during PEL assessment was 996ml (range 
482ml - 2670ml). Abnormal PEL (MaxPEL250 ³ 14.5 cm H2O/L) was detected in 7/13 
(54%) cases with complete data. In these cases, abnormal PEL was first detected 





5.4.1 Patient preferences in the management of MPE 
17/40 potential respondents (43%) completed the TPS. This modest response 
rate clearly limits the generalisability of the findings, however since all 17 
surveyed patients unanimously indicated a preference for first line TSP, it 
appears that from a patient perspective there remains a significant impetus to 
further optimise inpatient TSP pathways. The avoidance of long term indwelling 
prosthetic material was cited as the main reason for choosing TSP over IPC 
management. Universal IPC management appears unlikely to realistically be able 
to overcome this patient concern given the length of time required for 
ambulatory pleurodesis (median time to IPC removal approximately 10 weeks in 
IPC-PLUS [48]) and this was reflected in the survey findings in that only 4/17 
(24%) participants suggested they would consider ambulatory pleurodesis if 
available. In contrast, the majority of participants (88%) said they found the idea 
of PEL-directed treatment acceptable, presumably since this represented ‘TSP if 
possible’ and would only lead to IPC insertion if TSP was predicted to fail. To 
build on these findings, a more detailed qualitative exploration of patient 
preferences from a range of treatment centres is warranted to ensure future 
treatment developments are appropriately aligned to accommodate the range of 
patient priorities encountered in this condition.  
5.4.1.1 Relationship to previous studies  
The findings here are similar to those described by Seymour et al in the only 
comparable study in the current literature. [43] In their similar survey of patient 
attitudes, over half of patients who indicated a preference for first-line TSP 
would not consider IPC management, and 80% said they thought ambulatory 
management would have no effect, or a negative effect, on their quality of life.  
5.4.1.2 TSP strengths and limitations 
The embedded TPS commenced mid-way through pre-EDIT recruitment. This 
constrained the available sample size and caution is required in the 
interpretation of this small-scale single centre survey. Although TSP participants 
were provided with clear and objective treatment information summaries to 
read prior to completely the survey, there was clearly significant potential for 
institutional and investigator bias to influence the participant responses. 
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Additionally, the majority of respondents had also consented to participation in 
the full pre-EDIT trial (76%). Pre-EDIT eligibility criteria excluded those with a 
preference for first-line IPC management and this method of patient selection 
also clearly limits the generalisability of the survey findings. However, only 3/87 
(3%) consecutive patients pre-screened for pre-EDIT participation were excluded 
on the basis of a clear baseline preference for TSP or IPC.  
5.4.2 Performance of M-mode sonography in the detection of NEL 
The utility of M-mode sonography as a potential alternative NEL biomarker for 
use in future trials was explored during the conduct of pre-EDIT. Diagnostic M-
mode imaging was obtained in 10/15 EDIT management cases (67%). Two 
avoidable cases of missing data arose from investigator error during attempts to 
save the images, however in 3/15 (20%) it was technically impossible to 
complete an M-mode lung excursion assessment due to either breathing artefact 
or an inadequate acoustic window. It appears reasonable to assume that similar 
limitations might be encountered in clinical practice. Although pre-EDIT was not 
specifically designed to formally compare NEL assessment techniques, the 
success rate for completing an M-mode assessment encountered here (10/15 
(67%)) appears inferior to that of PEL assessment (13/15 (87%), rising to 13/13 
(100%) following a software update). Furthermore, the diagnostic performance 
of M-mode assessment for NEL was poor in the pre-EDIT series with an AUC of 
only 0.595. Although notable uncertainty exists around the diagnostic 
performance estimate here, we found no compelling new data to prioritise M-
mode sonography over PEL as means of NEL-directed MPE care.   
5.4.3 Validation of the definition of PEL 
Complete pre- and post-aspiration MRI imaging was obtained in 12 EDIT 
management subjects. Colleagues from the MR Physics group identified a high 
level of measurement precision when adopting pre-EDIT imaging protocols and 
Myrian® software to measure their deformable pleural phantom. Their 
measurement error was particularly low (0.6%-6.4%) in simulated effusions of 
volume ≥500ml, which accounted for the majority of pleural cavity volumes 
measured in pre-EDIT subjects. An extremely high level of inter-observer 
agreement (ICC > 0.98) was seen between independent MRI assessors which 
supports the reliability of this novel approach as a gold standard technique to 
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directly assess the pleural cavity volume. Very close agreement was seen 
between pleural fluid aspiration volume (VOUT) and directly measured pleural 
volume (DVMRI). This finding validates the indirect definition of PEL (DIPP/VOUT) 
which is widely used in clinical practice.  
A slight bias towards VOUT underestimating DVMRI was observed. This may have 
been accounted for by the unavoidable loss of small volumes of pleural fluid 
during insertion and removal of the DPM catheter. Importantly, it should be 
noted that none of the 12 EDIT subjects with complete MRI imaging had evidence 
of post-thoracentesis ex-vacuo pneumothorax. Had his occurred, it may be 
speculated that transient air ingress into the pleural cavity, either via pleuro-
parenchymal fistulation or through instrumentation, would lead to an increase in 
IPP (and therefore a reduction in DIPP) while simultaneously DVOUT (and DVMRI, if 
it had been measured) would continue to increase. The net effect may be a 
trend towards normalisation of PEL. This mechanism may account for some of the 
discordance seen in a larger observational study between PEL and radiographic 
NEL, [60] but this hypothesis could not be explored further in this series. 
5.4.4 Optimal Aspiration Volume for PEL assessment 
In cases where abnormal PEL was present, based on the novel MaxPEL250 
definition, this was first detected at a median volume of 325ml. The largest 
volume needed to pass this threshold was 800ml. These findings suggest that the 
hypothesis stated that a near-maximal fluid aspiration is need for acceptable 
diagnostic performance is inaccurate. A future elastance-directed pathway may 
therefore be optimised through the use of more modest aspiration volumes 
(potentially < 1L) which may in turn improve patient safety (larger residual 
volume for definitive Seldinger intervention) and convenience (shorter 
procedure).  
5.4.4.1 Use of a TUS effusion volume estimate 
Agreement between the Goecke TUS pleural effusion volume estimation and gold 
standard volumetric MRI assessment was poor in the majority of cases, and 
grossly inaccurate in 2 cases where the baseline effusion volume exceeded 3L. In 
hindsight, the inadequacy of VTUS may have been predicted since this method 
had originally been derived (indirectly from VOUT) from the complete aspiration 
of a series of effusions only up to 1650ml in volume. [87] The principle limitation 
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with the Goecke method in larger effusions is likely to relate to the inherent 
challenge in measuring the lateral height of a pleural effusion beyond the level 
of the axilla due to loss of acoustic access. This weakness in the Goecke TUS 
effusion volume estimate only became apparent early in the conduct of pre-
EDIT. As described in Chapter 4, section 4.3.3.3, it was clinically apparent that 
this method risked unnecessary early termination of pleural aspiration in cases 
with a large initial effusion thus potentially compromising the sensitivity of PEL 
assessment. The trial protocol was amended after the delivery of 2 episodes of 
EDIT management to allow the use of a mid-procedure assessment of residual 
effusion volume to guide the stop point for PEL assessment (aspiration 
terminated when horizontal lung-costal pleural distance £ 30mm). The original 
versions of the protocol had sought to provide maximal objectivity at each step 
of the pathway, hence the use of a pre-set maximum aspiration target, and 
reduce the need for the additional complexity of mid-procedure TUS 
assessments. However, this strategy was clearly unsuccessful. The experience of 
the amended method utilising a mid-procedure TUS assessment was positive 
from an operator perspective and arguably better reflects the real-time decision 
making required in clinical practice. The replacement of a pre-specified TUS-
based target aspiration volume with regular mid-procedure TUS assessment 
therefore represents a logical refinement to the EDIT pathway. 
5.4.5 Conclusions 
This chapter has generated a number of important findings that will be 
incorporated into future studies, including a definite Phase III trial of EDIT 
management. The embedded TPS within pre-EDIT has provided a valuable insight 
into patient preferences in the management of symptomatic MPE. Although 
caution must be taken not to overinterpret these findings, there appears to be 
at least some degree of appetite from a patient perspective to further refine 
TSP pathways. In that regard, the findings from pre-EDIT support the 
development of PEL-directed therapy. In addition, novel volumetric MRI data 
obtained here validates the widely adopted clinical ‘indirect’ definition of PEL 
(DIPP/VOUT), at least in those cases without ex-vacuo pneumothorax. The 
aspiration volume required to detect abnormal PEL where present, may be more 
modest than we hypothesised (£ 800ml in all EDIT cases with NEL) making a less 
than near-maximal aspiration a feasible option within a future larger EDIT trial. 
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However, the Goecke TUS method was demonstrated to be inaccurate, 
especially in larger effusions, and is therefore not suitable for computation of a 












6 Chapter 6: Conclusions 
The management of Malignant Pleural Effusion has evolved significantly in recent 
years, however Non-expansile Lung remains a prominent, but poorly defined and 
often occult, obstacle to effective palliation in a significant proportion of 
patients. Indwelling pleural catheters have led to a paradigm shift in the 
management of MPE and are increasingly recognised as a first-line definitive 
intervention in preference to talc slurry pleurodesis. However, IPCs are not 
universally acceptable to patients and come with important disadvantages, costs 
and risks. Therefore, the development of a robust and efficient treatment 
pathway for patients wishing to avoid indwelling prosthetic material, remains a 
clinical imperative.  
The initial observational work in this thesis has contributed to our understanding 
of the prevalence of NEL in MPE, the prognostic significance of this finding and 
the limitations of its radiographic detection. The challenges reported in Chapter 
3 in reliably detecting NEL strongly motivated our unit to use pleural manometry 
to develop of a stratified treatment pathway designed to reduce pleurodesis 
failure, moving away from use of PEL as way of detecting NEL per se. The 
subsequent pre-EDIT feasibility RCT (reported in Chapters 4 and 5) has greatly 
enhanced our knowledge of how such a goal may be delivered and facilitated 
evidence- and experience-based refinements to the design of a proposed future 
phase III study of EDIT management (the EDIT trial).  
6.1 Post-drainage radiographic identification of non-expansile lung and 
its prognostic significance 
In this multicentre observational study, the proportion of patients with NEL 
(defined here as less than 50% pleural apposition) in a cohort of patients with 
MPE undergoing LAT was high (17–34%). This definition identified gross 
radiographic NEL which would preclude an attempt at TSP. The high prevalence 
of NEL encountered suggests that NEL is under-represented in important 
landmark trials of IPC-based MPE management such as TIME-2 (6% NEL) and 
AMPLE (3% NEL). [2,3] As such, clinical equipoise between IPC and TSP for all 
patients with MPE cannot be assumed, and refinements to TSP pathways are 
required.  
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Radiographic identification of NEL was subject to a high level of inter-observer 
variation. NEL was associated with adverse survival in both retrospective cohorts 
studied. However, the independence of this relationship was not externally 
validated, probably due to a type II statistical error and the potential for 
misclassification of borderline cases given the limitation of single-observer 
radiographic classification. In the analysis of ‘extreme expansion phenotypes’, 
the possibility of misclassification was eliminated and this work supports the 
hypothesis that there is a genuine prognostic disadvantage associated with NEL.   
The findings from this study should be considered in clinical practice. In cases 
with borderline NEL, the opinion of a second observer (and even a third, in the 
event of disagreement) may be justified to improve the consistency of clinical 
decision-making. Furthermore, the results are pertinent to the design and 
conduct of future MPE trial design which should seek to identify NEL biomarkers 
which are associated with less inter-observer variation. As previously discussed, 
the ideal biomarker would allow reliable detection of NEL at an early stage prior 
to complete effusion drainage thereby creating the potential to improve patient 
outcomes through the avoidance of futile TSP attempts.  
6.2 Feasibility of a randomised controlled trial of elastance-directed 
management in malignant pleural effusion 
6.2.1 Recruitment and technical feasibility 
Pre-EDIT was the first randomised controlled trial in which pleural management 
was directly guided by pleural manometry data. The successful conduct of the 
trial has shown that it is feasible to recruit patients with symptomatic MPE to an 
RCT of an elastance-directed treatment pathway in sufficient numbers (31 
patients over 55 weeks from a single centre) to justify progressing to an 
appropriately powered multicentre trial of efficacy of such a pathway. 
Importantly, EDIT management was also safe (no directly related SAEs) and 
technically deliverable (complete PEL assessment and delivery of per-protocol 
definitive intervention in 13/13 (100%) after an early DPM software update). 
EDIT management was also time efficient; in all EDIT cases, a definitive 
intervention was delivered within 24 hours of PEL assessment, with only 1/15 
(7%) requiring the use of pneumothorax induction due to insufficient residual 
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fluid. In pre-EDIT, the (MRI-incompatible) manometry catheter had to be 
removed before placement of the elastance-directed treatment (IPC or ICD). 
However, in future research, and ultimately clinical practice, a guidewire could 
simply be placed through the lumen of the manometry catheter facilitating 
immediate replacement for an IPC or ICD, thereby further improving the 
efficiency the pathway, and likely completely negating the need for 
pneumothorax induction. 
6.2.2 Diagnostic performance of PEL 
Although pre-EDIT included insufficient cases to comment on clinically defined 
treatment success rates (e.g. at 3 month follow-up), a post-hoc analysis 
reassuringly identified that MaxPEL250 detected NEL with a high degree of 
sensitivity (100% (95% CI 51-100%)) and an acceptable level of specificity (67% 
(95% CI 35-88%)). These estimates of diagnostic performance are necessarily 
associated with wide confidence intervals given the small sample size, but 
nonetheless support the use of MaxPEL250 ≥ 14.5 cm H2O/L as a NEL biomarker in 
future research into elastance-directed therapy. 
6.3 Optimisation of an elastance-directed management pathway for 
malignant pleural effusion 
6.3.1 Treatment preferences 
The conduct of pre-EDIT provided an invaluable opportunity to refine the EDIT 
management pathway and ensure it was aligned with patient treatment 
preferences and priorities. The patient survey embedded within pre-EDIT, 
identified a strong preference for inpatient TSP over first-line IPC insertion. The 
generalisability of the TPS findings may have been limited by patient selection 
as the majority of respondents (13/17 (76%)) were full pre-EDIT participants and 
had opted not to have a first-line IPC. However, since only 3% of those pre-
screened for pre-EDIT were excluded on the basis of treatment preference, the 
magnitude of any patient selection bias should be low. The avoidance of ‘long 
term’ indwelling prosthetic material (assuming TSP success) was the most 
common reason for choosing first-line TSP (53% of respondents). When presented 
with hypothetical alternative management strategies, the addition of a pleural 
elastance assessment was considered acceptable by 88%, whereas only 24% 
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indicated they would choose ambulatory pleurodesis over TSP if both options 
were available. While obviously limited by selection bias, as discussed, and a 
small sample size, these findings are supportive of efforts to improve the success 
of inpatient TSP using PEL as a NEL biomarker.  
6.3.2 Choice of NEL biomarker 
M-mode sonographic assessment of atelectatic lung has been described as a 
potentially widely deployable non-invasive biomarker of NEL. It was therefore 
logical to evaluate this technique in parallel with PEL within pre-EDIT. M-mode 
acquisition was hampered by poor reliability (20% technical failure rate) and 
poor diagnostic performance (area under ROC curve 0.595). There was therefore 
no new data recorded to support a shift away from PEL to M-mode TUS for 
detection of NEL. Additionally, volumetric MRI data from 12 EDIT patients with 
complete imaging validated the clinical definition of PEL (DIPP/VOUT) in patients 
without post-thoracentesis NEL, and lends further weight to the development of 
PEL as a clinical biomarker. 
6.3.3 PEL assessment aspiration volume 
Using the novel MaxPEL250 definition to identify NEL, only a modest aspiration 
volume (median 325ml, range 250ml - 800ml) was required to detect abnormal 
physiology. Large aspiration volumes (> 1.5L) in excess of BTS guidelines 
therefore appear unnecessary to reliably detect NEL. Furthermore, the Goecke 
effusion estimation used initially to guide the maximal aspiration volume in pre-
EDIT was inaccurate. This was swiftly replaced (after 2 EDIT cases) with a real-
time TUS assessment which was more akin to routine clinical decision making. 
This streamlined method was associated with a positive operator experience 
and, importantly, achieved a high sensitivity for NEL detection (100%) achieved. 
This experience suggests mid-procedure TUS should be integrated into future 
iterations of EDIT management.  
Finally, assuming the Rocket Medical DPM equipment can be suitably adapted to 
provide real-time elastance data, then PEL assessment could also be terminated 
as soon as an abnormal PEL250 value is identified. Ideally, this process would be 
fully automated by integrating real-time flow measurement into the DPM 
system, but in the shorter term could probably be achieved with a software 
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update to allow the operator to manually record the removal of each 50ml 
aspiration aliquot during the procedure.   
6.4 Future work 
The work presented in this thesis has ultimately informed the design of the 
proposed ‘EDIT trial’, a phase III study of the efficacy of EDIT management. The 
experience and data gathered from each aspect of the pre-EDIT trial has been 
used to refine and optimise the EDIT trial protocol; a proposed trial synopsis is 
presented in Appendix 10. Funding for the EDIT trial has been secured at the 
time of publication of this thesis and recruitment is expected to commence in 
Q3/4 2021.  
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Appendix 3 Pre-EDIT screening visit consent form 
  
 197 

















































Appendix 10 Proposed EDIT trial synopsis 
 
Title EDIT: A randomised Phase III trial testing the effect of 
Elastance-Directed Intra-pleural catheter or Talc 
Pleurodesis (EDIT) management on pleurodesis failure rate 
in Malignant Pleural Effusion  
Design Multi-centre, randomised (1:1), open-label superiority trial 
Trial 
Participants 
Patients with symptomatic Malignant Pleural Effusion 
without clinically obvious non-expansile lung (NEL) 
Sample Size In order to detect a reduction in TP failure rate from 25% 
in the control arm (talc pleurodesis) to 10% in the 
intervention arm (EDIT), with 90% power, a 2-sided a = 
0.05, and assuming a 10% loss to follow-up, 292 patients 
are required (146 patients in each arm). 
Trial Centres Lead Centre: Glasgow 




Cancer Research-UK Glasgow Clinical Trials Unit 
Trial Period 36 months [Set up: 6 months, Recruitment: 24 months, 
Follow-up: 6 months]  
Sponsor NHS Greater Glasgow & Clyde 
Funding Charitable grant from Clydeside Action on Asbestos and an 
unrestricted commercial grant from Rocket Medical (UK) 
 Trial Objectives Associated End-points 
Primary  To determine whether EDIT 
management reduces TP 
failure rate from 25% in the 
control arm to 10% in the 
intervention arm 
TP failure, as defined by 
the need for repeat 
ipsilateral pleural 
intervention for recurrent 
symptomatic pleural 
effusion, within 3 months of 
randomisation. 
Secondary  To determine the diagnostic 
performance of the P EL 
threshold used to allocate 
patients in the EDIT arm to 
placement of an IPC  
Sensitivity and Specificity 
(of MaxPEL250 ≥ 14.5 cm 
H2O/L) relative to 
radiologically defined NEL 
To determine the safety and 
tolerability of EDIT 
management 
Adverse Events (AE) and 
Serious AE (SAE) rate. The 
occurrence of chest pain, 
cough or breathlessness.  
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To determine the health 
economic impact of EDIT 
management 
Total healthcare costs, 
including those associated 
with index treatment and 
all subsequent attendances, 
including re-admissions  
To determine the diagnostic  
utility of M-mode assessment 
of cardiac impulse lung 
displacement for NEL 
M-mode assessment of 
cardiac impulse lung 
displacement relative to 




• Clinically confident diagnosis of MPE, defined as any 
of the following: 
o Pleural effusion with histo-cytologically proven 
pleural malignancy OR 
o Pleural effusion in the context of histo-
cytologically proven malignancy elsewhere, 
without a clear alternative cause for fluid OR 
o Pleural effusion with typical features of 
malignancy with pleural involvement on cross-
sectional imaging (CT/MRI) 
• Degree of breathlessness for which therapeutic 
pleural intervention would be offered 
• Age >18 years 
• Expected survival > 3 months 
• Written Informed Consent 
 
Exclusion Criteria: 
• Clinical suspicion of NEL or known expansion status  
• Patient preference for 1st-line IPC insertion 
• Previous ipsilateral failed TP 
• Any C/I to chest drain or IPC insertion, including 
irreversible coagulopathy, inaccessible pleural 
collection or lack of suitable IPC tunnel site 





Patients with symptomatic MPE will be identified at cancer 
MDTs, routine outpatient appointments, and during 
inpatient reviews. Those patients meeting all Inclusion 
Criteria and without assessable Exclusion Criteria will be 
provided with a Patient Information Sheet (PIS) and given 
sufficient time to consider participation. There must be at 
least 24 hours between the patient receiving the PIS and 
giving consent to trial participation. 
Consent will be a two-stage process. After initial 
introduction to the trial, a member of clinical staff, usually 
a nurse specialist will make separate contact with the 
patient to assess whether they wish to consider 
participation. This will typically be done the following day. 
If patients are agreeable to trial involvement, a member of 
the research team, usually a research fellow or nurse will 
identify a suitable opportunity to address any questions 
and to seek written informed consent to screening.  
Formal screening will allow complete assessment for 
potential exclusion criteria. Patients meeting all eligibility 
criteria then give additional written consent to 
randomisation and trial enrolment. 
Randomisation 
and Allocation 
Following consent and baseline assessments, patients will 
be randomised using an online system 
(sealedenvelope.com) and allocated 1:1 using random 
permuted blocks to one of two groups: 
• Intervention arm: EDIT management 
• Control arm: Talc Slurry Pleurodesis  
Recruitment 
Rate 
The lead centre will recruit at least 30 patients/year over 
the study period. Up to 10 additional centres within the UK 
(+/- US) will recruit 10-20 patients per year.   
Trial 
Procedures 
Intervention: EDIT management 
1. Large volume pleural aspiration with 
recording of IPP and VOUT after every 
50ml of fluid aspirated 
2. Computation of Peak PEL250, defined as 
the rolling average PEL over preceding 
250ml aspirated. 
MaxPEL250 ≥ 14.5 cm H2O/L at any 
point: allocated to IPC 
MaxPEL250 < 14.5 cm H2O/L at all 
points: allocated to TP 
3. EDIT-directed 1st-line treatment, using 
the manometry catheter to place a 
guidewire, facilitating immediate ICD 











Re-intervention criteria in both arms: 
The need for repeat pleural intervention for symptomatic 
recurrence of effusion will be based on the treating 
clinician’s judgment, assuming at least 50% of the 
ipsilateral hemithorax is occupied by fluid on the PA chest 
radiograph. If <50% fluid recollection, the agreement of a 
blinded colleague must be sought before intervention. 
 
Trial Follow-up Visits 
Patients in both treatment arms will receive identical 
follow-up, including trial visits, ideally combined with 
routine clinical appointments at 4 weeks and 3 months 
after treatment. Electronic review of case records +/- 
telephone visit will be permitted in patients unfit to attend 
clinic. 
 
End of  Trial The trial will end after all 292 patients have been 
recruited and all have completed their 3-month follow up 
appointment, or have died whichever occurs first.  
Procedures for 
Safe Monitoring 
All AEs will be reported directly to the sponsor. Any 
unexpected SAEs that are related to the use of the DPM or 
subsequent pleural procedures in the EDIT management 
arm will be subject to expedited reporting. 
Trial Costs Detailed trial costs will be generated after a decision on 
the feasibility of commercial support via Rocket Medical 
(UK). The outline costs provided below are likely to be 
broadly representative and are based on recently funded 
clinical trials in the lead centre. These costs assume that 
EDIT management consumables (Rocket DPM) will be 
supplied by Rocket Medical UK. 
 
 
Year 1 Year 2 Year 3 Category Total
CRUK-CTU costs
1. Project Manager 10,678 10,678 10,678 32,034
2. Trial Statistician 10,488 10,488 10,488 31,464
3. IT programmer 3,949 3,949 3,949 11,847
4. Clinical Trial Coordinator 6,594 6,594 6,594 19,782
5. Trial Registration,Office Costs 8,250 0 0 8,250
Clinical Research Fellow 62,600 62,600 62,600 187,800
Trial Visits 5,000 10,000 5,000 20,000
EDIT Consumables 0 0 0 0
Site training & Initiation Visits 5,000 0 0 5,000
Total 112,559 104,309 99,309 316,177
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